Announcements

6 December 2024
MDPI INSIGHTS: The CEO's Letter #18 - MDPI UK, Basel Job Fair, CETEF'24

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

MDPI’s First UK Summit Held in Manchester

On 29 November, we hosted our first annual MDPI UK Summit, bringing together over 30 Chief Editors and Editorial Board Members (EBMs) to discuss MDPI’s mission, achievements, and collaborations in the UK.

Throughout the day we had talks from several members of MDPI, roundtable discussions on the peer-review process and upholding research integrity, and an engaging presentation from the Editor-in-Chief (EiC) of MDPI journal Mathematics, Francisco Chiclana, about his involvement with the Research Excellence Framework.

“This was a great first summit for MDPI UK and received excellent feedback”

 In the following I highlight some of the sessions and the discussion topics covered in each session.

Session 1: Opening Speech and Introduction to MDPI

I shared an overview of MDPI’s mission, achievements, and commitment to quality. The Q&A touched on key topics such as perception and reputation management, expanding our arts and humanities portfolio, and funding challenges for open access (OA) in the UK.

A takeaway from this session was that in 2025, we will circulate a mini annual report to all editors, helping them understand MDPI’s mission and achievements beyond the context of their specific journals.

Session 2: MDPI and the Research Excellence Framework (REF)
Prof. Francisco Chiclana (EiC of Mathematics) highlighted MDPI’s role in REF, its purpose, and future directions.

Session 3: Editorial Process, Ethics, and Research Integrity
Dr. Giulia Stefenelli presented on the various editorial roles and responsibilities, quality metrics, and procedures for dealing with misconduct. The Q&A centred on AI in publishing, institutional roles in research integrity, and better data management practices.

Session 4: Institutional Open Access Program (IOAP)
Becky Castellon presented on IOAP benefits, including MDPI’s partnership with JISC, which includes more than 60 UK institutions, and highlighted the advantages of pure OA over transformative agreements.

Session 5: Round Table Discussion
Colleagues from our MDPI Manchester office Jaime Anderson and Dr. Michael O’Sullivan, along with colleagues from our Basel office Damaris Critchlow and Giulia Stefenelli, discussed innovations in peer review, challenges in maintaining scientific integrity, and future solutions.

Session 6: MDPI PR and the Voice of the Customer
I recapped our customer satisfaction drivers, including speed and editorial support. I also spoke about tackling misinformation about OA and MDPI in general, and outlined a way forward for us all to participate in advocating for open science.

This was a great first summit for MDPI UK and received excellent feedback from our EiCs, SEiCs, and EBMs. A BIG thank-you to our Manchester team (pictured below) and everyone else involved in organizing this event. Their hard work and dedication are much appreciated!

Impactful Research

MDPI and UK Publications

The UK is an important market for MDPI, ranking ninth in total submissions to MDPI and eighth in total MDPI publications, with over 72,200 publications to date. As at October 2024, there were more than 3,600 EBMs from the UK, 48% of whom have an H-index above 26. We also have 46 EiCs, and 63 SEiCs in the UK, some of whom joined us in Manchester for the UK Summit.

The UK is a strong advocate of OA publishing, with nearly three quarters of all articles in 2023 published on open access platforms. The country enjoys a large academic market, producing high-quality papers, and is home to some of the world’s top universities. Among MDPI’s 825 IOAP agreements, over 60 of these are in the UK, facilitated through our partnership with JISC.

“The UK is a strong advocate of OA publishing”

 Visit to MDPI’s Manchester Office

Last week, I visited our Manchester office to see the expanding office space, connect with our staff, and present at the MDPI UK Summit held in Manchester.

Throughout the day, I met with various teams to better understand their work and discuss their future development plans in greater depth. Hearing from group leads about the progress we have made and the challenges we face offered many valuable insights. I also had the chance to connect personally with members of the content team. It’s great to see how this young and ambitious team is coming together.

I also took the opportunity to address the entire office about the role of MDPI UK within the wider company. During this session, I answered questions about growth and public relations initiatives. Giulia Stefenelli joined us to address questions about the role of AI in MDPI’s future.

Jaime Anderson (Office Manager) and the Manchester team have done a great job of growing the office since its establishment in 2019. Today, it has around 150 staff members across various departments, including English editing, editorial services, marketing and communications, and IOAP. The team is highly active in local marketing initiatives, such as author training sessions, scholar visits, and conferences.

For more information and updates on our Manchester office, follow MDPI UK on LinkedIn.

Inside MDPI

Basel Job Fair

In November, the HR team from our Basel office connected with over 300 young professionals at the Basel Job Fair 2024. This is my biased opinion, of course, but we had the best branded booth and merchandise, which drew a lot of attention from young talent wanting to learn about current and future job opportunities at MDPI.

Our HR team also helped review CVs on the spot, providing advice on how to improve them and making a positive impression on the future workforce in Basel.

This is a reminder that MDPI is not only focused on supporting young researchers but that we also recruit and develop young talent. We have seen MDPI HR do this really well throughout all of our offices, from Asia Pacific to Europe and North America.

HR plays an important role in our growing company, helping us meet our recruitment targets as well as providing support for local teams, guidance on management and best practices, a safe space for employees, and brand recognition for MDPI, among many other things.

“MDPI is not only focused on supporting young researchers: we also recruit and develop young talent”

This is a quick appreciation post to all HR staff working to support MDPI and our colleagues, cultivating talent and supporting careers at every stage. Thanks HR staff, keep up the great work!

Coming Together for Science

Pharmaceuticals 2024 – Recent Advances in Pharmaceutical Sciences Towards a Healthy Life (The 20th Anniversary)

I am pleased to share that the Pharmaceuticals 2024 – Recent Advances in Pharmaceutical Sciences Towards a Healthy Life took place from 27 to 29 November 2024 in Barcelona, Spain. It was chaired by Prof. Dr. Amelia Pilar Rauter from the Universidade de Lisboa, Portugal; Dr. Alfredo Berzal Herranz from Instituto de Parasitología y Biomedicina López-Neyra (IPBLN) CSIC, Spain; and Prof. Dr. Mary Jane Meegan from Trinity College Dublin, Ireland.

The conference took place in Casa Convalescència, a part of the Sant Pau Art Nouveau Site. The three-day event included three plenary sessions and eight invited speakers, from eight countries, and 29 selected talks. Of the presentations on site, there were 32 posters and 29 oral presentations.

The main goal of the ‘Pharmaceuticals 2024’ international conference was to cover the newest technologies and research areas including medicinal chemistry, natural products, organic synthesis, radiopharmaceuticals, pharmacology, toxicology, and biomolecular and glycosciences, in a meeting that brought together experts to present their latest findings on combatting infection, inflammation, pain, and neurodegeneration, to mention just a few of the topics that were discussed.

“The main goal of ‘Pharmaceuticals 2024’ was to cover the newest technologies and research areas”

20th Anniversary of Pharmaceuticals

The year 2024 marks the 20th anniversary of Pharmaceuticals – a journal dedicated to medicinal chemistry and related drug sciences, which is published monthly online by MDPI. To honour this milestone, we are reflecting on our past accomplishments and embarking on an exciting new chapter. This celebration is also one of the reasons why we organized the conference Pharmaceuticals 2024. With an Impact Factor of 4.3 and a CiteScore of 6.1, the journal is covered in Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus/SciFinder, and other databases. Pharmaceuticals has published over 6,000 papers from more than 37,000 authors. More than 10,000 reviewers have reviewed for it at least once.

20th Anniversary of Pharmaceuticals: The Video

This video captures the experiences of the conference chairs, honorary guests and committee members of the conference.

 

Thank you to our partnering societies

A special thank-you is due to our partnering societies the Spanish Society Of Medicinal Chemistry (SEQT) and the Spanish Society For Biochemistry And Molecular Biology (SEBBM) for their support of the Pharmaceuticals 2024 conference. I am also pleased to report that we presented two awards, sponsored by the journal Pharmaceuticals, including the Best Presentation Award and the Best Oral Presentation Award, recognizing the contributions of our participants.

Closing Thoughts

Presenting at the 4th Central European Technology Forum

I visited Krakow, Poland in November to participate in the 4th Central European Technology Forum (CETEF’24), which took place on 18 and 19 November.

CETEF is an international conference that has been jointly organized since 2014 by the Polish Chamber of Commerce for Advanced Technologies (IZTECH) and the Polish Federation of Engineering Associations, with the support of the European Parliament and the European Commission, in cooperation with universities, research institutes and the high-tech industry. The 2024 event focused on presentation to advance the European science and technology agenda for 2025–2030.

MDPI participated as a key publishing sponsor. We had an exhibition booth and held two key presentations during the conference. On Monday, I presented MDPI’s vision, purpose, and achievements.

On Tuesday, Dr. Giulia Stefenelli shared how MDPI supports advancements in high technology and energy transition, highlighting our portfolio, services, tools and initiatives for promoting progress and interdisciplinary collaboration.

We received positive feedback from scientists and government representatives in attendance.

A big thank-you goes to our colleagues from the Krakow office for their support in organizing our participation and managing the MDPI booth.

Special thanks are owing to Weronika Gorka-Kumik, Igor Matic, Vincent Di, Agnieszka Rydz, Ksenia Shubenkova, Anna Krakowka and Klaudia Kasprowicz.

Below is a photo with the President of the Polish Chamber of Commerce conference (centre), along with MDPI colleagues Giulia Stefenelli, Weronika Gorka-Kumik, and Igor Matic (left to right).

“This year’s event focused on ideas and proposals to advance the European science and technology agenda for 2025–2030”

Stefan Tochev
Chief Executive Officer
MDPI AG

4 December 2024
685 MDPI Editors Named Highly Cited Researchers in 2024


We extend our heartfelt congratulations to the 685 Editorial Board Members of our journals – from 39 different countries and territories – who have been recognized as Highly Cited Researchers for 2024 by Clarivate. This distinction highlights their exceptional scientific achievements and significant contributions, which transcend academic boundaries to advance global knowledge, sustainability, security, and well-being.

Clarivate's annual Highly Cited Researcher™ list identifies the most influential scientists of the past decade, whose work has had a profound and widespread impact across various scientific and social science disciplines. Their impactful papers rank among the top 1% by citations in one or more of the 21 fields analyzed within the "Essential Science Indicators," marking them as leaders in their respective domains.

"Highly Cited Researchers have demonstrated significant and broad influence in their field(s) of research," according to Clarivate. In 2024, a total of 6,886 Highly Cited Researcher designations were awarded to 6,636 individuals.

The following is a list of MDPI's Editorial Board Members named Highly Cited Researchers in 2024. We congratulate them for their achievement and their contributions to advancing knowledge in their respective fields.


Abate, Antonio
Abbate, Antonio
Aguilera, Ruth V.
Ahmed, Warish
Ahn, Myung-Ju
Ambretti, Simone
Anasori, Babak
Andersson, Dan I.
Annabi, Nasim
Antinori, Spinello
Arbabi, Amir
Ariga, Katsuhiko
Astruc, Didier
Bajpai, Vivek K.
Balaj, Leonora
Balsamo, Gianpaolo
Bando, Yoshio
Banks, William A.
Barnes, Peter J.
Barnholtz-Sloan, Jill S.
Barros, Lillian
Bashir, Ali Kashif
Basit, Abdul W.
Bassetti, Matteo
Batley, Jacqueline
Battino, Maurizio
Benediktsson, Jon Atli
Bjarnsholt, Thomas
Blaschke, Thomas
Blay, Jean-Yves
Blumwald, Eduardo
Blunt, John W.
Bonomo, Robert A.
Bourke, Paula
Boyd, Robert W.
Boyer, Cyrille
Bruyere, Olivier
Bu, Wenbo
Bush, Ashley I.
Byrd, John C.
Cabeza, Luisa F.
Cai, Baoping
Cai, Lei
Cai, Xingjuan
Cambria, Erik
Cao, Guozhong
Cao, Xingzhong
Carvalho, Andre F.
Chan, Jasper Fuk-Woo
Chan, Timothy A.
Chao, Dongliang
Chen, Bin
Chen, Bo
Chen, Chaoji
Chen, Fahu
Chen, Hualan
Chen, Jun
Chen, Kunsong
Chen, Lidong
Chen, Lingxin
Chen, Mou
Chen, Peng
Chen, Qianwang
Chen, Shaowei
Chen, Shuai
Chen, Shuangming
Chen, Xiangyu
Chen, Xiao
Chen, Xiaobo
Chen, Xu
Chen, Yimin
Chen, Yulin
Cheng, Gong
Cheng, Huanyu
Cheng, Laifei
Cheng, Qiang
Chiclana, Francisco
Choi, Wonyong
Choi, Young Hae
Chowdhary, Anuradha
Clevers, Hans
Collins, Maurice N.
Cortes, Javier
Cortes, Jorge
Cottin, Vincent
Creutzig, Felix
Crommie, Michael F.
Cuadrado, Antonio
Cui, Yi
Dai, Hongjie
Dai, Shifeng
Daiber, Andreas
Davis, Steven J.
Davis, Thomas P.
Dawson, Ted M.
de Vries, Rory D.
de Vries, Wim
Deng, Xiangzheng
Desneux, Nicolas
Ding, Aijun
Ding, Jianxun
Dokmeci, Mehmet Remzi
Dolgui, Alexandre
Dou, Shi Xue
Dragicevic, Tomislav
Du, Bo
Du, Qian
Du, Yonghua
Duan, Xidong
Dufresne, Alain
Dummer, Reinhard
Ebi, Kristie L.
Edwards, David
Enjuanes, Luis
Fabbro, Doriano
Facchetti, Antonio
Fan, Junliang
Fan, Kelong
Fan, Xiulin
Fang, Chuanglin
Fang, Jingyun
Fang, Yongjin
Fasano, Alessio
Felser, Claudia
Feng, Xuning
Ferdinandy, Péter
Filippi, Massimo
Flavian, Carlos
Fortino, Giancarlo
Fowler, Michael
Franceschi, Claudio
Fu, Gengtao
Fu, Yongshuo
Fujita, Hamido
Gagaoua, Mohammed
Gai, Francesco
Gaisford, Simon
Galano, Annia
Galluzzi, Lorenzo
Galvano, Fabio
Gao, Huijun
Gao, Huile
Gao, Junkuo
Gao, Peng
Garbe, Claus
Garcia, Hermenegildo
Gasbarrini, Antonio
Genevet, Patrice
Geng, Yong
Gerdts, Gunnar
Geschwind, Daniel H.
Ghaffari, Roozbeh
Ghamisi, Pedram
Giampieri, Francesca
Gobbetti, Marco
Godos, Justyna
Gogotsi, Yury
Golding, Nick
Gong, Jinlong
Gong, Peng
Gotor, Cecilia
Govindan, Kannan
Grancini, Giulia
Grant, William B.
Graus, Francesc
Green, Douglas R.
Greenberg, Dan
Grigoriev, Igor
Grosso, Giuseppe
Gu, Zhanjun
Guan, Cao
Gueimonde, Miguel
Gui, Guan
Guo, Hengyu
Guo, Jianping
Guo, Jinghua
Guo, Song
Guo, Zaiping
Gutzmer, Ralf
Győrffy, Balázs
Haase, Dagmar
Hagger, Martin S.
Han, Buxing
Han, Fudong
Han, Heesup
Hanes, Justin
Hao, Junnan
He, Bao-Jie
He, Chi
He, Debiao
He, Hongwen
He, Jiaqing
He, Jr-Hau
He, Ping
He, Xiangming
He, Xijun
He, Zhili
Heinrich, Michael
Heneka, Michael Thomas
Henry, Brandon Michael
Herrera, Francisco
Herrera-Estrella, Luis
Hilal, Nidal
Hong, Danfeng
Hossain, Ekram
Hu, Enyuan
Hu, Jin-Song
Hu, Wenbin
Hu, Xiaosong
Huang, Bo
Huang, Haitao
Huang, Hongwei
Huang, Jianping
Huang, Qing
Huang, Yan
Huang, Yu
Hubacek, Klaus
Hwang, Jinsoo
Italiano, Antoine
Iwata, Hiroji
Izzo, Angelo A.
Jaiswal, Amit K.
Jankovic, Joseph
Jelezko, Fedor
Jeon, Byong-Hun
Ji, Jian
Ji, Xiaobo
Ji, Xiaoyuan
Jiang, Lei

Jiang, Lianzhou
Jiang, Shibo
Jiang, Yuji
Jiang, Yuyan
Jiang, Zhongyi
Jiao, Licheng
Jin, Hailing
Jin, Yuanxiang
Jin, Zhengyu
Jin, Zhong
Jing, Qingshen
Kalantar-zadeh, Kourosh
Kamal, Mohammad Amjad
Kaneti, Yusuf Valentino
Kang, Xudong
Kang, Zhenhui
Karagiannidis, George K.
Karki, Rajendra
Karniadakis, George Em
Kataoka, Kazunori
Katritch, Vsevolod
Kawi, Sibudjing
Kepp, Oliver
Khademhosseini, Ali
Kiessling, Fabian
Kim, Jong Seung
Kim, Jong-Hoon
Kim, Sung-Bae
Kim, Sunghwan
Kirkwood, John M.
Kivshar, Yuri
Klein, Christian
Klenk, Hans-Peter
Koh, Lenny
Kong, Baohua
Krause, Robert
Kroemer, Guido
Kudo, Masatoshi
Kumar, Anil
Kumar, Prashant
Kumar, Sudhir
Kurths, Juergen
Kurzrock, Razelle
Kyrpides, Nikos C.
La Vecchia, Carlo
Lam, Tommy Tsan-Yuk
Lan, Ke
Lancellotti, Patrizio
Landi, Francesco
Landi, Marco
Lavie, Carl J.
Lee, Chengkuo
Lee, Jin-Wook
Lee, Pooi See
Lehmann, Johannes
Lei, Yaguo
Li, Bing
Li, Chunzhong
Li, Dawei
Li, Dongfang
Li, Dongsheng
Li, Jingchao
Li, Jing-Feng
Li, Jinghong
Li, Linlin
Li, Meng
Li, Neng
Li, Ning
Li, Shutao
Li, Xiang
Li, Xuecao
Li, Yaping
Li, Yat
Li, Yong
Li, Yonghui
Li, Yurui
Liang, Hanfeng
Liang, Shuquan
Lin, Jun
Lin, Yi
Lin, Yuehe
Lippi, Giuseppe
Liu, Chengmei
Liu, Feng
Liu, Hong
Liu, Hongyu
Liu, Jian-Kui (Jack)
Liu, Meilin
Liu, Min
Liu, Shujuan
Liu, Xianhu
Liu, Xiaoping
Liu, Xuejun
Liu, Yu
Loh, Xian Jun
Long, Guankui
Long, Hualou
Long, Ying
Lu, Jianquan
Lu, Junling
Lu, Nanshu
Lu, Shun
Lu, Yingying
Lugato, Emanuele
Lund, Henrik
Luo, Jie
Luo, Jingshan
Luo, Yangchao
Luo, Zisheng
Lutolf, Matthias P.
Lv, Wei
Lyons, Timothy W.
Ma, Chao
Ma, Tianyi
Ma, Yanming
Mahmood, Nasir
Mahmoudi, Morteza
Mandalà, Mario
Mao, Jianfeng
Mao, Like
Martin-Belloso, Olga
Martinez, Luis
Mateos, Maria Victoria
Mathiesen, Brian Vad
Matyjaszewski, Krzysztof
McCauley, Darren
Mei, Lin
Melenhorst, Jan Joseph
Melero, Ignacio
Meyerholz, David K.
Miao, Song
Miroshnichenko, Andrey E.
Mittler, Ron
Montagne, Axel
Moreau, Philippe
Mu, Shichun
Muhammad, Khan
Mulligan, Mark J.
Mumtaz, Shahid
Nauen, Ralf
Nemeroff, Charles B.
Niaura, Raymond S.
Nussinov, Ruth
Oganov, Artem R.
Oh, Deog Hwan
O'Reilly, Eileen M.
Ouyang, Minggao
Ozcan, Aydogan
Pacher, Pal
Pan, Anlian
Pan, Anqiang
Pan, Caofeng
Pan, Genxing
Pan, Xiaoqing
Parati, Gianfranco
Peng, Qiang
Peng, Qing
Peng, Shushi
Perlin, David S.
Perlman, Stanley
Petruzzelli, Antonio Messeni
Peyrin-Biroulet, Laurent
Pitt, Bertram
Pöhlmann, Stefan
Polasky, Stephen
Pommier, Yves
Poor, H. Vincent
Portincasa, Piero
Potenza, Marc N.
Prinsep, Michele R.
Pu, Hongbin
Pu, Kanyi
Putnik, Predrag
Qi, Jianping
Qiang, Yujie
Qin, Yuanwei
Qiu, Jieshan
Qu, Xiaogang
Ragauskas, Arthur J.
Ramkissoon, Haywantee
Ran, Jingrun
Rao, Zhonghao
Ren, Jinsong
Rengel, Zed
Rezania, Shahabaldin
Rho, Junsuk
Riahi, Keywan
Ribeiro-Soriano, Domingo
Richardson, Paul G.
Rignot, Eric
Robert, Caroline
Rocca, Maria A.
Rodriguez-Manas, Leocadio
Rojas, Orlando J.
Rojo, Teofilo
Rossolini, Gian Maria
Saad, Walid
Saif, Linda J.
Saliba, Michael
Sander, Chris
Saso, Luciano
Scaldaferri, Franco
Schafer, Alexandra
Schatzberg, Alan F.
Schwab, Matthias
Scolyer, Richard A.
Scorrano, Luca
Scott, Stuart A.
Serruys, Patrick W.
Shao, Minhua
Shao, Shuai
Shao, Zongping
Shen, Guozhen
Shen, Liyin
Shen, Zexiang
Shi, Kai
Shi, Pei-Yong
Shi, Peng
Shi, Yi
Shin, Hyeon Suk
Shin, Su Ryon
Siano, Pierluigi
Simões, Manuel
Simpson, Richard J.
Sing, Swee Leong
Singh, Vijay P.
Skouta, Rachid
Smagghe, Guy

Song, Jibin
Song, Yanlin
Sood, Anil K.
Souto, Eliana B.
Speiser, Daniel E.
Stadler, Marc
Stephanopoulos, Gregory
Sternberg, Cora N.
Stoumpos, Constantinos C.
Su, Chao
Su, Dong
Sun, Cuixia
Sun, Fengchun
Sun, Guangyong
Sun, Jian
Sun, Litao
Sun, Xian
Sun, Zaicheng
Sun, Zhipei
Sureda, Antoni
Svenning, Jens-Christian
Tan, Chaoliang
Tang, Ben Zhong
Tang, Chuan-He
Tang, Chuyang
Tang, Dianping
Tang, Yawen
Tang, Yongbing
Tanzi, Rudolph E.
Tao, Yang
Teichmann, Sarah
Telenti, Amalio
Tian, He
Tian, He
Timsit, Jean-Francois
Tohge, Takayuki
Tran, Lam-Son Phan
Tress, Wolfgang
Trivedi, Pankaj
Tsao, Rong
Tsuda, Kenichi
Tukker, Arnold
Tung, Chen-Ho
van der Werf, Guido
Van Mierlo, Joeri
Vandenbroucke, Roosmarijn E.
Varsani, Arvind
Vatanen, Tommi
Verbeke, Kristin
Verpoorte, Robert
Vieta, Eduard
Vincent, Jean-Louis
Vinu, Ajayan
Vita, Antonio
Wagner, Wolfgang
Walters, William
Wan, Jiafu
Wanek, Wolfgang
Wang, Chunsheng
Wang, Dawei
Wang, Dongdong
Wang, Fang
Wang, Fayuan
Wang, Gongming
Wang, Guoxiu
Wang, Haihui
Wang, Huanting
Wang, John
Wang, Joseph
Wang, Lianzhou
Wang, Lihui
Wang, Qi
Wang, Qingsong
Wang, Rui
Wang, Shaojian
Wang, Sibo
Wang, Tao
Wang, Wenguan
Wang, Yanbo
Wang, Yong
Wang, Yonghong
Wang, Yu
Wang, Zhiyu
Wang, Zhong Lin
Wang, Zhongrui
Wang, Zifa
Wang, Ziyun
Wang, Zuankai
Wedzicha, Jadwiga
Wei, Haotong
Wei, Leyi
Wei, Mingyang
Wei, Zhixiang
Wei, Zhongbao
Weiskirchen, Ralf
Weissleder, Ralph
Wen, Guanghui
Wenwu, Yu
Wesemael, Bas van
Witlox, Frank
Wu, Di
Wu, Haijun
Wu, Hao
Wu, Hao Bin
Wu, Jianzhong
Wu, Lifeng
Wu, Qinglin
Wu, Shuilin
Wu, Tom
Wu, Yongning
Wu, Yongzhen
Wu, Yuping
Wu, Zheng-Guang
Wu, Zhong-Shuai
Xia, Jianguo (Jeff)
Xia, Xinhui
Xia, Xiufang
Xia, Yongyao
Xia, Zhiguo
Xiang, Quanjun
Xin, Sen
Xing, Wei
Xiong, Rui
Xu, Jianping
Xu, Li Da
Xu, Ping
Xu, Wu
Xu, Xiaomin
Xu, Xiaopeng
Xu, Zhenjiang Zech
Yan, Chong
Yan, Jun
Yan, Qingyu
Yang, Chenguang
Yang, Hongshun
Yang, Jianping
Yang, Shihe
Yang, Wei
Yang, Xin-She
Yang, Xinsong
Yang, Yongqing
Yang, Yun-Gui
Yao, Yonggang
Ye, Jun
Yin, Shen
Yin, Shou-Wei
Yin, Yulong
Yin, Zongyou
Yokoya, Naoto
Young, Allan H.
Yu, Bin
Yu, Guihua
Yu, Minghao
Yu, Shu-Hong
Yuan, Qiangqiang
Yuan, Yifei
Yue, Dong
Yue, Wenze
Zeadally, Sherali
Zeng, Xiaoxiong
Zhai, Guangtao
Zhai, Tianyou
Zhang, Anna Jinxia
Zhang, Bin
Zhang, Fang
Zhang, Fucang
Zhang, Fusuo
Zhang, Guangyu
Zhang, Guoqing
Zhang, Hengjie
Zhang, Jian
Zhang, Kai
Zhang, Lefei
Zhang, Liangpei
Zhang, Linqi
Zhang, Qiaobao
Zhang, Shanqing
Zhang, Shaoqing
Zhang, Shujun
Zhang, Tierui
Zhang, Wenjun
Zhang, Xian-Ming
Zhang, Xiaodong
Zhang, Xiaoling
Zhang, Yi-Zhou
Zhang, Yong-Wei
Zhang, Yu Shrike
Zhang, Yu-Dong
Zhang, Yue-Jun
Zhang, Yuelin
Zhang, Zhien
Zhao, Biao
Zhao, Guochun
Zhao, Jie
Zhao, Kangning
Zhao, Li-Dong
Zhao, Qing
Zhao, Yi
Zhavoronkov, Alex
Zheng, Hao
Zheng, Weitao
Zheng, Yufeng
Zhong, Cheng
Zhong, Yanfei
Zhou, Di
Zhou, Feng
Zhou, Jizhong
Zhou, Kun
Zhou, Lei
Zhou, Liang
Zhou, Peng
Zhou, Weijia
Zhou, Weiqi
Zhou, Yanhong
Zhou, Yuyu
Zhou, Zhigang
Zhu, Chengzhou
Zhu, Hongwei
Zhu, Junfa
Zhu, Jun-Jie
Zhu, Yongfa
Zhu, Zhe
Zhuang, Xiaodong
Zipfel, Stephan
Zou, Guoqiang
Zou, Ruqiang
Zoulim, Fabien
Zuo, Chao

21 November 2024
Current Oncology | National Stomach Cancer Awareness Month

National Stomach Cancer Awareness Month in November aims to increase public knowledge, support those affected, and encourage research toward more effective treatments and early diagnosis. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings in the related fields, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field.

Laparoscopic vs. Open Gastrectomy for Locally Advanced Gastric Cancer: A Propensity Score-Matched Retrospective Case-Control Study
by Stefano Caruso, Rosina Giudicissi, Martina Mariatti, Stefano Cantafio, Gian Matteo Paroli and Marco Scatizzi
Curr. Oncol. 202229(3), 1840-1865; https://doi.org/10.3390/curroncol29030151

Laparoscopic versus Open Total Gastrectomy for Locally Advanced Gastric Cancer: Short and Long-Term Results
by Sara Di Carlo, Leandro Siragusa, Alessia Fassari, Enrico Fiori, Francesca La Rovere, Paolo Izzo, Valeria Usai, Giuseppe Cavallaro, Marzia Franceschilli, Sirvjo Dhimolea et al.
Curr. Oncol. 202229(11), 8442-8455; https://doi.org/10.3390/curroncol29110665

A Case Series of Metastatic Malignant Gastrointestinal Neuroectodermal Tumors and Comprehensive Genomic Profiling Analysis of 20 Cases
by Taylor Kandler, Eliane Cortez, Lani Clinton, Amanda Hemmerich, Osama Ahmed, Ralph Wong, Taylor Forns, Andrea J. MacNeill, Trevor D. Hamilton, Mohammadali Khorasani et al.
Curr. Oncol. 202229(2), 1279-1297; https://doi.org/10.3390/curroncol29020109

Circulating Tumor DNA in Gastric and Gastroesophageal Junction Cancer
by Lisa Paschold and Mascha Binder
Curr. Oncol. 202229(3), 1430-1441; https://doi.org/10.3390/curroncol29030120

Endoscopic Treatment of Superficial Gastric Cancer: Present Status and Future
by Hiroyuki Hisada, Yoshiki Sakaguchi, Kaori Oshio, Satoru Mizutani, Hideki Nakagawa, Junichi Sato, Dai Kubota, Miho Obata, Rina Cho, Sayaka Nagao et al.
Curr. Oncol. 202229(7), 4678-4688; https://doi.org/10.3390/curroncol29070371

Extended Lymphadenectomy for Gastric Cancer in the Neoadjuvant Era: Current Status, Clinical Implications and Contentious Issues
by Luigi Marano, Ludovico Carbone, Gianmario Edoardo Poto, Valeria Restaino, Stefania Angela Piccioni, Luigi Verre, Franco Roviello and Daniele Marrelli
Curr. Oncol. 202330(1), 875-896; https://doi.org/10.3390/curroncol30010067

High-LET-Radiation-Induced Persistent DNA Damage Response Signaling and Gastrointestinal Cancer Development
by Kamendra Kumar, Santosh Kumar, Kamal Datta, Albert J. Fornace, Jr. and Shubhankar Suman
Curr. Oncol. 202330(6), 5497-5514; https://doi.org/10.3390/curroncol30060416

Feasibility of Implementation and the Impact of a Digital Prehabilitation Service in Patients Undergoing Treatment for Oesophago-Gastric Cancer
by Krishna Moorthy, Laura J. Halliday, Nigel Noor, Christopher J. Peters, Venetia Wynter-Blyth and Catherine E. Urch
Curr. Oncol. 202330(2), 1673-1682; https://doi.org/10.3390/curroncol30020128

Precision Oncology in Gastrointestinal Stromal Tumors
by Hiba Mechahougui, Montemurro Michael and Alex Friedlaender
Curr. Oncol. 202330(5), 4648-4662; https://doi.org/10.3390/curroncol30050351

Relevant Special Issues:
Combination Therapy in Gastrointestinal Cancers
Guest Editor: Dr. Hiroyuki Uetake

Immunotherapy for Gastrointestinal Cancer
Guest Editor: Dr. Patrick M. Boland

Gastrointestinal Cancer Imaging
Guest Editor: Prof. Dr. Timm Denecke

You are welcome to submit relevant papers to the journal Current Oncology. For any questions, please feel free to contact us.

Current Oncology Editorial Office

21 November 2024
Current Oncology | National Pancreatic Cancer Awareness Month


November is National Pancreatic Cancer Awareness Month, dedicated to raising awareness, supporting patients, and advancing research for better diagnosis and treatments. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings in the related fields, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field.

Pain Relief after Stereotactic Radiotherapy of Pancreatic Adenocarcinoma: An Updated Systematic Review
by Milly Buwenge, Alessandra Arcelli, Francesco Cellini, Francesco Deodato, Gabriella Macchia, Savino Cilla, Erika Galietta, Lidia Strigari, Claudio Malizia, Silvia Cammelli et al.
Curr. Oncol. 2022, 29(4), 2616-2629; https://doi.org/10.3390/curroncol29040214

Implication of ERBB2 as a Predictive Tool for Survival in Patients with Pancreatic Cancer in Histological Studies
by Miguel A. Ortega, Leonel Pekarek, Oscar Fraile-Martinez, Cielo Garcia-Montero, Miguel A. Saez, Angel Asúnsolo, Miguel A. Alvarez-Mon, Jorge Monserrat, Lidia Ruiz-Llorente, Natalio García-Honduvilla et al.
Curr. Oncol. 2022, 29(4), 2442-2453; https://doi.org/10.3390/curroncol29040198

Prognostic Impact of Resection Margin Status on Distal Pancreatectomy for Ductal Adenocarcinoma
by Maia Blomhoff Holm and Caroline Sophie Verbeke
Curr. Oncol. 2022, 29(9), 6551-6563; https://doi.org/10.3390/curroncol29090515

Preoperative C-Reactive Protein-to-Albumin Ratio Predicts Postoperative Pancreatic Fistula following Pancreatoduodenectomy: A Single-Center, Retrospective Study
by Naotake Funamizu, Takeshi Utsunomiya, Masahiko Honjo, Chihiro Ito, Mikiya Shine, Mio Uraoka, Tomoyuki Nagaoka, Kei Tamura, Katsunori Sakamoto, Kohei Ogawa et al.
Curr. Oncol. 2022, 29(12), 9867-9874; https://doi.org/10.3390/curroncol29120775

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
by Rita Balsano, Valentina Zanuso, Angelo Pirozzi, Lorenza Rimassa and Silvia Bozzarelli
Curr. Oncol. 2023, 30(4), 3871-3885; https://doi.org/10.3390/curroncol30040293

An Overview of Pancreatic Neuroendocrine Tumors and an Update on Endoscopic Techniques for Their Management
by Osama O. Elkelany, Fred G. Karaisz, Benjamin Davies and Somashekar G. Krishna
Curr. Oncol. 2023, 30(8), 7566-7580; https://doi.org/10.3390/curroncol30080549

Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma—A Critical Review of Randomised Trials
by Mathilde Weisz Ejlsmark, Tine Schytte, Uffe Bernchou, Rana Bahij, Britta Weber, Michael Bau Mortensen and Per Pfeiffer
Curr. Oncol. 2023, 30(7), 6820-6837; https://doi.org/10.3390/curroncol30070499

Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms
by Jasmeet Kaur and Namrata Vijayvergia
Curr. Oncol. 2023, 30(9), 8653-8664; https://doi.org/10.3390/curroncol30090627

You are welcome to submit relevant papers to the journal Current Oncology. For any questions, please feel free to contact us.

Current Oncology Editorial Office

5 November 2024
MDPI INSIGHTS: The CEO's Letter #17 - OA Week, Basel Open Day, Beijing Graphene Forum

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

Open Access Week: Forging the Future of Open Access through Global Reach and Collaboration

From 21 to 27 October, we celebrated International Open Access Week (OAW), highlighting the importance of making research accessible to everyone. This campaign reinforced our commitment to advancing open access (OA) and showcased how we are helping research communities worldwide adopt OA as their standard.

 

“OA publishing is now a cornerstone of global research”

Throughout the week, we featured MDPI’s efforts to support quality open research through blog posts on topics such as how Research Integrity Promotes OA Practices, our Preprints.org platform, and supporting societies with different OA models. These initiatives capture our commitment to making research more inclusive and accessible to all.

OA publishing is now a cornerstone of global research, with more researchers choosing OA over traditional paywalled models, and embracing new, community-driven models.

Benefits of Open Access and Open Research

  • Accelerated Discoveries: OA speeds up scientific progress by allowing immediate access to findings, enabling researchers to build on each other’s work faster.
  • Community-Led Innovation: Open research empowers communities to manage their own platforms, creating collaboration and shared knowledge.
  • Increased Visibility: OA broadens the reach of your research, leading to greater recognition, collaboration, and impact.
  • Cross-Disciplinary Connections: By removing financial and geographical barriers, OA unites diverse fields, sparking innovation across disciplines.

MDPI Singapore Celebrates Open Access Week

MDPI Singapore also hosted its first-ever OAW event at the Marina Bay Sands Convention Centre, bringing together academics, researchers, and students to discuss the future of open scholarship. Conversations focused on the potential of new publishing models, alternative funding strategies, and the importance of communicating research to wider audiences.

As OA evolves, MDPI remains a committed partner in advancing open science and creating a transparent, inclusive research environment. For a full recap of the week’s highlights and resources, visit our campaign page.

Impactful Research

MDPI Connection to Nobel-Winning Protein Research

David Baker, an American biochemist, and Demis Hassabis and John M. Jumper, two scientists from Google DeepMind, have been awarded the 2024 Nobel Prize in Chemistry for their groundbreaking advancements in better understanding the structure of proteins, the molecular engines of life’s processes.

One half of the prize was awarded to Professor David Baker from the University of Washington for his development of revolutionary protein design software enabling the creation of novel proteins for vaccines, nanomaterials, and sensors. Prof. Baker co-authored a 2016 paper in MDPI’s Toxins journal on protein-based therapeutics.

Meanwhile, DeepMind’s Demis Hassabis and John M. Jumper received recognition for AlphaFold, the AI model that predicts protein structures from amino acid sequences, fulfilling a long-held scientific dream.

“We congratulate this year’s Nobel laureates for their groundbreaking contributions to the study of life”

 Nobel Prize Laureates Entrust MDPI with Their Research

As at October 2024, 45 Nobel laureates had contributed to more than 115 articles across

35 MDPI journals. The privilege of hosting the research of such contributors, who significantly influence the open access movement, resonates deeply with our editorial teams.

We are proud to list the names of Pierre Agostini, Hiroshi Amano, Werner Arber, Aaron Ciechanover, Robert H. Grubbs, Oliver Hart, Gerard ‘t Hooft, Michael Houghton, Harald zur Hausen, Katalin Karikó, Jean-Marie Lehn, Gérard Mourou, Ferid Murad, Shuji Nakamura, William Nordhaus, Kostya S. Novoselov, Giorgio Parisi, Charles M. Rice, Alvin E. Roth, Donna Strickland, K. Barry Sharpless, George F. Smoot, Anne L’Huillier, Drew Weissman, Kurt Wüthrich, Ada Yonath, Tomas Lindahl, Thomas C. Südhof, Stanley B. Prusiner, Roger Kornberg, Robert F. Engle, Richard J. Roberts, Ōmura Satoshi, Kenneth J. Arrow, John B. Goodenough, Jennifer Doudna, Hamilton Othanel Smith, Eric R. Kandel, Carlo Rubbia, Bernard Feringa, Barry J. Marshall, Anthony J. Leggett, Andrew Victor Schally, and David Baker.

Notable MRNA Published in Cells

On 7 October 2024, the 2024 Nobel Prize in Physiology or Medicine was jointly awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation.

MicroRNAs are proving to be fundamentally important for how organisms develop and function. Some interesting papers about microRNA research are published in the MDPI journal Cells. I invite you browse through the notable papers related to microRNA research in Cells.

Inside MDPI

Basel Open Day

On 21 October, we held the Basel Open Day at our headquarters, welcoming a group of journal Editors-in-Chief (EiC) and Editorial Board Members (EBMs) for a full-day workshop. The event featured presentations and discussions on MDPI’s latest editorial updates, data integrity policies, society collaborations, and local market insights.

The following MDPI journals were represented during the visit: Physics, Journal of Personalized Medicine (JPM), Sci, Remote Sensing, Animals, Cells, Buildings, Histories, Sensors, and International Journal of Environmental Research and Public Health (IJERPH).

This was a great opportunity to showcase our new office space while gathering feedback from leading journal stakeholders. To get everyone on the same page, we took 60 minutes for round-table introductions, which helped set a collaborative tone and ground us in MDPI’s mission of disseminating open science.

“This was a great opportunity to gather feedback from leading journal stakeholders”

The general feedback from the day highlighted positive developments around our editorial and ethics policies, as well as areas for improvement, including flexibility regarding reviewer deadlines. There was a genuine appreciation and push for our ongoing efforts to share more about MDPI, including company updates and promoting high-quality research through our blog, announcements, and social media channels, which we have been growing and expanding.

Our Basel Open Day was a positive experience, bringing together key journal stakeholders and gathering insights to guide MDPI’s continued engagement with the academic community. We look forward to hosting future events of this kind and welcoming more scholars to our headquarters in Basel, Switzerland.

Coming Together for Science

ncRNA 2024 Conference in Basel

I am pleased to share that we held Non-coding RNA World 2024: Exploring Mechanisms, Designing Medicines (ICM 2024) in Basel, Switzerland this past 7–9 October.

The three-day event attracted just over 100 attendees, including two Chairs, 10 invited speakers and two keynotes from Prof. Mauro Giacca and Prof. Ling-Ling Chen. Of the presentations on site, there were 35 posters and 44 oral presentations.

The overall feedback was positive, with people enjoying the intimate event and the unique activities offered, including a guided tour around Basel’s Old Town (a must-see for anyone visiting the city) and a memorable conference dinner.

It was cool to see the winners of the 2024 Nobel Prize in Physiology or Medicine announced during the conference days. This was exciting for attendees, as the winners discovered a new class of RNA molecules (miRNAs). As one invited speaker put it, “It's exciting to be among fellows when something that important for the field is announced.”

“It's exciting to be among fellows when something that important for the field is announced”

Every attendee receives a conference survey, and I’m always pleased to see a high percentage of ‘Very Satisfied’ responses when asked about ‘treatment from conference personnel’. Kudos to our conference team for meeting our attendees’ needs. These events are a great opportunity for us to reach new audiences, as 92% of the respondents had never been to an MDPI conference, so I am thrilled to see us connecting with a new demographic of your researchers in the RNA field.

A special thank-you to our partnering societies The Epigenetics Society, The French Society of Genetics, LS2 / USGEB (Union of Swiss Societies for Experimental Biology), and The RNA Biology Group, as well as to our sponsors New England Biolabs and Arraystar for their support of the ncRNA 2024 conference. I am also pleased to report that we presented two awards, including the Best Presentation Award and two Best Poster Award, recognizing the contributions of our participants.

Upcoming In-Person Event

27–29 November 2024
Pharmaceuticals 2024 – Recent Advances in Pharmaceutical Sciences Towards a Healthy Life
Location: Barcelona, Spain

The discovery of new molecules, their properties, and actions to enhance human health and quality of life.

Find more upcoming MDPI events here.

Closing Thoughts

Beijing Graphene Forum 2024

I am pleased to share that we had a successful time at the Beijing Graphene Forum 2024, which drew around 1,000 attendees, including Konstantin Novoselov (2015 Nobel Prize in Physics) and other high-profile scholars in materials science and chemistry. It was a great opportunity to present MDPI on the big stage, with university presidents from institutions such as Peking University also in attendance.

I had the honour of awarding Prof. Zhongfan Liu, Chairman of the Chemical Science Committee, with a medal and presenting certificates to the members of the Chemical Science Committee; this is an important initiative to help expand MDPI’s journals and influence in China. These are highly respected scholars, and we enjoyed connecting with them over lunch as well.

“This is an important initiative to help expand MDPI’s journals and influence in China”

I also had the chance to speak about MDPI and open access, giving a five-minute speech during the opening ceremony and a 20-minute presentation at the close. MDPI hosted a sub-forum where both academic scholars and MDPI members shared insights, and we engaged with attendees at our MDPI booth.

This was a great opportunity to spotlight MDPI as the main publishing partner for the event, and I was proud to represent us on stage. We also met with scholars to discuss topics such as their publishing needs and institutional policies, open access, impact journals, and IOAP.

Stefan Tochev
Chief Executive Officer
MDPI AG

25 October 2024
Current Oncology | National Breast Cancer Awareness Month


National Breast Cancer Awareness Month is an annual campaign that takes place in October to increase awareness of this disease. It aims to promote early detection, education, and support for those affected by breast cancer. We would like to take this opportunity to express our gratitude to all the researchers who have contributed to this field. In particular, we would like to share some innovative research findings in related fields, published in Current Oncology (ISSN: 1718-7729). We hope that this announcement will provide some useful information for this field.

Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer
by Valentina K. Todorova, Stephanie D. Byrum, Allen J. Gies, Cade Haynie, Hunter Smith, Nathan S. Reyna and Issam Makhoul
Curr. Oncol. 2022, 29(2), 613-630; https://doi.org/10.3390/curroncol29020055

Applying Deep Learning for Breast Cancer Detection in Radiology
by Ella Mahoro and Moulay A. Akhloufi
Curr. Oncol. 2022, 29(2), 613-630; https://doi.org/10.3390/curroncol29020055

Prevalence and Persistence of Anxiety and Depression over Five Years since Breast Cancer Diagnosis—The NEON-BC Prospective Study
by Catarina Lopes, Luisa Lopes-Conceição, Filipa Fontes, Augusto Ferreira, Susana Pereira, Nuno Lunet and Natália Araújo
Curr. Oncol. 2022, 29(3), 2141-2153; https://doi.org/10.3390/curroncol29030173

Radiomic and Artificial Intelligence Analysis with Textural Metrics Extracted by Contrast-Enhanced Mammography and Dynamic Contrast Magnetic Resonance Imaging to Detect Breast Malignant Lesions
by Roberta Fusco, Elio Di Bernardo, Adele Piccirillo, Maria Rosaria Rubulotta, Teresa Petrosino, Maria Luisa Barretta, Mauro Mattace Raso, Paolo Vallone, Concetta Raiano, Raimondo Di Giacomo et al.
Curr. Oncol. 2022, 29(3), 1947-1966; https://doi.org/10.3390/curroncol29030159

Patient-Reported Experiences of Breast Cancer Screening, Diagnosis, and Treatment Delay, and Telemedicine Adoption during COVID-19
by Simo Du, Laura Carfang, Emily Restrepo, Christine Benjamin, Mara M. Epstein, Ricki Fairley, Laura Roudebush, Crystal Hertz, Leah Eshraghi and Erica T. Warner
Curr. Oncol. 2022, 29(8), 5919-5932; https://doi.org/10.3390/curroncol29080467

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
by Roberta Rosso, Marta D’Alonzo, Valentina Elisabetta Bounous, Silvia Actis, Isabella Cipullo, Elena Salerno and Nicoletta Biglia
Curr. Oncol. 2023, 30(2), 1461-1472; https://doi.org/10.3390/curroncol30020112

Obesity and Breast Cancer: Interaction or Interference with the Response to Therapy?
by Silvia Riondino, Vincenzo Formica, Elena Valenzi, Cristina Morelli, Valeria Flaminio, Ilaria Portarena, Francesco Torino and Mario Roselli
Curr. Oncol. 2023, 30(1), 1220-1231; https://doi.org/10.3390/curroncol30010094

Machine Learning Approaches with Textural Features to Calculate Breast Density on Mammography
by Mario Sansone, Roberta Fusco, Francesca Grassi, Gianluca Gatta, Maria Paola Belfiore, Francesca Angelone, Carlo Ricciardi, Alfonso Maria Ponsiglione, Francesco Amato, Roberta Galdiero et al.
Curr. Oncol. 2023, 30(1), 839-853; https://doi.org/10.3390/curroncol30010064

Relevant Special Issues:

Breast Cancer Imaging and Therapy
Guest Editor: Prof. Dr. Jean Seely

Breast Cancer: A Multi-Disciplinary Approach from Imaging to Therapy
Guest Editor: Dr. Daniele Ugo Tari

Radiation Therapy for Breast Cancer: Current Status and Future Perspectives
Guest Editors: Dr. Benjamin W. Corn, Dr. Shira L. Galper and Prof. Dr. Merav A. Ben-David

Advances in Surgical Treatment of Breast Cancer
Guest Editors: Dr. Rona Cheifetz and Dr. Elaine McKevitt

You are welcome to submit relevant papers to the Current Oncology journal. For any questions, feel free to contact us.

Current Oncology Editorial Office

22 October 2024
Meet Us at the 2024 International Kidney Cancer Symposium: North America, 7–9 November 2024, Louisville, KY, USA


The 2024 International Kidney Cancer Symposium: North America will be held from 7 to 9 November 2024, in Louisville, KY, USA. The conference is organized by the Kidney Cancer Association.

IKCS meetings are dynamic, multidisciplinary events that explore current trends and future directions in kidney cancer. Their community includes leading experts across academia, clinical care, industry, and advocacy who are committed to exchanging innovative ideas and pushing boundaries to advance kidney cancer care.

The following MDPI journals will be represented:

If you are participating in this conference, please feel free to engage with us online prior to attendance. Our delegates look forward to meeting you in person at booth #7 and answering any questions you may have.

For more information regarding the conference, please visit the following link: https://www.kidneycancer.org/ikcs/2024-ikcs-north-america.

16 October 2024
MDPI's Newly Launched Journals in September 2024

Five new journals covering a diverse range of subjects launched their inaugural issue in September 2024. Like other journals in MDPI’s portfolio, these journals are dedicated to sharing the latest research through open access, reflecting our commitment to making knowledge accessible to all.

We extend our sincere gratitude to the Editorial Board Members for their dedication to the launch and development of our new journals. Each journal will ensure its high-quality output via excellent editorial and rigorous peer-review processes so that the published articles achieve significant impact and broad visibility.

We invite you to explore and learn more about these new journals below.

Journal Founding Editor-in-Chief Journal Topics (Selected)
Prof. Dr. Nejat Düzgüneş, University of the Pacific, USA | Editorial | view inaugural issue biological therapy and stem-cell therapy; drug therapy; chemotherapy; radiation and other nonsurgical therapeutic strategies | view journal scope | submit an article
Prof. Dr. Magda Tsolaki, Greek Federation of Alzheimer’s Disease, Greece; Aristotle University of Thessaloniki, Greece | Editorial | view inaugural issue surgical/procedural complications; complications; perioperative adverse events; postoperative adverse events | view journal scope | submit an article
Prof. Dr. Steven R. Fassnacht, Colorado State University, USA; Cooperative Institute for Research in the Atmosphere, USA | Editorial | view inaugural issue ice as a mineral; atmospheric ice; sea ice; freshwater ice; ice sheets; ice caps and ice shelves | view journal scope | submit an article
Dr. Francisco Epelde, Hospital Universitari Parc Tauli, Spain; University Autonoma of Barcelona, Spain | Editorial | view inaugural issue hospital management; hospital facilities; hospital services; hospital risk management; health law | view journal scope | submit an article
Prof. Dr. Nicola Ferri, University of Padova, Italy | Editorial | view inaugural issue lipids in cells and whole organisms; lipid structure and function; lipid products and processes; dietary lipids and nutrition | view journal scope | submit an article

We wish to thank everyone who has supported the development of open access publishing. You are welcome to send an application here or contact the New Journal Committee ([email protected]) if you would like to create more new journals.

4 October 2024
MDPI INSIGHTS: The CEO's Letter #16 - UNGA79 Science Summit, OASPA, Peer Review Week

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

MDPI Joins the Science Summit at UNGA79 (23–27 September 2024, New York)

On Friday 27 September, I had the privilege of giving the opening talk at the “Youth at the Science Summit” panel during the Science Summit conference, held in New York at the 79th session of the United Nations General Assembly (UNGA). Together, we discussed the future of science, publishing, innovation, and sustainable development.

It was a great opportunity to learn from our young leaders, whose voices must be included in the conversation as science shapes the future of artificial intelligence, climate mitigation, healthcare, technology, and more. This was also a powerful reminder of how essential global collaboration is in solving the major challenges we face. I left inspired by the dedication of these young researchers to making the world a better place!

Today’s youth are not just the leaders of tomorrow – they are already leading the change today.

Stefan Tochev (second from left) at the UNGA Science Summit 2024: “A great opportunity to learn from our young leaders.”

MDPI Supports the Future Generation of Scientists

This aligns with MDPI’s mission to support the next generation of scientists and early-career researchers by recognizing their achievements through our various MDPI awards, including the Young Investigator Awards, Best PhD Thesis Awards, Travel Awards, and more.

Our presence at this global event showed our commitment to advancing Open Science as a key driver for sustainable development. As a leading Open Access (OA) publisher, MDPI’s role at the summit was to emphasize the critical importance of democratizing scientific knowledge, making it accessible to all, and promoting global collaboration.

Through OA publishing, we aim to address pressing global challenges such as climate change, public health, and inequality, in line with the United Nations Sustainable Development Goals (SDGs).

“We aim to address pressing global challenges”

MDPI and the SDGs

In 2020, the SDG Publishers Compact was launched to accelerate implementation of the SDGs by promoting content that informs, develops, and inspires action. MDPI joined this initiative in 2021 and subsequently launched the MDPI SDG Hub in 2022, offering free access to recent research within the scope of each of the 17 SDGs.

During the summit, we highlighted the connection between Open Science and the SDG Publishers Compact, supporting the core objective to “Leave No One Behind” (LNOB). The transformative promise of the SDGs relies heavily on the Open Access model, which serves as a fundamental enabler of Open Science. We advocate for the wider adoption of Open Science practices in order to achieve the SDGs by 2030.

Impactful Research

Presenting at the 1st International Conference of Environmental Medicine

In September, MDPI and our journals IJERPH and Diseases sponsored and participated in the 1st International Conference of Environmental Medicine: Environmental Threats to Human Health: From Genetics to Epigenetics, held in Chieti, Italy.

The conference was organized in collaboration with various societies, including the Italian Society of Environmental Medicine (SIMA), one of more than 160 societies partnering MDPI journals.

The conference brought together influential figures from the Italian scholarly community, such as Antonio Felice Uricchio (President of the National Agency for University Research Assessment [ANVUR]), Alessandro Miani (President of SIMA), and Liborio Stuppia (Director of ‘Gabriele d’Annunzio’ University of Chieti-Pescara), among others.

MDPI was the sole publishing sponsor of the conference, at which I had the opportunity to present on behalf of the company. I provided an overview of MDPI, covering key facts and figures, the peer-review process, our strong collaboration with the Italian market, and insights into Nobel Prize winners who have published with MDPI, ahead of Sir Richard Roberts’ Nobel lecture.

“As at September 2024, 44 Nobel laureates have contributed to over 115 articles across 35 MDPI journals”

The keynote speaker at the event was Sir Richard Roberts, Nobel Laureate and 1993 Nobel Prize winner in Medicine, recognized for his discovery of split genes.

Nobel Laureates’ Contributions to MDPI

As at September 2024, 44 Nobel laureates have contributed to over 115 articles across 35 MDPI journals. I’ll share more details on this in the October newsletter.

Hosting such prominent figures in their respective fields, who play a significant role in advancing the OA movement, of which we are leaders in, resonates deeply with our editorial teams.

Sponsoring and supporting academic conferences is something we do on a large scale, and it continues to grow. Attending and speaking about MDPI shows our commitment by taking the time to connect with the scholarly community in person.

MDPI’s Presence in Italy

Italy ranks third globally in total MDPI publications, with nearly 130,000 contributions. We collaborate with about 12,000 Editorial Board Members in Italy, over 6,100 of whom have an H-index of more than 25.

We have 83 Editors-in-Chief and 209 Section Editors-in-Chief from Italy. We also support 20 Italian universities through our Institutional Open Access Program (IOAP) agreements with major institutions such as Sapienza University of Rome, the University of Milan, and the University of Pisa, among others.

Inside MDPI

Celebrating Peer Review Week, 23–27 September 2024

As we conclude another productive month at MDPI, I am pleased to highlight our participation in this year’s Peer Review Week (PRW), which took place from 23–27 September 2024. This global, community-driven celebration underscores the vital importance of peer review in maintaining the integrity and reliability of academic work. PRW provide a platform for institutions, publishers, and scholars to come together and reflect on the processes that uphold the quality of scholarly communication.

“We remain committed to enhancing the peer review process”

The theme for PRW 2024 was ‘Innovation and Technology in Peer Review.’ At MDPI, we were proud to contribute through various online and in-person events, including webinars from Europe, Asia-Pacific, and a roundtable discussion on innovation and technology in peer review. These events offer an opportunity to explore new tools and technologies that are shaping the future of peer review, particularly the integration of AI. As a company, we remain committed to enhancing the peer review process with innovative solutions while preserving the essential human expertise that makes it effective.

Peer Review Innovation and Technology at MDPI

Our efforts to improve peer review extend beyond the activities of this week. We also released a blog article discussing New Tools for Advancing Research Integrity and Peer Review, where we highlight two tools that MDPI has developed to support research integrity: Eureka – Reviewer Recommender and Online Proofreader. We are continually refining SuSy, our in-house submission system, to provide a seamless experience for authors and reviewers alike.

Listening to MDPI’s Authors and Reviewers

We highly value the time of our reviewers, and so do the authors who contribute to our journals. Our editorial process is bolstered by a network of dedicated reviewers, a team of over 6,000 diligent, well-trained staff members, and an in-house article submission platform designed to ensure efficient processes.

We make it a point to continually improve the experiences of both our authors and our reviewers throughout the entire editorial process, from submission to publication. This is why we regularly ask for feedback by conducting surveys. Here is what some of our respondents recently had to say about working with MDPI:

Coming Together for Science

ICM 2024 – Advances in Material Innovation

I am pleased to share that we held The 5th International Conference on Materials: Advances in Material Innovation (ICM 2024) in Basel, Switzerland this past 25–27 September.

This intimate event brought together leading scientists, researchers, and industry experts to exchange insights on recent advancements in materials characterization, processing, and manufacturing. Key focus areas included nanotechnology in material sciences and engineering, optical, electrical, and magnetic materials, soft, biological, and biomaterials, fibres, membranes, thin films, sensing materials, as well as materials and devices for energy and solar fuels. In addition, discussions featured the integration of AI and machine learning in materials research.

We received 90 abstract submissions. Over the course of the three-day event, 18 posters were displayed, and 34 talks were delivered, including three plenary speeches, seven invited talks, and 24 selected oral presentations.

A special thank-you to our partnering societies The Polish Membrane Society and The North American Thermal Analysis Society, as well as our sponsor, Nanomegas, for their support of the ICM conference. I am also pleased to share that we presented three awards, including the Best Presentation Award and two Best Poster Awards, recognizing the outstanding contributions of our participants.

Upcoming In-Person Event

7–9 October 2024
Non-coding RNA World 2024: Exploring Mechanisms, Designing Medicines
Location: Basel, Switzerland

ncRNA 2024 will explore the latest advances in the field, covering topics from basic biology to medical and technological applications.

Find more upcoming MDPI events here.

Closing Thoughts

Reflections from OASPA 2024 Conference in Lisbon (16–18 September)

Amidst my September travels, I also had pleasure of attending the OASPA 2024 Conference in Lisbon from 16–18 September. It’s the first in-person Open Access Scholarly Publishing Association (OASPA) event in five years, and being in the sunny city of Lisbon made it even better! MDPI has long been a member of OASPA, and attending this conference gave us an opportunity to connect with other key members of the organization to see the latest developments in the OA movement.

“I believe that publishers have a lot to offer in terms of data and insights”

Main Themes from OASPA 2024

The main themes covered were equity and inclusivity, diamond OA, AI and openness, OA books, research integrity, and how OA can address broader societal challenges such as climate change. While it was great to see the latest developments in these areas, it was also clear that certain voices were missing, particularly those of major publishers. Although it’s not easy to incorporate every perspective, I believe that publishers, including MDPI, have a lot to offer in terms of data and insights. During the membership meeting, a few of us raised the point that large-scale publisher input could add value to these discussions.

It’s important to participate in industry conferences such as OASPA in order to be part of the discussions and remain at the forefront of the OA movement.

It’s an opportunity to build meaningful relationships with organizations that share our commitment to OA.

While sponsorship is one way to show our support, it’s clear that being part of the conversation through participating in the OASPA groups and committee is what really makes a difference.

It took the last 20 years for more than 50% of the world's research to be published via open access. This provides a sobering reminder that flipping the remaining 50% will be a big challenge.

An important takeaway for me was that there is no "one-size-fits-all" solution for OA challenges: different regions and different stakeholders need different forms of support, whether it is infrastructure, funding, education, or policy, for example. I also enjoyed Rebecca Ross' presentation on how OA can drive action on climate. A few panellists shared the need for transparency in the peer-review process, advocating for open review reports, which is something we have been offering since 2014.

Speaking of openness, we are excited to celebrate Open Access Week 2024 with the scholarly community from 21–27 October. I look forward to sharing a recap of our activities in the next newsletter.

Stefan Tochev
Chief Executive Officer
MDPI AG

29 September 2024
MDPI New Journal Proposal—Invitation to Shape the Future of Open Science Together


As a leader in open access publishing, MDPI is eager to explore new collaboration opportunities, including the launch of new journals and the transfer of existing ones. At present, MDPI publishes over 400 journals, more than 160 of which have established partnerships with academic organizations. Additionally, we publish 19 association journals.

In order to enhance exchange and cooperation with scientific researchers and share the results of open science, MDPI invites experts and scholars from various fields to submit proposals for new journal collaboration opportunities. If your proposal is approved, you could take on the role of Editor-in-Chief, Deputy Editor-in-Chief, or Editorial Board Member of the journal. This position allows you to manage the manuscript review process alongside our editorial department, participate in calls for papers, strengthen your network with scholars in the field, expand scientific research cooperation, enhance your personal and academic influence internationally, and play a leading role in academia.

Once the new journal is online, MDPI will provide a variety of promotional channels to market the journal internationally.

MDPI will offer various promotional channels to enhance its visibility and promote it internationally.

How can you determine the theme of a new journal?

  • Assess research hotspots/academic frontiers;
  • Assess pioneers in the field/key research directions of universities;
  • Determine whether MDPI has already established a journal in the field.

You can browse MDPI’s existing journals at the following link: https://www.mdpi.com/about/journals.

Advantages of collaborating with MDPI:

  • MDPI is a global leader in open-access publishing with extensive academic resources.
  • MDPI offers a professional publishing team that provides comprehensive support throughout the publishing process.
  • MDPI’s diverse promotional platforms and channels help journals quickly increase their international visibility and influence.

We invite you to submit new journal proposal here, and contribute to academic development! In addition, if your institution (university, institute, college, national key laboratory, society, etc.) intends to establish a journal, you can also submit a draft to MDPI on its behalf.

27 September 2024
MDPI’s 2023 Travel Awards—Winners Announced


MDPI journals frequently grant travel awards to empower junior researchers to showcase their latest research at academic conferences, thereby amplifying their impact within their research fields.

We extend our heartfelt congratulations to the 103 recipients of MDPI's 2023 Travel Awards from different countries and territories for their exceptional presentations. These outstanding individuals were selected by the journal editors based on the strength of their research proposals and the anticipated impact of their presentations at academic conferences. We commend their exceptional contributions and wish them continued success in their academic endeavors.

MDPI will continue to provide support and recognition to the academic community. To learn more about the list of awardees, please visit the following pages:

About MDPI Awards:

To reward the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help raise the influence of talented individuals who have been credited with outstanding achievements and are making a significant contribution to the advancement of their fields.

To explore more MDPI awards, please click here.

19 September 2024
Meet Us at the McGill International Palliative Care Congress 2024, 15–18 October 2024, Montreal, Canada


Conference:
McGill International Palliative Care Congress 2024
Date: 15–18 October 2024
Location: Montreal, Canada

MDPI will be attending the McGill International Palliative Care Congress 2024 as an exhibitor (booth: 10B), and we welcome researchers from different backgrounds to visit and share their latest ideas with us.

McGill University’s International Congress on Palliative Care is the longest running congress for this field. Founded in 1976 by Dr. Balfour Mount and his colleagues, it is now organized and hosted biennially by Palliative Care McGill. Over 1500 delegates, from more than 65 countries participate in making this one of the most interdisciplinary palliative care congresses. Every other year physicians, researchers, nurses, psychologists, social workers, pharmacists, music therapists, art therapists, physical therapists, spiritual care workers, volunteers and many others gather from around the globe to learn from and with each other for the betterment of palliative care. Please join us in celebrating and enriching palliative care around the world.

The following MDPI journals will be represented at the conference:

If you are planning to attend the above conference, please do not hesitate to start a conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. We welcome researchers from different backgrounds to visit and share their latest ideas with us.

For more information about the conference, please visit the following website: https://www.mcgill.ca/palliativecare/congress.

13 September 2024
Current Oncology | Blood Cancer Awareness Month


Blood Cancer Awareness Month in September is a significant global initiative aimed at increasing awareness surrounding blood cancer, its symptoms, and the profound impact it has. By enhancing early detection, advocating for prioritization by policymakers, and fostering a sense of community for individuals affected by blood cancer, this campaign strives to make a meaningful difference in the fight against this disease. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings in the related fields, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field.

“A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature”
by Adrian J. M. Bailey, Aidan M. Kirkham, Madeline Monaghan, Risa Shorr, C. Arianne Buchan, Christopher Bredeson and David S. Allan
Curr. Oncol. 2022, 29(1), 337-349; https://doi.org/10.3390/curroncol29010030  
Available online: https://www.mdpi.com/1718-7729/29/1/30

“Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series”
by Göran Ramin Boeckel, Silke Dorothea Hölscher, Christin Bürger, Torid Jacob, Carolin Krekeler, Evgenii Shumilov, Christian Reicherts, Annalen Bleckmann, Georg Lenz, Richard Vollenberg et al.
Curr. Oncol. 2022, 29(4), 2312-2325; https://doi.org/10.3390/curroncol29040188  
Available online: https://www.mdpi.com/1718-7729/29/4/188

“The Use of Virtual Care in Patients with Hematologic Malignancies: A Scoping Review”
by Adam Suleman, Abi Vijenthira, Alejandro Berlin, Anca Prica and Danielle Rodin
Curr. Oncol. 2022, 29(2), 892-900; https://doi.org/10.3390/curroncol29020076  
Available online: https://www.mdpi.com/1718-7729/29/2/76

“Antibody Response to COVID-19 mRNA Vaccines in Oncologic and Hematologic Patients Undergoing Chemotherapy”
by Manlio Mencoboni, Vincenzo Fontana, Azzurra Damiani, Antonino Spitaleri, Alessandro Raso, Luigi Carlo Bottaro, Giovanni Rossi, Luciano Canobbio, Antonella La Camera, Rosa Angela Filiberti et al.
Curr. Oncol. 2022, 29(5), 3364-3374; https://doi.org/10.3390/curroncol29050273  
Available online: https://www.mdpi.com/1718-7729/29/5/273

“Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada”
by John Kuruvilla, Emmanuel M. Ewara, Julia Elia-Pacitti, Ryan Ng, Maria Eberg, Atif Kukaswadia and Arushi Sharma
Curr. Oncol. 2023, 30(5), 4663-4676; https://doi.org/10.3390/curroncol30050352  
Available online: https://www.mdpi.com/1718-7729/30/5/352

“Estimating the Associated Burden of Illness and Healthcare Utilization of Newly Diagnosed Patients Aged ≥65 with Mantle Cell Lymphoma (MCL) in Ontario, Canada”
by Peter Anglin, Julia Elia-Pacitti, Maria Eberg, Sergey Muratov, Atif Kukaswadia, Arushi Sharma and Emmanuel M. Ewara
Curr. Oncol. 2023, 30(6), 5529-5545; https://doi.org/10.3390/curroncol30060418  
Available online: https://www.mdpi.com/1718-7729/30/6/418

“Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse”
by Parva Bhatt, Colin Kloock and Raymond Comenzo
Curr. Oncol. 2023, 30(2), 2322-2347; https://doi.org/10.3390/curroncol30020179  
Available online: https://www.mdpi.com/1718-7729/30/2/179

“Vitamin D and Multiple Myeloma: A Scoping Review”
by Naghmeh Mirhosseini, Athanasios Psihogios, Meagan D. McLaren and Dugald Seely
Curr. Oncol. 2023, 30(3), 3263-3276; https://doi.org/10.3390/curroncol30030248  
Available online: https://www.mdpi.com/1718-7729/30/3/248

You are welcome to submit relevant papers to the journal Current Oncology. If you have any questions, feel free to contact us.

Current Oncology Editorial Office

11 September 2024
MDPI’s 2023 Best PhD Thesis Awards—Winners Announced


MDPI’s Best PhD Thesis Awards are granted to promising young scholars whose PhD theses are deemed exceptional within their respective research fields. These awards aim to encourage young scholars to continue their outstanding accomplishments and further contribute to their field.

We extend our heartfelt congratulations to the 54 winners of the 2023 Best PhD Thesis Awards and wish them success with their future research endeavors.

MDPI will continue to provide support and recognition to the academic community. To learn more about all the awardees and their research projects in your field of study, please visit the following pages:

About MDPI Awards:

To reward the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help raise the influence of talented individuals who have been credited with outstanding achievements and are making a significant contribution to the advancement of their fields.

To explore more MDPI awards, please click here.

5 September 2024
Current Oncology | Gynecologic Cancer Awareness Month


In September, National Gynecological Cancer Awareness Month will focus on education, early detection, and preventing gynecological cancers affecting the female reproductive system, encompassing the cervix, ovaries, uterus, fallopian tubes, vagina, and vulva. This campaign informs individuals, healthcare providers, and communities in order to understand these cancers for improved health outcomes. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings and a high-quality Special Issue on the related fields that has been published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field.

“Advances in Radiation Oncology for the Treatment of Cervical Cancer”
by Mame Daro Faye and Joanne Alfieri
Curr. Oncol. 2022, 29(2), 928-944; https://doi.org/10.3390/curroncol29020079
Available online: https://www.mdpi.com/1718-7729/29/2/79

“Minimally Invasive Surgery for Cervical Cancer in Light of the LACC Trial: What Have We Learned?”
by Omar  Touhami and Marie Plante
Curr. Oncol. 2022, 29(2), 1093-1106; https://doi.org/10.3390/curroncol29020093
Available online: https://www.mdpi.com/1718-7729/29/2/93

“Outcomes of Enhanced Recovery after Surgery (ERAS) in Gynecologic Oncology: A Review”
by Steven P. Bisch and Gregg Nelson
Curr. Oncol. 2022, 29(2), 631-640; https://doi.org/10.3390/curroncol29020056
Available online: https://www.mdpi.com/1718-7729/29/2/56

“Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis”
by Antonia Pagkali, Ioannis Mamais, Adamantios Michalinos and Aris P. Agouridis
Curr. Oncol. 2022, 29(1), 321-336; https://doi.org/10.3390/curroncol29010029
Available online: https://www.mdpi.com/1718-7729/29/1/29

“New Targeted Therapies and Combinations of Treatments for Cervical, Endometrial, and Ovarian Cancers: A Year in Review”
by Adelina Silvana Gheorghe, Elena Adriana Dumitrescu, Isabela Anda Komporaly, Raluca Ioana Mihăilă, Cristian Virgil Lungulescu and Dana Lucia Stănculeanu
Curr. Oncol. 2022, 29(4), 2835-2847; https://doi.org/10.3390/curroncol29040231
Available online: https://www.mdpi.com/1718-7729/29/4/231

“Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study”
by Alexandra Moskalewicz, Amy Di Tomaso, Jacob J. Kachura, Samantha Scime, Rosane Nisenbaum, Ronita Lee, Rashida Haq, Christine Derzko and Christine Brezden-Masley
Curr. Oncol. 2022, 29(3), 1813-1827; https://doi.org/10.3390/curroncol29030149
Available online: https://www.mdpi.com/1718-7729/29/3/149

“Understanding the Challenges of HPV-Based Cervical Screening: Development and Validation of HPV Testing and Self-Sampling Attitudes and Beliefs Scales”
by Ovidiu Tatar, Ben Haward, Patricia Zhu, Gabrielle Griffin-Mathieu, Samara Perez, Emily McBride, Aisha K. Lofters, Laurie W. Smith, Marie-Hélène Mayrand Ellen M. Daley et al.
Curr. Oncol. 2023, 30(1), 1206-1219; https://doi.org/10.3390/curroncol30010093
Available online: https://www.mdpi.com/1718-7729/30/1/93

“Oncologic Outcomes of Surgically Treated Cervical Cancer with No Residual Disease on Hysterectomy Specimen: A 4C (Canadian Cervical Cancer Collaborative) Working Group Study”
by Christa Aubrey, Gregory R. Pond, Limor Helpman, Danielle Vicus, Laurie Elit, Marie Plante, Susie Lau, Janice S. Kwon, Alon D. Altman, Karla Willows et al.
Curr. Oncol. 2023, 30(2), 1977-1985; https://doi.org/10.3390/curroncol30020153
Available online: https://www.mdpi.com/1718-7729/30/2/153

Relevant Special Issue:
“New Frontiers in Treatment for Gynecologic Cancers”
Guest Editors: Dr. Laurie M. Elit and Dr. Taymaa May
Available online: https://www.mdpi.com/journal/curroncol/special_issues/Treatment_Gynecologic_Cancers

You are welcome to submit relevant papers to Current Oncology. For any questions, feel free to contact us.

Current Oncology Editorial Office

3 September 2024
MDPI INSIGHTS: The CEO's Letter #15 - CHORUS, Best Paper Award, August Events

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

I am pleased to share that MDPI is now an Affiliate Member of CHORUS, a not-for-profit organization dedicated to ensuring public access to articles reporting on U.S. government-funded research. This partnership highlights our long-standing commitment to advancing Open Access (OA) publishing and meeting funders’ open research requirements.

Read the full announcement here.

With the White House Office of Science and Technology Policy (OSTP) 2022 memorandum calling for immediate public access to all federally funded research by 2026, this partnership positions MDPI to further support academic institutions in adhering to national mandates while providing authors with fully compliant (CC-BY) OA journals.

The CHORUS platform went live in July 2014 and includes NASA, the U.S. Department of Energy, the U.S. Department of Defense, the U.S. Geological Survey, and the National Science Foundation.

“This partnership positions MDPI to further support academic institutions in adhering to national mandates”

Joining CHORUS perfectly aligns our mission as the leading OA publisher, which is to drive transparency and innovation in scholarly publishing, with that of CHORUS itself, which is to advance Open Access research. It will also support MDPI publications from organizations such as NASA, with 1,200 research papers published by NASA-affiliated authors as at 31 August 2024.

Impactful Research

MDPI’s Best Paper Awards—Award-Winning Papers in 2023 Announced

MDPI is committed to supporting and recognizing the academic community and is proud to announce the recipients of the 2023 Best Paper Awards, which recognize high-quality papers of significant scientific merit and impact. Each year, the editors of our journals carefully select papers that showcase outstanding scientific achievement.

This year, 115 Best Paper Awards were presented, chosen from 346 exceptional papers in a highly competitive selection process. Congratulations to the authors for their remarkable contributions!

To learn more about all the awardees and their research projects, visit the following pages:

About MDPI Awards
MDPI regularly offers various awards to recognize researchers, particularly young scientists, and to promote communication within the scientific community. These awards exist to inspire and acknowledge talented scientists who have made significant contributions to advancing their fields.

To find out more MDPI awards, please click here.

“Our awards exist to inspire and acknowledge talented scientists”

Inside MDPI

MDPI AI Team Presented at EuroSciPy 2024 in Poland

As part of the CEO Letter, I hold dear this ‘Inside MDPI’ section, where I have an opportunity to highlight various projects, teams and updates within our organization. As such, I’m happy to showcase the following presentations from members of MDPI’s Artificial Intelligence (AI) team, which were recently presented at the EuroSciPy 2024 (16th European Conference on Python in Science). This conference took place in Szczecin, Poland from 26–30 August.

“This event was a great opportunity to reinforce our commitment to innovation and excellence in publishing”

MDPI colleagues Frank Sauerburger (AI Tech Leader) and Daniele Raimondi (Senior Data Scientist) both presented at the conference. Frank discussed MDPI’s AI infrastructure, while Daniele showcased a new methodological approach we have been developing to track the journey of rejected academic manuscripts. This approach combines AI, data science and analytics to improve the identification of manuscripts and authors, enhancing our understanding of publishing dynamics.

This event was a great opportunity to reinforce our commitment to innovation and excellence in publishing. It also allowed us to contribute to the academic discussion on integrating AI and data science into scholarly communication.

From data analysis in Jupyter Notebooks to production applications: AI infrastructure at reasonable scale – Frank Sauerburger

Frank’s presentation on MDPI’s AI infrastructure provided a chance to showcase the advanced technological frameworks that power our operations. Given the technical and academic focus of EuroSciPy, this talk demonstrated how MDPI’s AI capabilities are not only cutting-edge but also central to driving efficiency and innovation in scholarly publishing. Engaging with the EuroSciPy community helps position MDPI as a leader in applying AI within the publishing industry, fostering potential collaborations and attracting interest from top researchers.

A Qdrant and Specter2 framework for tracking resubmissions of rejected manuscripts in academia – Daniele Raimondi

Daniele’s talk on the novel methodological approach that combines AI, Data Science, and Analytics was crucial in highlighting how MDPI is advancing the precision and effectiveness of manuscript and author identification. This approach is pivotal in enhancing our understanding of publishing dynamics and ensuring the quality and integrity of the academic content we manage. By presenting at EuroSciPy, we had the opportunity to engage with an audience deeply involved in scientific computing, gaining feedback and insights that could further refine our methodologies.

Thank you, Frank and Daniele, for representing MDPI so well!

I will share more about MDPI’s AI team and projects in upcoming CEO Letters, as we have a well-rounded AI and Data Team working on an exciting suite of AI products for MDPI and the scholarly community at large.

Coming Together for Science

The 1st International Conference on AI Sensors & The 10th International Symposium on Sensor Science

I am pleased to share the success of our MDPI conference The 1st International Conference on Artificial Intelligence (AI) Sensors and the 10th International Symposium on Sensor Science in Singapore this past 1–4 August.

With nearly 400 attendees, the event brought together researchers and industry experts from China, Singapore, Japan, Korea, Taiwan, India and other countries to share their findings on the latest developments in sensors, sensing technology, artificial intelligence for sensing applications and AI-enhanced sensing systems.

We accepted a total of 355 abstracts, featuring 772 authors from 28 countries. Over the course of the four-day event, 66 posters were displayed and 296 talks were delivered, including 4 plenary talks, 46 keynote speeches, 122 invited talks, and 124 selected oral presentations. View the event gallery here.

I am pleased to announce the winners of the four awards, including Best Presentation and Best Poster, recognizing the contributions of our participants during the conference.

Looking ahead, the 2nd International Conference on AI Sensors and Transducers is scheduled to take place from 29 July to 5 August, 2025, in Bangkok, Thailand.

Thank you to our Conference team, including Ionut Spatar, Teodora Nicoleta Cremene, Ang Kai Lin, Benjamin Tay, Leong Jin Yue Esther, Wong Jolin, Judith Wu, Alethea Liu and Flora Li, who were involved in making this event a success. A big thank-you also goes to our local MDPI colleagues for their support: Yu Nwe Soe, Hen Chu Yang, Kwah Zhi En Watcharapong, Zephan Yang, Daphne Neo, Huimin Cheng, Nathan Li and Ting Yin.

Upcoming In-Person Event

25–27 September, 2024
The 5th International Conference on Materials: Advances in Material Innovation
Location: Basel, Switzerland

ICM 2024 will unite experts to share insights on recent advancements in Materials Characterization, Processing and Manufacturing.

7–9 October, 2024
Non-coding RNA World 2024: Exploring Mechanisms, Designing Medicines
Location: Basel, Switzerland

ncRNA 2024 will explore the latest advances in the field, covering topics from basic biology to medical and technological applications.

Find more upcoming MDPI events here.

Closing Thoughts

The 2nd Sustainable Publishing Forum

In 2022, the International Association of Scientific, Technical and Medical Publishers (STM) outlined three goals to reflect the academic community’s shared aspirations: promoting Open Science, maintaining research integrity and fulfilling social responsibility. Open Science has evolved from the Open Access movement of the early 2000s to become a preferred model in academic publishing. Publishers and academic journals play a crucial role in ensuring research integrity, with efforts to prevent misconduct markedly on the increase now.

As the world faces sustainability challenges, the academic publishing industry is increasingly committed to contributing the achievement of the United Nations Sustainable Development Goals (SDGs). Many publishers are implementing strategies to support these objectives, including ours, which you can view here.

The 2nd MDPI Sustainable Publishing Forum provided a platform for global editors and publishers to discuss these themes, aiming to strengthen collaboration and advance the contributions that scientific publishing can make to academia and society.

“Open Science has evolved to become a preferred model in academic publishing”

The 2nd Sustainable Publishing Forum

We hosted MDPI’s 2nd Sustainable Publishing Forum in Beijing, China, on 15–16 August, attracting nearly 120 attendees from local and international publishers, university presses, scientific and technical journal associations, libraries and the Chinese Academy of Sciences. The event focused on promoting Open Science, maintaining research integrity, and fulfilling social responsibility.

This was an excellent opportunity for us to share more with conference attendees about the approach of our research integrity team. Our Head of Publishing, Peter Roth, also participated, speaking on how to identify and avoid predatory publishers and about the principles that underpin ethical academic publishing.

I extend my thanks to all of our conference speakers, including Hylke Koers (STM Solutions), who presented on STM Trends 2028 and shared insights on the STM Integrity Hub, of which MDPI is a member.

Stefan Tochev
Chief Executive Officer
MDPI AG

30 August 2024
Meet Us at the 37th Annual Congress of the European Association of Nuclear Medicine, 19–23 October 2024, Hamburg, Germany


The 37th Annual Congress of the European Association of Nuclear Medicine, organized by the European Association of Nuclear Medicine, will be held from 19 to 23 October 2024, in Hamburg, Germany.

This conference will offer a platform to exchange and discuss the latest theranostic advances, alongside the most impactful clinical evidence, recently developed radiopharmaceuticals, and novel imaging and detection technologies. Several topics will be discussed during the “Technologists’ Track”, including, among many others, whole-body multimodality imaging principles, PET-CT in oncologic disease-staging applications, radio-guided surgery, brain PET studies, and recent advancements regarding artificial intelligence and radiomics, as well as one of the most relevant aspects of healthcare—patient advocacy.

The following MDPI journals will be represented at the conference:

If you are attending this conference, please feel free to start a conversation by contacting us online. Our delegates look forward to meeting you in person at our booth and answering any questions that you may have. For more information about the conference, please visit the following link: https://eanm24.eanm.org/.

19 August 2024
MDPI’s 2023 Young Investigator Awards—Winners Announced


MDPI’s Young Investigator Awards recognize promising early career scientists, acknowledge their contributions, and foster collaboration within the scientific community. We are proud to announce the recipients for 2023, who were carefully selected by the journals’ esteemed Award Evaluation Committee.

We extend our heartfelt congratulations to the 79 winners of MDPI’s 2023 Young Investigator Awards for their excellent contributions in their research field. We look forward to seeing these rising stars continue to contribute to the advancement of science.

MDPI will continue to support and recognize the academic community. To explore details about the awardees by field, please visit the individual pages listed below:

Congratulations to all the winners for their exceptional contributions and dedication to advancing scientific research.

About MDPI Awards:
To support the academic community, particularly young researchers, and to enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help to elevate the profiles of talented individuals who have made outstanding achievements and are making significant contributions to advancements in their respective fields.

To find out more about MDPI awards, please click here.

7 August 2024
MDPI Insights: The CEO's Letter #14 - New Headquarters, Marketing, Poland

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

MDPI Moves to New Headquarters in Basel, Switzerland

I am excited to share that MDPI has moved to a new state-of-the-art office space in Basel, Switzerland. This move consolidates our operations by bringing together our two previously separated Basel offices into one central location.

We are always growing our talent pool and encourage you to view our Careers Page for the positions available in Basel and across our offices.

New Address: Grosspeteranlage 5, CH-4052 Basel, Switzerland

Effective Date: 1 July 2024

This new chapter in our company’s journey is designed to continue our mission of positioning MDPI as a leader in Open Access (OA) publishing, highlighting our commitment to making scholarly research accessible to everyone.

Boasting modern amenities, improved meeting and event spaces designed to support our growing needs, the new location provides a more collaborative and efficient working environment for our employees. The location offers convenient accessibility to public transportation and is situated near the Basel SBB railway station, with a variety of nearby services and amenities.

In fact, I can see the trains right outside of my window as I write these lines!

This move marks an exciting milestone in MDPI’s development, and I am confident that the new headquarters will serve as an inspiring and productive space for everyone. We also very much look forward to welcoming visitors here. You can read more about MDPI's history here.

“This new chapter continues our mission of positioning MDPI as a leader in OA publishing”

For Those New to MDPI

A pioneer in scholarly, Open Access publishing, MDPI has supported academic communities since 1996. MDPI is leading the transition to Open Science by making a greater proportion of the research conducted worldwide free and accessible to everyone. To date, over 3.5 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of 6,000 professional, well-trained staff members, and an in-house article submission platform designed to ensure efficient processes within its 440 fully Open Access titles. MDPI supports more than 800 academic institutions worldwide, helping them adhere to national mandates while facilitating authors’ publication in fully compliant (CC BY) Open Access journals.

Impactful Research

New and Emerging MDPI Journals Making an Immediate Impact

Unpacking some of the Impact Factor updates from the June CEO Letter, I wanted to dive a little deeper into the 137 MDPI journals which received Impact Factor for the first time.

Academic authors highly value efficient publishing processes, robust editorial support, and the opportunity to publish in high-impact journals. We are proud that our newly launched journals typically achieve coverage in the Emerging Sources Citation Index (ESCI) of the Web of Science within just a few years, with a median time of only three years from release to inclusion.

As part of our commitment to advancing academic research and providing high-quality OA publishing, we actively seek new research areas to expand our portfolio of journals. We have a proven track record of successfully establishing new journals.

Our dedicated teams excel in fostering dynamic editorial boards and working closely with Editors-in-Chief (EiC) to define the precise scope and focus of each new journal. Our expertise extends to collaborating with indexing services, ensuring that our journals comply with best practices and are indexed promptly in all relevant databases.

Emerging Titles Ranked for the First Time

Our commitment to excellence is reflected in the annual impact metrics released this past June. The latest edition of the Journal Citation Reports (JCR) showcases the integration of journals from the ESCI in the new unified category rankings, providing a simplified and more complete view of all journals within each subject category, including newly established titles.

Out of 137 new and developing MDPI journals ranked in the 2024 release, 79 are in the top half (Q1 or Q2) of their categories. Here is a breakdown of the number of MDPI’s ESCI-indexed journals by quartile in the JCR:

Quartile No. of journals
Q1 17 (12.4%)
Q2 62 (45.3%)
Q3 43 (31.4%)
Q4 15 (10.9%)
Not ranked (humanities-related journals) 2

These rankings highlight our success in rapidly establishing high-impact new journals. Among those that made it directly into the top 25% of their category are the International Journal of Neonatal Screening, Journal of Xenobiotics, Polysaccharides, Smart Cities, and thirteen other journals.

You can browse MDPI journals by Indexing. Simply visit our Journals page and select from the list of Indexing bodies in the top left-hand corner.

For quick reference, as at 31 July 2024:

Inside MDPI

MDPI Corporate Marketing Strategy and Team Meeting 2024

In July, I hosted the annual Corporate Marketing strategy and team-building activity with 15 of our team members.

The aim was to align the Corporate Marketing strategy with MDPI's goal of becoming the world's most trusted OA publisher. While we provide a high-level publishing experience for our authors, as seen from our surveys, we need to keep building on our transparent and open communication to foster trust within the scholarly community and continue enhancing our reputation.

The Corporate Marketing team plays an important role as the mouthpiece for all our major activities within MDPI, especially those that model what it means to be a trusted partner. The purpose of the strategy meeting was to develop a feeling of trust in one another and an understanding of how to inspire trust in the stakeholders with whom we interact.

“We need to keep building on our transparent and open communication to foster trust within the scholarly community”

We conducted a set of activities to facilitate that sense of mutual trust and trustworthiness. Examples of some activities we worked on during this strategy-building event include:

  • Exploring what trust means
    • ‘Letter to self’
    • ‘The brand I most trust’
  • Most Trusted Academic Publisher
    • ‘The brand I would like MDPI to become’
    • ‘The 2029 MDPI Annual Report’
    • Voice of Customer and Share of Voice – survey/data update on MDPI Brand Experience and Brand Perception
  • Integrate Trust-Based Objective into Marketing Plan
    • ‘Becoming the MDPI experience’
    • ‘Trusting the next steps’

While two days is not enough to finalize a marketing strategy, it is sufficient to get everyone who attended into the mindset of the direction in which we are working. From here, we will develop a program with next steps on main projects, update communications, and collaborate with team leads to incorporate this approach into our work going forward.

As a marketing team, we can communicate our messages, but trust has to be built at every touchpoint in the stakeholder journey. Just talking about it isn’t enough. We need to be about it. That’s a role each of us plays, from editorial to IT, from marketing to HR. We must build trust from the inside out. It starts with each manager and resonates out via every team member.

As a company, our goal is to give all stakeholders with whom we interact – whether internal or external – the experience of working with an organization it can trust.

Coming Together for Science

MDPI in Poland: Krakow Office

In July, I had the pleasure of visiting our Krakow office, following my recent trip to Warsaw to meet with the Polish Ministry of Science and Higher Education.

During these visits, I prioritized meeting with our Office Manager, Editorial Director, Group Leads, and members from various teams, including editorial, production, marketing, and journal relationship specialists, to understand their roles and current challenges. Instead of a formal presentation, I opted for an open discussion, sharing updates from headquarters to engage with colleagues in a more personal way.

Our Krakow office has many things to be proud of, including a large number of PhD colleagues (over a third of its staff holds a PhD degree). Krakow provides an opportunity for expanding beyond the 100 colleagues we currently have, by adding new hires in departments including editorial, production and marketing, among others.

About our Krakow office

  • Opened in 2020
  • 99 staff members as at 1 August 2024
  • Main Departments include Editorial, Production, English Department, JRS, PR

Our Krakow office participates in international conferences, conducts author trainings and scholar visits, and engages in local market outreach. The office is also a member of the Polish Chamber of Commerce for High Technology (IZTECH) and is working on expanding its local engagement.

Krakow is the second-largest city in Poland, with a population of about 800,000. It also has a large student population of around 128,000, with seven universities. This means that roughly one in every eight residents is a student.

Poland and MDPI

Poland is a crucial market for MDPI. From 2020 to June 2024, Poland ranked 7th in submissions and 5th in publications for MDPI research articles. As at 31 July 2024, Poland ranks 7th in total MDPI publications, with approximately 70,000 research papers.

Between 2020 and June 2024, 61,500 authors from Poland published with MDPI. As at 30 June 2024, there are 1,205 active Editorial Board Members (EBMs) from Poland, with 661 EBMs (55% of the total) having an H-index over 25.

We also have four Editors-in-Chief (EiC) from Poland leading our journals: Coatings, Venereology, Advances in Respiratory Medicine, and Limnological Review, along with six Section EiC.

In 2023, we received approximately 21,000 submissions from Polish-affiliated authors, of which 12,032 were published.

“Poland is a crucial market for MDPI”

Meeting with Ministry of Education

On 22 July, we visited Warsaw to meet with the Polish Ministry of Science and Higher Education.

We were pleased to learn that they are strong supporters of the OA publishing model and value MDPI’s approach to the peer-review process, including our high ethical standards for quality control.

In 2023 Polish authors predominantly published their papers in OA, with MDPI holding the largest market share in OA publications within the country.

Our commitment to collaborating with Polish institutions is evident through our 33 Institutional Open Access Program (IOAP) agreements with prestigious institutions such as the University of Warsaw, the University of Wroclaw, the Jagiellonian University, and Gdańsk University of Technology. Through IOAP discounts, a healthy waiver rate, and our peer-review voucher system, we provide the Polish scholarly community with significant savings in OA publishing. The Minister greatly appreciated these efforts and our commitment to offsetting some of the APC costs.

We discussed industry concerns about the threat of papermills and presented the preventive measures MDPI has in place to mitigate this risk and uphold high ethical standards. We informed them of our commitment to combating papermills, including our involvement with United2Act and the STM Research Integrity Hub, as well as our efforts to expand our research integrity team and explore proactive measures.

Closing Thoughts

MDPI Thought Leadership Op-ed on Open Access is Now Live on Politico

I am pleased to share that our thought leadership Op-ed piece on Open Access (OA) is now live on Politico. This is a nice push for continued influence and support of OA among policymakers and industry leaders.

Why Politico?

Politico's reputation as a highly credible and influential news platform makes it an important venue to reach key opinion leaders (KOL) from academia, policymakers, and thought leaders from many industries. This visibility helps promote the OA philosophy.

Open Access: A Moral Imperative for Progress

In this piece, I discuss the necessity of making scientific research freely available to all. I argue that publicly funded research should be publicly accessible, highlighting how OA democratizes scientific knowledge, accelerates research availability, and fosters collaboration.

“Open Access is a fundamental right for all citizens”

Democratizing scientific communication
The impulse to democratize scientific communication is nothing new. OA may seem like a recent innovation, but its principles have historical roots traceable to Europe in the 15th century. Just as the printing revolution accelerated the dissemination of new ideas, OA publishing unlocks new scientific insights that would otherwise only be accessible to a few.

Benefits for scholars: amplifying impact through Open Access
Authors publishing in an OA journal can expect more citations of their work, increasing its potential impact. Research findings that are freely available are more likely to be cited than those hidden behind a paywall. Freedom of access greatly increases the potential audience for each paper, fostering a sense of community among researchers worldwide. Heightened visibility can attract prospective collaborators and employers for young scientists. At MDPI, we believe that all these factors can only accelerate the advance of science. Additionally, authors retain copyright in their work instead of signing it away, permitting broader dissemination under Creative Commons licenses and increasing its capacity for impact.

The moral imperative
OA is not just a matter of scientific policy; it is a fundamental right for all citizens and a prerequisite for a brighter, more informed future. Publicly funded research should be a top priority, and I am pleased to see policy moving in this direction. Our capacity to generate transformative scientific insights has to be democratized. The question today is no longer whether we can afford to embrace OA; rather, it is whether we can afford not to.

Stefan Tochev
Chief Executive Officer
MDPI AG

2 August 2024
MDPI Romania Author Training Sessions in May

In May, MDPI Romania held three author training sessions – one endorsing an external event and two stand-alone sessions.

The National Session of Scientific Student Communications took place at Technical University Cluj on 17 and 18 May 2024. MDPI Romania sponsored this event and contributed an author training session on the production of research papers and case study analyses. JRS Norbert Kiss gave a presentation called The World of Open Access to explain different open access publishing models and the benefits of open access publishing. His presentation highlighted the impact of open access publishing on scientific progress and innovation.

On 29 May 2024, MDPI Romania hosted an author training session for Ph.D. students, early career researchers, and professors at the Carol Davila University of Medicine and Pharmacy. In collaboration with Prof. Andreea Arsene, JRS Ioana Paunescu prepared two presentations: The Steps of the Publishing Process and Elaboration of a Peer Review Report. In her first presentation, she delved into MDPI’s history and mission, MDPI’s editorial process, and MDPI journals of various scopes that are accepting submissions. Her second presentation outlined the types of peer review, the contents of a peer review report by an MDPI reviewer, and the responsibilities of an MDPI reviewer.

MDPI Romania also hosted an author training session at the Iasi University of Life Sciences on 29 May 2024. JRSs Laurentiu Preda and Cosmin Artan gave four presentations: Efficient Writing of an ISI-Indexed Scientific Article, Benefits of Publishing in the Open Access Model, Various Methods of Open Access Publishing, and MDPI Guide for the Article Review Process. The first three presentations offered guidance on how to improve academic writing, the fourth focused on how to write peer review reports. A highly interactive discussion followed the presentations, during which the JRSs provided extensive answers to attendees’ questions.

MDPI is grateful for all the attendees, speakers, and organizers involved in these events. Through their enthusiasm and dedication, these events were great successes.

1 August 2024
Meet Us at the 2024 CAMO Annual Scientific Meeting, 24–26 October 2024, Ottawa, ON, Canada


Conference: 2024 CAMO Annual Scientific Meeting

Date: 24–26 October 2024

Location: Ottawa, ON, Canada

The Canadian Association of Medical Oncologists (CAMO) is a national specialty society of the Royal College of Physicians and Surgeons of Canada. Their mission is to contribute to cancer control, through research, education, and clinical practice in prevention, screening, diagnosis, treatment, supportive care, palliative care, and rehabilitation. The Association is committed to achieving and maintaining, among its members, excellence in clinical and scholarly activity, within a culture of compassion and respect for human dignity. CAMO Annual Scientific Meetings have been held since 2014.

The following MDPI journals will be represented at the 2024 CAMO Annual Scientific Meeting:

Our delegates look forward to meeting you in person at the booth at the conference and answering any questions you may have. For more information regarding the conference, please visit the following link: https://camo-acom.ca/page-1549450.

1 August 2024
Current Oncology | World Lung Cancer Day


World Lung Cancer Day is marked on 1st August every year with the aim of raising awareness about lung cancer and promoting prevention, screening, and treatment. This global event seeks to increase public understanding of the risk factors associated with lung cancer and drive governments, organizations, and individuals to take action in order to reduce the incidence and mortality rates of lung cancer. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings and a high-quality Special Issue in the related fields published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field.

“Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology”
by Hamid Mithoowani and Michela Febbraro
Curr. Oncol. 2022, 29(3), 1828–1839; https://doi.org/10.3390/curroncol29030150
Available online: https://www.mdpi.com/1718-7729/29/3/150

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date”
by Sébastien Gendarme, Olivier Bylicki, Christos Chouaid and Florian Guisier
Curr. Oncol. 2022, 29(2), 641–658; https://doi.org/10.3390/curroncol29020057
Available online: https://www.mdpi.com/1718-7729/29/2/57

“Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence”
by Ilaria Attili, Antonio Passaro, Pasquale Pisapia, Umberto Malapelle and Filippo de Marinis
Curr. Oncol. 2022, 29(1), 255–266; https://doi.org/10.3390/curroncol29010024
Available online: https://www.mdpi.com/1718-7729/29/1/24

“Novel Harmonization Method for Multi-Centric Radiomic Studies in Non-Small Cell Lung Cancer”
by Marco Bertolini, Valeria Trojani, Andrea Botti, Noemi Cucurachi, Marco Galaverni, Salvatore Cozzi, Paolo Borghetti, Salvatore La Mattina, Edoardo Pastorello, Michele Avanzo et al.
Curr. Oncol. 2022, 29(8), 5179–5194; https://doi.org/10.3390/curroncol29080410
Available online: https://www.mdpi.com/1718-7729/29/8/410

“Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer”
by Steven Olsen, Jiemin Liao and Hidetoshi Hayashi
Curr. Oncol. 2022, 29(7), 4811–4826; https://doi.org/10.3390/curroncol29070382
Available online: https://www.mdpi.com/1718-7729/29/7/382

“Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options”
by Francesco Petrella, Stefania Rizzo, Ilaria Attili, Antonio Passaro, Thomas Zilli, Francesco Martucci, Luca Bonomo, Filippo Del Grande, Monica Casiraghi, Filippo De Marinis et al.
Curr. Oncol. 2023, 30(3), 3160–3175; https://doi.org/10.3390/curroncol30030239
Available online: https://www.mdpi.com/1718-7729/30/3/239

“Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices”
by Brandon S. Sheffield, Kiefer Eaton, Bruno Emond, Marie-Hélène Lafeuille, Annalise Hilts, Patrick Lefebvre, Laura Morrison, Andrea L. Stevens, Emmanuel M. Ewara and Parneet Cheema
Curr. Oncol. 2023, 30(2), 2348–2365; https://doi.org/10.3390/curroncol30020180
Available online: https://www.mdpi.com/1718-7729/30/2/180

“Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives”
by Chiara Lazzari, Calogera Claudia Spagnolo, Giuliana Ciappina, Martina Di Pietro, Andrea Squeri, Maria Ilenia Passalacqua, Silvia Marchesi, Vanesa Gregorc and Mariacarmela Santarpia
Curr. Oncol. 2023, 30(4), 3684–3696; https://doi.org/10.3390/curroncol30040280
Available online: https://www.mdpi.com/1718-7729/30/4/280

Relevant Special issue:
Current State of Immunotherapy for Lung Cancer
Guest Editor: Prof. Dr. Barbara Melosky

You are welcome to submit relevant papers to the journal Current Oncology. For any questions, feel free to contact us.

Current Oncology Editorial Office

11 July 2024
Current Oncology | 30th Anniversary


This year marks the 30th anniversary of Current Oncology (ISSN: 1718-7729), a peer-reviewed open access journal on clinical oncology. With an Impact Factor of 2.8 and a CiteScore of 3.3, the journal is covered in Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases. The journal has published more than 4,100 papers from more than 17,200 authors, who are from 101 countries. This breakthrough could not have been achieved without our readers, authors, peer reviewers, editors, and all the people working for the journal who have combined their tremendous efforts over the years.

We invite you to explore our dedicated webpage, where you will find special content commemorating this milestone: https://www.mdpi.com/journal/curroncol/anniversary.

We have prepared a video showcasing the evolution of Current Oncology and featuring warm congratulations from our Editor-in-Chief, Prof. Dr. Shahid Ahmed.

30th Anniversary Special Issue:
The 30th Anniversary of Current Oncology: Perspectives in Clinical Oncology Practice

If you have any questions, suggestions, or recommendations, please do not hesitate to contact us at [email protected].

Current Oncology Editorial Office

10 July 2024
MDPI's Newly Launched Journals in June 2024

Five new journals covering multiple subjects have launched their inaugural issue in June 2024. We are excited to be able to share with you the newest research rooted in the value of open access.

We would like to express our deepest appreciation to all the Editorial Board Members and each journal will ensure its high-quality output using excellent editorial and rigorous peer review processes, to ensure that the articles achieve high impact and visibility.

Please feel free to browse and discover more about the new journals below.

Journal

Founding Editor-in-Chief

Journal Topics (Selected)

Anesthesia Research Logo

Prof. Dr. Marco Ranucci, IRCCS Policlinico San Donato, Italy
| Editorial | view inaugural issue

anaesthetic medications; blood and fluid management; pain management; critical care; critical illness | view journal scope | submit an article

Complications Logo

Dr. Giovanni E. Cacciamani, University of Southern California, USA
| Editorial | view inaugural issue

surgical/procedural complications; complications; perioperative adverse events; postoperative adverse events | view journal scope | submit an article

Laboratories Logo

Prof. Dr.  Gassan Hodaifa, Universidad Pablo de Olavide, Spain
| Editorial | view inaugural issue

laboratory management; laboratory safety; protective equipment; laboratory problems and challenges; laboratory Innovation | view journal scope | submit an article

Pets Logo

Prof. Dr. Jan S. Suchodolski, Texas A&M University, USA
| Editorial | view inaugural issue

companion animals health and disease; veterinary care and nutrition; genetics and genomics; behavior and welfare; human-animal relations | view journal scope | submit an article

Real Estate Logo

Prof. Dr. Pierfrancesco De Paola, University of Naples Federico II, Italy
| Editorial | view inaugural issue

real estate appraisal; economic and financial valuation of real estate projects; sustainable real estate; housing and urban economics | view journal scope | submit an article

We wish to thank everyone who has supported the development of open access publishing. You are welcome to send an application here, or contact the New Journal Committee ([email protected]) if you would like to create more new journals.

5 July 2024
Current Oncology | Sarcoma and Bone Cancer Awareness Month

July is Sarcoma and Bone Cancer Awareness Month, which is an important campaign dedicated to increasing the awareness and understanding of these unique and challenging diseases. Sarcomas are a rare group of cancers that originate in the bones or soft tissues of the body. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings and high-quality Special Issues in the related fields, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field.

“Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment”
by Matthew Ho, Alexander Xiao, Dongni Yi, Saurabh Zanwar and Giada Bianchi
Curr. Oncol. 2022, 29(11), 8975-9005; https://doi.org/10.3390/curroncol29110705
Available online:  https://www.mdpi.com/1718-7729/29/11/705

“Minimally Invasive Interventional Procedures for Metastatic Bone Disease: A Comprehensive Review”
by Nicolas Papalexis, Anna Parmeggiani, Giuliano Peta, Paolo Spinnato, Marco Miceli and Giancarlo Facchini
Curr. Oncol. 2022, 29(6), 4155-4177; https://doi.org/10.3390/curroncol29060332
Available online:  https://www.mdpi.com/1718-7729/29/6/332

“Safety and Feasibility of Steerable Radiofrequency Ablation in Combination with Cementoplasty for the Treatment of Large Extraspinal Bone Metastases”
by Claudio Pusceddu, Davide De Francesco, Nicola Ballicu, Domiziana Santucci, Salvatore Marsico, Massimo Venturini, Davide Fior, Lorenzo Paolo Moramarco and Eliodoro Faiella
Curr. Oncol. 2022, 29(8), 5891-5900; https://doi.org/10.3390/curroncol29080465
Available online:  https://www.mdpi.com/1718-7729/29/8/465

“Updates in Pathology for Retroperitoneal Soft Tissue Sarcoma”
by Tanner Mack and Bibianna Purgina
Curr. Oncol. 2022, 29(9), 6400-6418; https://doi.org/10.3390/curroncol29090504
Available online:  https://www.mdpi.com/1718-7729/29/9/504

“Staging Systems and Nomograms for Soft Tissue Sarcoma”
by Maria Danieli and Alessandro Gronchi
Curr. Oncol. 2023, 30(4), 3648-3671; https://doi.org/10.3390/curroncol30040278
Available online:  https://www.mdpi.com/1718-7729/30/4/278

“Surgical Management of Retroperitoneal Sarcoma”
by Dana A. Dominguez, Sagus Sampath, Mark Agulnik, Yu Liang, Bao Nguyen, Vijay Trisal, Laleh G. Melstrom, Aaron G. Lewis, Isaac Benjamin Paz, Randall F. Roberts et al.
Curr. Oncol. 2023, 30(5), 4618-4631; https://doi.org/10.3390/curroncol30050349
Available online:  https://www.mdpi.com/1718-7729/30/5/349

The list of relevant Special Issues is as follows:

“Treatment of Bone Metastasis”
Guest Editor: Dr. Costantino Errani
Available online: https://www.mdpi.com/journal/curroncol/special_issues/Treatment_Bone_Metastasis

“Bone and Soft Tissue Tumors: Clinical Features, Imaging and Treatment”
Guest Editors: Dr. Andrea Sambri, Dr. Michele Fiore and Dr. Massimiliano De Paolis
Available online: https://www.mdpi.com/journal/curroncol/special_issues/COMBGQV12M

“What’s New in Musculoskeletal Oncology?”
Guest Editors: Dr. Andreas F. Mavrogenis, Dr. Costantino Errani and Dr. Shinji Tsukamoto
Available online: https://www.mdpi.com/journal/curroncol/special_issues/J418745AG0

You are welcome to submit relevant papers to the Current Oncology journal. For any questions, please feel free to contact us.

Current Oncology Editorial Office

26 June 2024
Current Oncology Receives an Updated Impact Factor of 2.8 and CiteScore of 3.3

We are pleased to share that the Current Oncology (ISSN: 1718-7729) was awarded an increased Impact Factor of 2.8 in the 2023 Journal Citation Reports™ released by Clarivate in June 2024. The Current Oncology ranks upgraded from Q3 to Q2 (157 among 322 titles) in the “Oncology” category.

Additionally, according to data released by Scopus (Elsevier), the Current Oncology received an updated CiteScore™ of 3.3, an increase of 27% compared with the 2022 metric. Current Oncology’s CiteScore ranks Q3 (238 among 404 titles) in the “Oncology” category.

2.8

2023 Impact Factor

157/322 (Q2)

Oncology

6,836

Citations in 2023

3.3

2023 CiteScore

238/404 (Q3)

Oncology

0.792

SNIP

For further statistics, please visit https://www.mdpi.com/journal/curroncol/stats. For more information about MDPI flagship journals' citation metrics, please see here.

At MDPI, our mission is simple yet powerful, and we strive every day to make scientific research freely accessible to everyone, everywhere. With over 3.5 million authors choosing MDPI, we have established ourselves as a key player driving the open access initiative.

Our journals have received over 13 million citations in the Web of Science, making us the most cited open access publisher. With over 800 institutional partners, MDPI continues to demonstrate its dedication to providing reliable and collaborative publishing services.

Current Oncology Editorial Office

26 June 2024
Current Oncology | Cancer Immunotherapy Awareness Month

Cancer Immunotherapy Awareness Month, taking place in June, is dedicated to raising awareness of the importance and potential of immunotherapy in the treatment of cancer. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings and a high-quality Special Issue in the field of cancer immunotherapy, published in Current Oncology (ISSN: 1718-7729). We hope that this announcement will provide useful information regarding this field.

“Immunotherapy in Gastric Cancer”
by Anica Högner and Markus Moehler
Curr. Oncol. 2022, 29, 1559-1574. https://doi.org/10.3390/curroncol29030131
Available online: https://www.mdpi.com/1718-7729/29/3/131

“The Role of Immunotherapy in Pancreatic Cancer”
by Reetu Mukherji, Dipanjan Debnath, Marion L. Hartley and Marcus S. Noel
Curr. Oncol. 2022, 29, 6864-6892. https://doi.org/10.3390/curroncol29100541
Available online: https://www.mdpi.com/1718-7729/29/10/541

“Immunotherapy in Squamous Cell Cancer of the Esophagus”
by Peter Thuss-Patience and Alexander Stein
Curr. Oncol. 2022, 29, 2461-2471. https://doi.org/10.3390/curroncol29040200
Available online:  https://www.mdpi.com/1718-7729/29/4/200

“Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma”
by Jong Chul Park, Hari N. Krishnakumar and Srinivas Vinod Saladi
Curr. Oncol. 2022, 29, 4185-4198. https://doi.org/10.3390/curroncol29060334
Available online:  https://www.mdpi.com/1718-7729/29/6/334

“Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients”
by Justin Tong, Adi Kartolo, Cynthia Yeung, Wilma Hopman and Tara Baetz
Curr. Oncol. 2022, 29, 7953-7963. https://doi.org/10.3390/curroncol29100629
Available online:  https://www.mdpi.com/1718-7729/29/10/629

“Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review”
by Raida M. Khwaja and Quincy S.-C. Chu
Curr. Oncol. 2022, 29, 479-489. https://doi.org/10.3390/curroncol29020043
Available online:  https://www.mdpi.com/1718-7729/29/2/43

The list of relevant Special Issues is as follows:
Immunotherapy for Gastrointestinal Cancer
Guest Editor: Dr. Patrick M. Boland
Available online: https://www.mdpi.com/journal/curroncol/special_issues/Immunotherapy_GI

Immune Checkpoint Inhibitors in Cancer Therapy: State of the Art and Future Perspectives
Guest Editors: Dr. Aparna Jayachandran, Prof. Dr. George Kannourakis and Dr. Prashanth Prithviraj
Available Online: https://www.mdpi.com/journal/curroncol/special_issues/Immune_Checkpoint_Inhibitors_Cancer_Therapy

You are welcome to submit relevant papers to the Current Oncology journal. For any questions, please feel free to contact us.
Current Oncology Editorial Office

20 June 2024
2023 Impact Factors for MDPI Journals Released


MDPI is pleased to announce the inclusion of 237 journals in the 2024 release of the Journal Citation Reports (JCR) and share the key results (see above).

This year, journals covered in the Emerging Sources Citation Index (ESCI) received category ranks together with journals in the Science Citation Index Expanded (SCIE) and Social Sciences Citation Index (SSCI). Overall, 139 MDPI journals indexed in ESCI are included in the new unified rankings for the first time.

Enhanced Comparability of Data

According to Clarivate, "the creation of unified category rankings [provides] a simpler and more complete category view for the evaluation of journal performance. [...] The category-first approach simplifies journal performance assessment with a holistic view of all journals in each subject category."

We are thrilled to announce that 72% of our ranked MDPI journals (171 of 237) are above average, in Q1 or Q2. Twenty-nine of our journals received their first Impact Factor this year, accounting for more than 5% of the journals accepted into the Web of Science last year.

MDPI Journals Ranked in JCR

The following data includes all MDPI journals indexed in SCIE, SSCI, ESCI and AHCI.

Journal

Impact Factor

Rank Quartile

Category

Acoustics

1.3

Q3

Acoustics

Actuators

2.2

Q2

Engineering, Mechanical

Q2

Instruments & Instrumentation

Administrative Sciences

3.0

Q2

Management

Advances in Respiratory Medicine

1.8

Q3

Respiratory System

Aerospace

2.1

Q2

Engineering, Aerospace

Agriculture

3.3

Q1

Agronomy

Agriengineering

3.0

Q2

Agricultural Engineering

Agronomy

3.3

Q1

Agronomy

Q1

Plant Sciences

AI

3.1

Q2

Computer Science, Artificial Intelligence

Q2

Computer Science, Interdisciplinary Applications

Algorithms

1.8

Q3

Computer Science, Artificial Intelligence

Q2

Computer Science, Theory & Methods

Animals

2.7

Q1

Agriculture, Dairy & Animal Science

Q1

Veterinary Sciences

Antibiotics

4.3

Q1

Infectious Diseases

Q1

Pharmacology & Pharmacy

Antibodies

3.0

Q3

Immunology

Antioxidants

6.0

Q1

Biochemistry & Molecular Biology

Q1

Chemistry, Medicinal

Q1

Food Science & Technology

Applied Sciences

2.5

Q2

Chemistry, Multidisciplinary

Q1

Engineering, Multidisciplinary

Q3

Materials Science, Multidisciplinary

Q2

Physics, Applied

Applied System Innovation

3.8

Q2

Computer Science, Information Systems

Q2

Engineering, Electrical & Electronic

Q2

Telecommunications

Arts

0.3

N/A

Humanities, Multidisciplinary

Atmosphere

2.5

Q3

Environmental Sciences

Q3

Meteorology & Atmospheric Sciences

Atoms

1.7

Q3

Physics, Atomic, Molecular & Chemical

Audiology Research

2.1

Q1

Audiology & Speech-language Pathology

Axioms

1.9

Q1

Mathematics, Applied

Batteries

4.6

Q2

Electrochemistry

Q2

Energy & Fuels

Q2

Materials Science, Multidisciplinary

Behavioral Sciences

2.5

Q2

Psychology, Multidisciplinary

Beverages

3.0

Q2

Food Science & Technology

Big Data and Cognitive Computing

3.7

Q2

Computer Science, Artificial Intelligence

Q2

Computer Science, Information Systems

Q1

Computer Science, Theory & Methods

Bioengineering

3.8

Q2

Engineering, Biomedical

Biology

3.6

Q1

Biology

Biomedicines

3.9

Q2

Biochemistry & Molecular Biology

Q2

Medicine, Research & Experimental

Q1

Pharmacology & Pharmacy

Biomimetics

3.4

Q1

Engineering, Multidisciplinary

Q3

Materials Science, Biomaterials

Biomolecules

4.8

Q1

Biochemistry & Molecular Biology

Biosensors

4.9

Q1

Chemistry, Analytical

Q1

Instruments & Instrumentation

Q2

Nanoscience & Nanotechnology

Biotech

2.7

Q3

Biotechnology & Applied Microbiology

Birds

1.5

Q1

Ornithology

Brain Sciences

2.7

Q3

Neurosciences

Buildings

3.1

Q2

Construction & Building Technology

Q2

Engineering, Civil

C-Journal of Carbon Research

3.9

Q2

Materials Science, Multidisciplinary

Cancers

4.5

Q1

Oncology

Cardiogenetics

0.5

Q4

Cardiac & Cardiovascular Systems

Catalysts

3.8

Q2

Chemistry, Physical

Cells

5.1

Q2

Cell Biology

Ceramics

2.7

Q1

Materials Science, Ceramics

Q3

Materials Science, Multidisciplinary

Chemengineering

2.8

Q2

Engineering, Chemical

Chemistry

2.4

Q3

Chemistry, Multidisciplinary

Chemosensors

3.7

Q2

Chemistry, Analytical

Q2

Electrochemistry

Q1

Instruments & Instrumentation

Children

2.0

Q2

Pediatrics

Clean Technologies

4.0

Q2

Engineering, Environmental

Q2

Environmental Sciences

Q3

Green & Sustainable Science & Technology

Climate

3.0

Q2

Meteorology & Atmospheric Sciences

Clinics and Practice

1.7

Q2

Medicine, General & Internal

Clocks & Sleep

2.1

Q3

Clinical Neurology

Q3

Neurosciences

Coatings

2.9

Q2

Materials Science, Coatings & Films

Q3

Materials Science, Multidisciplinary

Q2

Physics, Applied

Colloids and Interfaces

2.5

Q3

Chemistry, Physical

Computation

1.9

Q2

Mathematics, Interdisciplinary Applications

Computers

2.6

Q2

Computer Science, Interdisciplinary Applications

Condensed Matter

1.9

Q3

Physics, Condensed Matter

Cosmetics

3.4

Q2

Biochemistry & Molecular Biology

Q2

Dermatology

Cryptography

1.8

Q3

Computer Science, Information Systems

Q2

Computer Science, Theory & Methods

Crystals

2.4

Q2

Crystallography

Q3

Materials Science, Multidisciplinary

Current Issues in Molecular Biology

2.8

Q3

Biochemistry & Molecular Biology

Current Oncology

2.8

Q2

Oncology

Data

2.2

Q3

Computer Science, Information Systems

Q2

Multidisciplinary Sciences

Dentistry Journal

2.5

Q2

Dentistry, Oral Surgery & Medicine

Dermatopathology

1.6

Q3

Dermatology

Diabetology

2.4

Q3

Endocrinology & Metabolism

Diagnostics

3.0

Q1

Medicine, General & Internal

Diseases

2.9

Q2

Medicine, Research & Experimental

Diversity

2.1

Q2

Biodiversity Conservation

Q3

Ecology

Drones

4.4

Q1

Remote Sensing

Earth

2.1

Q3

Environmental Sciences

Q3

Geosciences, Multidisciplinary

Ecologies

1.7

Q3

Ecology

Econometrics

1.1

Q3

Economics

Economies

2.1

Q2

Economics

Education Sciences

2.5

Q1

Education & Educational Research

Electronics

2.6

Q2

Computer Science, Information Systems

Q2

Engineering, Electrical & Electronic

Q2

Physics, Applied

Energies

3.0

Q3

Energy & Fuels

Entropy

2.1

Q2

Physics, Multidisciplinary

Environments

3.5

Q2

Environmental Sciences

Epigenomes

2.5

Q3

Genetics & Heredity

European Burn Journal

1.0

Q4

Critical Care Medicine

Q4

Dermatology

European Journal of Investigation in Health Psychology and Education

3.0

Q1

Psychology, Clinical

Fermentation

3.3

Q2

Biotechnology & Applied Microbiology

Fibers

4.0

Q2

Materials Science, Multidisciplinary

Fire

3.0

Q2

Ecology

Q1

Forestry

Fishes

2.1

Q2

Fisheries

Q2

Marine & Freshwater Biology

Fluids

1.8

Q3

Mechanics

Q3

Physics, Fluids & Plasmas

Foods

4.7

Q1

Food Science & Technology

Forecasting

2.3

Q2

Multidisciplinary Sciences

Forests

2.4

Q1

Forestry

Fractal and Fractional

3.6

Q1

Mathematics, Interdisciplinary Applications

Fuels

2.7

Q3

Energy & Fuels

Q3

Engineering, Chemical

Future Internet

2.8

Q2

Computer Science, Information Systems

Galaxies

3.2

Q2

Astronomy & Astrophysics

Games

0.6

Q4

Economics

Q4

Mathematics, Interdisciplinary Applications

Q4

Social Sciences, Mathematical Methods

Gastroenterology Insights

1.5

Q3

Gastroenterology & Hepatology

Gastrointestinal Disorders

0.9

Q4

Gastroenterology & Hepatology

Gels

5.0

Q1

Polymer Science

Genealogy

0.8

Q3

Ethnic Studies

Q4

Family Studies

Q3

Sociology

Genes

2.8

Q2

Genetics & Heredity

Geosciences

2.4

Q2

Geosciences, Multidisciplinary

Geriatrics

2.1

Q3

Geriatrics & Gerontology

Healthcare

2.4

Q2

Health Care Sciences & Services

Q2

Health Policy & Services

Hemato

0.9

Q4

Hematology

Hematology Reports

1.1

Q4

Hematology

Heritage

2.0

N/A

Humanities, Multidisciplinary

Q2

Multidisciplinary Sciences

Horticulturae

3.1

Q1

Horticulture

Humanities

0.3

N/A

Humanities, Multidisciplinary

Hydrology

3.1

Q2

Water Resources

Immuno

2.1

Q4

Immunology

Infectious Disease Reports

3.4

Q2

Infectious Diseases

Informatics

3.4

Q2

Computer Science, Interdisciplinary Applications

Information

2.4

Q3

Computer Science, Information Systems

Infrastructures

2.7

Q2

Construction & Building Technology

Q2

Engineering, Civil

Q2

Transportation Science & Technology

Inorganics

3.1

Q2

Chemistry, Inorganic & Nuclear

Insects

2.7

Q1

Entomology

International Journal of Financial Studies

2.1

Q2

Business, Finance

International Journal of Molecular Sciences

4.9

Q1

Biochemistry & Molecular Biology

Q2

Chemistry, Multidisciplinary

International Journal of Neonatal Screening

4.0

Q1

Genetics & Heredity

Q1

Pediatrics

International Journal of Turbomachinery Propulsion and Power

1.3

Q2

Engineering, Aerospace

Q3

Engineering, Mechanical

Inventions

2.1

Q2

Engineering, Multidisciplinary

ISPRS International Journal of Geo-Information

2.8

Q2

Computer Science, Information Systems

Q2

Geography, Physical

Q2

Remote Sensing

Journal of Cardiovascular Development and Disease

2.4

Q2

Cardiac & Cardiovascular Systems

Journal of Clinical Medicine

3.0

Q1

Medicine, General & Internal

Journal of Composites Science

3.0

Q2

Materials Science, Composites

Journal of Developmental Biology

2.2

Q3

Developmental Biology

Journal of Functional Biomaterials

5.0

Q1

Engineering, Biomedical

Q2

Materials Science, Biomaterials

Journal of Functional Morphology and Kinesiology

2.6

Q1

Sport Sciences

Journal of Fungi

4.2

Q2

Microbiology

Q1

Mycology

Journal of Imaging

2.7

Q3

Imaging Science & Photographic Technology

Journal of Intelligence

2.8

Q1

Psychology, Multidisciplinary

Journal of Low Power Electronics and Applications

1.6

Q3

Engineering, Electrical & Electronic

Journal of Manufacturing and Materials Processing

3.3

Q2

Engineering, Manufacturing

Q1

Engineering, Mechanical

Q2

Materials Science, Multidisciplinary

Journal of Marine Science and Engineering

2.7

Q1

Engineering, Marine

Q2

Engineering, Ocean

Q2

Oceanography

Journal of Personalized Medicine

3.0

Q2

Health Care Sciences & Services

Q1

Medicine, General & Internal

Journal of Sensor and Actuator Networks

3.3

Q2

Computer Science, Information Systems

Q2

Telecommunications

Journal of Theoretical and Applied Electronic Commerce Research

5.1

Q1

Business

Journal of Xenobiotics

6.8

Q1

Toxicology

Journal of Zoological and Botanical Gardens

2.1

Q2

Biodiversity Conservation

Journalism and Media

2.0

Q2

Communication

Land

3.2

Q2

Environmental Studies

Languages

0.9

N/A

Language & Linguistics

Q2

Linguistics

Laws

1.3

Q1

Law

Life

3.2

Q1

Biology

Logistics

3.6

Q2

Management

Q2

Operations Research & Management Science

Lubricants

3.1

Q2

Engineering, Mechanical

Machine Learning and Knowledge Extraction

4.0

Q2

Computer Science, Artificial Intelligence

Q2

Computer Science, Interdisciplinary Applications

Q2

Engineering, Electrical & Electronic

Machines

2.1

Q3

Engineering, Electrical & Electronic

Q2

Engineering, Mechanical

Magnetochemistry

2.6

Q2

Chemistry, Inorganic & Nuclear

Q3

Chemistry, Physical

Q3

Materials Science, Multidisciplinary

Marine Drugs

4.9

Q1

Chemistry, Medicinal

Q1

Pharmacology & Pharmacy

Materials

3.1

Q3

Chemistry, Physical

Q2

Materials Science, Multidisciplinary

Q1

Metallurgy & Metallurgical Engineering

Q2

Physics, Applied

Q2

Physics, Condensed Matter

Mathematical and Computational Applications

1.9

Q2

Mathematics, Interdisciplinary Applications

Mathematics

2.3

Q1

Mathematics

Medicina

2.4

Q1

Medicine, General & Internal

Membranes

3.3

Q2

Chemistry, Physical

Q2

Engineering, Chemical

Q2

Materials Science, Multidisciplinary

Q2

Polymer Science

Metabolites

3.4

Q2

Biochemistry & Molecular Biology

Metals

2.6

Q3

Materials Science, Multidisciplinary

Q2

Metallurgy & Metallurgical Engineering

Methods and Protocols

2.3

Q3

Biochemical Research Methods

Microbiology Research

2.1

Q3

Microbiology

Micromachines

3.0

Q2

Chemistry, Analytical

Q2

Instruments & Instrumentation

Q3

Nanoscience & Nanotechnology

Q2

Physics, Applied

Microorganisms

4.1

Q2

Microbiology

Minerals

2.2

Q2

Geochemistry & Geophysics

Q2

Mineralogy

Q2

Mining & Mineral Processing

Modelling

1.3

Q3

Engineering, Multidisciplinary

Molbank

0.6

Q4

Chemistry, Organic

Molecules

4.2

Q2

Biochemistry & Molecular Biology

Q2

Chemistry, Multidisciplinary

Multimodal Technologies and Interaction

2.4

Q3

Computer Science, Artificial Intelligence

Q2

Computer Science, Cybernetics

Q3

Computer Science, Information Systems

Nanomaterials

4.4

Q2

Chemistry, Multidisciplinary

Q2

Materials Science, Multidisciplinary

Q2

Nanoscience & Nanotechnology

Q2

Physics, Applied

Neurology International

3.2

Q2

Clinical Neurology

Neurosci

1.6

Q3

Clinical Neurology

Q4

Neurosciences

Nitrogen

1.6

Q4

Environmental Sciences

Non-Coding RNA

3.6

Q2

Biochemistry & Molecular Biology

Q2

Genetics & Heredity

Nursing Reports

2.4

Q1

Nursing

Nutrients

4.8

Q1

Nutrition & Dietetics

Oceans

1.5

Q3

Marine & Freshwater Biology

Q3

Oceanography

Optics

1.1

Q4

Optics

Organics

1.4

Q3

Chemistry, Organic

Particles

1.7

Q3

Astronomy & Astrophysics

Q2

Physics, Nuclear

Q3

Physics, Particles & Fields

Pathogens

3.3

Q2

Microbiology

Pathophysiology

2.7

Q2

Pathology

Pediatric Reports

1.4

Q3

Pediatrics

Pharmaceuticals

4.3

Q2

Chemistry, Medicinal

Q1

Pharmacology & Pharmacy

Pharmaceutics

4.9

Q1

Pharmacology & Pharmacy

Pharmacy

2.0

Q3

Pharmacology & Pharmacy

Philosophies

0.6

Q2

History & Philosophy of Science

N/A

Philosophy

Photonics

2.1

Q2

Optics

Physics

1.5

Q2

Physics, Multidisciplinary

Plants

4.0

Q1

Plant Sciences

Plasma

1.9

Q3

Physics, Fluids & Plasmas

Polymers

4.7

Q1

Polymer Science

Polysaccharides

4.7

Q1

Polymer Science

Processes

2.8

Q2

Engineering, Chemical

Prosthesis

2.8

Q4

Materials Science, Biomaterials

Proteomes

4.0

Q2

Biochemistry & Molecular Biology

Psychiatry International

1.2

Q4

Psychiatry

Publications

4.6

Q1

Information Science & Library Science

Quantum Beam Science

1.3

Q3

Instruments & Instrumentation

Q3

Materials Science, Characterization & Testing

Q4

Quantum Science & Technology

Quaternary

2.3

Q2

Geosciences, Multidisciplinary

Reactions

2.2

Q3

Chemistry, Multidisciplinary

Recycling

4.6

Q2

Green & Sustainable Science & Technology

Religions

0.7

N/A

Religion

Remote Sensing

4.2

Q2

Environmental Sciences

Q1

Geosciences, Multidisciplinary

Q2

Imaging Science & Photographic Technology

Q2

Remote Sensing

Reports

0.8

Q3

Medicine, General & Internal

Reproductive Medicine

1.1

Q4

Obstetrics & Gynecology

Q4

Reproductive Biology

Resources

3.6

Q2

Environmental Sciences

Q3

Green & Sustainable Science & Technology

Risks

2.0

Q2

Business, Finance

Robotics

2.9

Q2

Robotics

Safety

1.8

Q3

Public, Environmental & Occupational Health

Scientia Pharmaceutica

2.3

Q3

Pharmacology & Pharmacy

Sensors

3.4

Q2

Chemistry, Analytical

Q2

Engineering, Electrical & Electronic

Q2

Instruments & Instrumentation

Separations

2.5

Q3

Chemistry, Analytical

Sexes

1.2

Q2

Medicine, General & Internal

Q3

Psychology, Multidisciplinary

Q2

Social Sciences, Interdisciplinary

Q2

Womens Studies

Smart Cities

7.0

Q1

Engineering, Electrical & Electronic

Q1

Urban Studies

Social Sciences

1.7

Q2

Social Sciences, Interdisciplinary

Societies

1.7

Q2

Sociology

Soil Systems

2.9

Q2

Soil Science

Solids

2.4

Q3

Chemistry, Physical

Q3

Materials Science, Multidisciplinary

Sports

2.2

Q2

Sport Sciences

Stats

0.9

Q4

Mathematics, Interdisciplinary Applications

Q3

Statistics & Probability

Surfaces

2.3

Q3

Chemistry, Physical

Q3

Materials Science, Multidisciplinary

Surgical Techniques Development

0.1

Q4

Surgery

Sustainability

3.3

Q2

Environmental Sciences

Q2

Environmental Studies

Q3

Green & Sustainable Science & Technology

Symmetry

2.2

Q2

Multidisciplinary Sciences

Systems

2.3

Q1

Social Sciences, Interdisciplinary

Technologies

4.2

Q1

Engineering, Multidisciplinary

Telecom

2.1

Q3

Telecommunications

Thalassemia Reports

0.6

Q4

Hematology

Tomography

2.2

Q2

Radiology, Nuclear Medicine & Medical Imaging

Toxics

3.9

Q2

Environmental Sciences

Q1

Toxicology

Toxins

3.9

Q2

Food Science & Technology

Q1

Toxicology

Tropical Medicine and Infectious Disease

2.8

Q2

Infectious Diseases

Q2

Parasitology

Q1

Tropical Medicine

Universe

2.5

Q2

Astronomy & Astrophysics

Q2

Physics, Particles & Fields

Urban Science

2.1

Q3

Environmental Sciences

Q3

Environmental Studies

Q2

Geography

Q3

Regional & Urban Planning

Q2

Urban Studies

Vaccines

5.2

Q1

Immunology

Q1

Medicine, Research & Experimental

Vehicles

2.4

Q2

Engineering, Mechanical

Q2

Transportation Science & Technology

Veterinary Sciences

2.0

Q2

Veterinary Sciences

Vibration

1.9

Q3

Engineering, Mechanical

Q3

Mechanics

Viruses

3.8

Q2

Virology

Water

3.0

Q2

Environmental Sciences

Q2

Water Resources

World

2.0

Q2

Economics

Q2

Political Science

Q1

Social Sciences, Interdisciplinary

World Electric Vehicle Journal

2.6

Q2

Engineering, Electrical & Electronic

Q2

Transportation Science & Technology

Source: 2023 Journal Impact Factors, Journal Citation Reports TM (Clarivate, 2024)


About MDPI

A pioneer in scholarly, open access publishing, MDPI has supported academic communities since 1996. MDPI is leading the transition to open science by making more research free and accessible to everyone. Over 3.5 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of 6000 professional, well-trained staff members, and an in-house article submission platform that was designed to ensure efficient processes within its 440 fully open access titles.

19 June 2024
Current Oncology | Cancer Survivors Month


June is Cancer Survivors Month, which is a month-long observance that celebrates the strength, resilience, and triumph of those who have battled cancer. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings in fields concerning cancer survivors, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information regarding this field.

“A Narrative Review on the Collection and Use of Electronic Patient-Reported Outcomes in Cancer Survivorship Care with Emphasis on Symptom Monitoring”
by Corina J. G. van den Hurk, Floortje Mols, Manuela Eicher, Raymond J. Chan, Annemarie Becker, Gijs Geleijnse, Iris Walraven, Annemarie Coolbrandt, Maryam Lustberg, Galina Velikova et al.
Curr. Oncol. 2022, 29(6), 4370-4385; https://doi.org/10.3390/curroncol29060349
Available online: https://www.mdpi.com/1718-7729/29/6/349

“Sexual Function in Women Survivors of Hematologic Malignancy after Autologous Hematopoietic Stem Cell Transplantation”
by Ioanna Tsatsou, Kyriaki Mystakidou, Theodoula Adamakidou, Theocharis Konstantinidis, Ioannis Kalemikerakis, Antonis Galanos and Ourania Govina
Curr. Oncol. 2023, 30(3), 2916-2927; https://doi.org/10.3390/curroncol30030223
Available online: https://www.mdpi.com/1718-7729/30/3/223

“’Beyond Cancer’ Rehabilitation Program to Support Breast Cancer Survivors to Return to Health, Wellness and Work: Feasibility Study Outcomes”
by Dianne M. Sheppard, Moira O’Connor, Michael Jefford, Georgina Lamb, Dorothy Frost, Niki Ellis and Georgia K. B. Halkett
Curr. Oncol. 2023, 30(2), 2249-2270; https://doi.org/10.3390/curroncol30020174
Available online: https://www.mdpi.com/1718-7729/30/2/174

“Personality Traits and Coping Strategies Relevant to Posttraumatic Growth in Patients with Cancer and Survivors: A Systematic Literature Review”
by Klara Knauer, Anne Bach, Norbert Schäffeler, Andreas Stengel and Johanna Graf
Curr. Oncol. 2022, 29(12), 9593-9612; https://doi.org/10.3390/curroncol29120754
Available online: https://www.mdpi.com/1718-7729/29/12/754

“Assessing the Relationship between Socioeconomic Status, Race, and Psychological Distress in Cancer Survivors: A Population Based Study”
by Ikechukwu Chidobem, Fan Tian, Chisom Mgbodile, Francis Mgbodile, Tahereh Orouji Jokar, Esther Ogbuokiri and Nazia Khan
Curr. Oncol. 2022, 29(4), 2575-2582; https://doi.org/10.3390/curroncol29040211
Available online: https://www.mdpi.com/1718-7729/29/4/211

“Clinical Management of Financial Toxicity–Identifying Opportunities through Experiential Insights of Cancer Survivors, Caregivers, and Social Workers”
by Christopher J. Longo, Louisa G. Gordon, Rebecca L. Nund, Nicolas H. Hart, Laisa Teleni, Carla Thamm, Olivia Hollingdrake, Fiona Crawford-Williams, Bogda Koczwara, Tamara Ownsworth et al.
Curr. Oncol. 2022, 29(10), 7705-7717; https://doi.org/10.3390/curroncol29100609
Available online: https://www.mdpi.com/1718-7729/29/10/609

You are welcome to submit relevant papers to the Current Oncology journal. For any questions, please feel free to contact us.

Current Oncology Editorial Office

7 June 2024
MDPI Calls for Greater Open Access to Science for Ocean Protection

On UNESCO’s 2024 Oceans Day, MDPI encourages the scientific community to increase the accessibility of ocean research to accelerate ocean conservation.

Basel, Switzerland, June 7, 2024: MDPI, a leading open access (OA) publisher, is proud to announce its active support for World Oceans Day 2024, celebrated under UNESCO’s Ocean Decade framework. MDPI’s CEO, Stefan Tochev hopes that “the latest ocean research can be made freely accessible to help empower scientists and communities at large to save our oceans,” under UNESCO’s Ocean Decade until 2030.

Open Access: A Catalyst for Ocean Action

MDPI’s presence at the UNESCO Ocean Decade Conference 2024 highlights our unwavering commitment to using OA to advance ocean science, support research communities, and promote sustainable ocean management.

"Our involvement in the UNESCO Ocean Decade Conference underscores MDPI's commitment to the underfunded Ocean SDG. By promoting OA to scientific articles and books on SDGs, we aim to inspire critical actions," said Tochev. "Our initiatives, like the World Sustainability Award and Emerging Sustainability Award, further demonstrate our dedication to advancing sustainability.”

Showcasing MDPI’s Contributions to Ocean Research

Over the past three years, MDPI has published 30,000 papers focused on ocean research and related topics. Key MDPI journals contributing to this body of work include:

  • Journal of Marine Science and Engineering (4.9k papers)
  • Remote Sensing (2.6k papers)
  • Sustainability (2k papers)
  • International Journal of Molecular Sciences (IJMS) (1.7k papers)
  • Marine Drugs (1.5k papers)
  • Water (1.5k papers)

These publications highlight MDPI’s contributions to ocean science, reinforcing our role in the broader sustainability agenda by promoting blue innovation and economy.

Additionally, MDPI has launched Oceans, an international, peer-reviewed forum specifically aimed at publishing studies related to all branches of oceanography with an emphasis on the functioning of the ocean and the sustainable use of its resources and ecosystem services.

Affirming MDPI’s Commitment to Ocean Science

MDPI’s commitment to OA is pivotal in addressing critical global challenges, from climate change to ocean sustainability. Our efforts resonate with Outcome 4 of the UNESCO Ocean Decade action roadmap: an accessible ocean with open and equitable access to data, information, technology, and innovation. By aligning with UNESCO’s goals, MDPI continues to contribute to shaping a sustainable future for our oceans, reinforcing our position as a forward-thinking publisher dedicated to environmental stewardship and scientific excellence.


For more information, contact Rui Duarte at [email protected] or +41764313242.


About MDPI

A pioneer in scholarly, open access publishing, MDPI has supported academic communities since 1996. MDPI is leading the transition to open science by making more research free and accessible to everyone. Over 3.5 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of over 6000 professional, well-trained staff members, and an in-house article submission platform that was designed to ensure efficient processes within its 430 fully open access titles.

 

5 June 2024
MDPI Sets a New Benchmark for Publishing Excellence


95% of authors rate MDPI’s publication process as excellent or good, setting a new benchmark in scientific publishing – reveals 2023 Annual Report. 

Basel, Switzerland, June 4, 2024: MDPI, the leading open access (OA) publisher, proudly announces the release of its 2023 Annual Report, detailing remarkable achievements and reaffirming its leadership in advancing OA publishing. In 2023, MDPI received 655,065 submissions, of which 285,244 articles were published. The company now commands a 17% market share in gold open access articles, with a median publication time of six weeks.

Stefan Tochev, MDPI's CEO, stated, "As a pioneer in open access publishing, MDPI has long been a game-changer in the scholarly community, serving millions of authors around the world to ensure the latest research is freely available. Reflecting on our incredible journey at MDPI, 2023 has been marked by growth in paper submissions, ambitious projects and initiatives aimed at improving our internal processes and delivering top-notch services to our scientists."

MDPI's 2023 Annual Report highlights several key achievements:

  • 17% market share in gold open access articles across all disciplines.
  • Record satisfaction rates: 95% of authors, 82% of reviewers, and 85% of guest editors.
  • Enhanced editorial standards and feedback processes.
  • Increased reach and impact with 54 new MDPI journal inclusions in Scopus, 29 in Web of Science, and 77 in DOAJ.

MDPI’s unwavering commitment to advancing OA has transformed the landscape of scholarly publishing, making high-quality research freely accessible to the global scientific community. The continuous improvement in our editorial standards and feedback processes underscores MDPI’s dedication to ensuring academic integrity and excellence.

Global Reach and Collaboration

MDPI’s global footprint continues to expand, with authors from diverse regions: 37% from Asia/Pacific, 36% from Europe, 15% from the Americas, and 12% from other parts of the world. The company’s fully OA platform attracted nearly 14 million monthly visitors in 2023, reflecting its widespread influence in the scientific community.

Commitment to Partnerships

With over 800 institutional partners, MDPI continues to demonstrate its dedication to providing reliable and collaborative publishing services. The introduction of a transparent flat-fee model highlights MDPI's ongoing efforts to enhance affordability and support to the academic community. For more details read our 2023 Annual Report.

For more information, contact Rui Duarte at [email protected] or +41764313242.


About MDPI

A pioneer in scholarly, open access publishing, MDPI has supported academic communities since 1996. MDPI is leading the transition to open science by making more research free and accessible to everyone. Over 3.5 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of over 6000 professional, well-trained staff members, and an in-house article submission platform that was designed to ensure efficient processes within its 430 fully open access titles.

 

5 June 2024
Meet Us at the ESMO Congress 2024, 13–17 September 2024, Barcelona, Spain


The ESMO Congress is a globally influential oncology platform that unites clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. ESMO 2024 will disseminate the latest cutting-edge data, providing high-quality education and excellent networking opportunities for oncologists and other stakeholders on an international level.

The following MDPI journals will be represented:

If you are participating in this conference, please feel free to engage with us online prior to attendance. Our delegates look forward to meeting you in person at booth #P627 and answering any questions you may have. For more information regarding the conference, please visit the following link: https://www.esmo.org/meeting-calendar/esmo-congress-2024.

4 June 2024
MDPI Insights: The CEO's Letter #12 - First Term as CEO, Tu Youyou Award, Books Report

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

Renewed Term as CEO of MDPI

I released the first CEO Letter at the end of June 2023, reflecting on my first month as CEO. Looking back at the first release, I’m pleased to see a marked consistency of content – from talking about open access (OA) and highlighting the great work being done at MDPI, to bringing together the science community with our conferences and building relations with our editorial board members and our industry as a whole.

For example, in the first letter, I highlighted our meeting with Dr. Eric O. Freed, the founding and current Editor-in-Chief (EiC) of our journal Viruses. Meeting with Eric is a pleasure, as he has a strong commitment and clear vision for the journal. 

On 21 May, 2024 we met with EiC Prof. Dr. Antonino Carbone, and Section EiC Prof. Dr. Alberto Signore (pictured on the left), of our journal Hemato (tracked for Impact Factor, and indexed in Scopus), showing our continued and active collaboration with our chief editors to develop the visions for the journal. Over the course of the day, we gathered feedback and gained an understanding of the journal's expectations and focus on strategic growth.

Reflections on my first year as CEO: achievements and initiatives

During my first year as CEO, there have been many remarkable moments, including a strong focus on bringing people together, focusing on company communications and performance.

According to a recent study of 3,400 people across 10 countries, “Managers impact employees’ mental health (69%) more than doctors (51%) or therapists (41%) — and even the same as a partner (69%).” This is an important topic for me, and perhaps that’s why I place a high value on management culture due to its tangible impact on people’s lives.

When I joined MDPI, I created a weekly meet-up for the Corporate Marketing department and their team leads. On the final Thursday of every month, we hold a Global Marketing meet-up to present projects, share knowledge, and conduct training. For years, I’ve maintained the tradition of ending each of our monthly global calls with a group photo to boost morale, motivation, and productivity, and to finish on a positive note.

In keeping with this, when I stepped into the role of CEO, I launched a bi-weekly management meeting, chairing over 20 MDPI Management Team meetings in my first year. These sessions provide an opportunity for managers to present their team’s work, focusing on their achievements and the challenges they face, while at the same time creating space for sharing knowledge.

“I firmly believe that OA is the future of publishing”

I co-organized and co-led the 2023 MDPI Strategy Management meeting this past October, from which we established an Executive Task Force that meets monthly to prioritize projects aimed at building MDPI into the world’s most trusted publisher. To achieve our goals, we as managers need to maintain collaborative communication and connect to the bigger picture.

As CEO, I focused on leadership communication by publishing 12 CEO Letters, one for each month of my tenure, to share more about MDPI news and achievements. I also produced ten videos to help further communicate our message.

I was happy to attend eight publishing and conference events, including STM in Frankfurt and Washington, APE, and R2R, and facilitate critical company meetings with Elsevier, Web of Science, ResearchGate, DOAJ, and others. It was a pleasure to meet and have discussions with key organizations and governing bodies such as CAS in China and ANVUR in Italy.

The best part was the opportunity to visit seven MDPI offices across Europe and Asia-Pacific, meeting with local managers and colleagues and supporting them in person. As part of this, I conducted training sessions while continuing to lead the Corporate Marketing department.

Looking ahead

My goal for my second year as CEO is to continue building on the initiatives from the past, including leadership communications, public relations, educational marketing, and company culture, while representing MDPI to the best of my ability. Additionally, I have a few new projects I hope to launch that I believe will be valuable to MDPI and the industry at large.

I firmly believe that OA is the future of publishing, and I am grateful to be in a position to advocate for this belief as part of MDPI, the world's leading open access publisher.

Thank you to our staff and industry friends for your genuine support in this role.

Impactful Research

Nominations Open for the Prestigious Tu Youyou Award 2024

I am pleased to share that MDPI has opened nominations for the 2024 Tu Youyou Award, a prestigious recognition established in honour of Professor Tu Youyou, Nobel Laureate, whose work has significantly transformed the global fight against malaria.

The Tu Youyou Award offers CHF 100,000

In 2015, Professor Tu Youyou was awarded the Nobel Prize in Physiology or Medicine for her discovery of artemisinin, significantly reducing mortality rates from malaria and shaping global health policies. Artemisinin-based combination therapies (ACTs) are now the standard treatment endorsed by the World Health Organization (WHO), saving countless lives, especially in regions heavily burdened by malaria.

MDPI Special Issue

To mark Professor Tu’s 80th birthday in 2009, MDPI’s journal Molecules issued a Special Issue focusing on her contributions to medical research. Recognizing her continuous contribution, MDPI created the Tu Youyou Award in 2016 to honour outstanding achievements in natural products and medicinal chemistry.

The deadline for nominations is 31 December 2024

Nominations are open to scientists excelling in natural products and medicinal chemistry. Eligible nominators include academic institutes, universities, and societies. The deadline for nominations is 31 December 2024, with the winners to be announced on 30 April 2025. The Tu Youyou Award offers CHF 100,000, split equally among the winners.

MDPI encourages the academic community to nominate individuals who have demonstrated excellence and innovation in line with Professor Tu’s legacy. This award not only honours individual achievement but also encourages further scientific exploration and discovery in critical areas of medicine.

This award embodies our deep commitment to groundbreaking research that drives societal progress and celebrates the legacy of one of the greatest medical innovators of our time.

Inside MDPI

2023 MDPI Books Report

In past CEO letters, I have highlighted our publishing process and the impactful peer-reviewed articles that represent the core output of scholarly publishing. However, scholarly books are another pillar of publishing that MDPI also services, which our core audience may not be fully aware of. In this section, I highlight the 2023 MDPI Books report, released by our MDPI Books team in May 2024.

Download the 2023 MDPI Books Report

In the report, you will find a summary of MDPI Books’ 10th anniversary, the books indexed in the Web of Science Book Citation Index, our market outreach, and our outlook for 2024.

MDPI Books celebrated its 10th anniversary in 2023

MDPI Books published its first OA Reprint, “From the Renaissance to the Modern World,” in 2013. Over the past ten years, MDPI Books has seen a significant increase in both the volume and nature of published Reprints. As of December 2023, our catalogue includes a total of 7,369 Reprints, with 1,811 of them added in 2023 alone. MDPI Books includes monographs, book series, edited books and reprints of special issues and topical collections, among other book types.

We’re also celebrating the 10-year MDPI anniversary of Laura Wagner, Head of MDPI Books.

Laura Wagner (Head of Books Division)

Laura holds a Bachelor’s degree in Art History and History from the University of Basel. After her studies, she started her career at an art gallery in Basel.

Since joining MDPI in 2014, Laura has held several roles within the company. This included editorial work, development of reprint and book services, and the temporary management of the journal Arts.

Currently Laura holds the role of Head of Books Division and is in charge of the development and strategic direction of MDPI Books.

MDPI Books indexed in Web of Science Book Citation Index

Another milestone in 2023 was the indexing of four book titles in the Web of Science Book Citation Index. The indexing of our open access books is crucial for their reach and accessibility, ensuring higher visibility within the open science community.

  1. Self-Representation in an Expanded Field: From Self-Portraiture to Selfie, Contemporary Art in the Social Media Age by editor Ace Lehner
  2. Towards Socially Integrative Cities: Perspectives on Urban Sustainability in Europe and China by editors Bernhard Müller, Jian Liu, Jianming Cai, Paulina Schiappacasse, Hans-Martin Neumann, and Baojun Yang
  3. Transitioning to Gender Equality by editors Christa Binswanger and Andrea Zimmermann
  4. Under Construction: Performing Critical Identity by editor Marie-Anne Kohl

If you would like to learn more about MDPI Books, please visit: www.mdpi.com/books

If you are thinking of writing or editing a book, you can submit your proposal at www.mdpi.com/books/publish-with-us, or email us at [email protected].

Coming Together for Science

Polymers 2024 – Polymers for a Safe and Sustainable Future

Our conference team successfully managed the Polymers 2024 – Polymers for a Safe and Sustainable Future international conference which took place from 28–31 May 2024 in Athens, Greece. The conference was chaired by Prof. Dr. Dimitrios Bikiaris and Prof. Dr. Konstantinos Triantafyllidis from the Aristotle University of Thessaloniki, Greece, and Dr. Ioanna Deligkiozi from AXIA Innovation, Germany. In total, the conference had 259 accepted abstracts and over 300 attendees from 22 different countries.

The conference featured three keynote speakers and 12 invited speakers, including esteemed scholars from Europe, Asia, Africa, and Canada. It included 60 selected talks and 189 posters, chosen by the 24 members of the Scientific Committee along with the three Conference Chairs. The event explored the latest scientific advancements and innovations in polymer science, focusing on creating safe, sustainable, and environmentally friendly materials. Emphasizing green polymer chemistry and the use of bioresources, the conference promoted the synthesis of biobased and biodegradable polymers.

The conference featured esteemed scholars from Europe, Asia, Africa, and Canada

Conference awards

The conference also presented three awards: two sponsored by the journal Polymers – The Best Poster Award (€500) and the Best Oral Presentation Award (€600) – and one sponsored by Ossila, the Best Student Poster Award (€500).

Thank you to our 16 sponsors, three partnering societies (Hellenic Polymer Society, European Polymer Federation, and North American Thermal Analysis Society [NATAS]) and eight media partners.

Upcoming in-person event

1–4 August, 2024
The 1st International Conference on AI Sensors & The 10th International Symposium on Sensor Science
Location: Singapore

The AI Sensors 2024 Conference will unite innovators and experts in the realms of sensors, sensing technology, and artificial intelligence.

Find more upcoming MDPI events here.

Closing Thoughts

3rd World Forum Principles of Scientific Publications

I’m pleased to share that MDPI sponsored and attended the 3rd World Forum on Principles of Scientific Publications, which took place from 22–24 May in Malaga, Spain. The event brought together academic professionals and leading researchers to discuss critical topics in the realm of publishing and research. Presentation topics included Open Science, AI in Publishing, Predatory Journals, Fake Publications, Challenges for Non-native English Speakers, and more.

“It was great to see strong support from MDPI authors in the audience”

MDPI presentations


Stefan Tochev (CEO, MDPI) presenting at the 3rd World Forum Principles of Scientific Publications

I had the privilege of attending and presenting at the event, along with my colleague Dr. Enric Sayas (Business Analyst, MDPI) from our Barcelona office, who explored the ethical concerns and opportunities brought by AI in publishing.

I took the opportunity to present on Open Science, the benefits of Open Access, and MDPI’s performance, operations, and investment in ethics. Special thanks to Evan Escamilla (Project Manager, MDPI Books) and Facundo Santomé (Sr. Marketing Manager, MDPI) who also joined the conference.

It was great to see strong support from MDPI authors in the audience who shared their positive experiences publishing with us. Their story reflects the experience of the vast majority of authors who choose to work with MDPI.

We also encountered some conservative views on OA, which created an opportunity for open discussion aimed at addressing concerns about OA and MDPI. Engaging in such discussions is important, as scepticism sometimes arises from misinformation or from a misunderstanding of who we are and how we operate. When we engage in open and honest discussion, we tend to see people getting a better understanding of MDPI, which helps address any misconceptions they may have had.


Left to right: Dr. Enric Sayas (Business Analyst, MDPI), Stefan Tochev (CEO, MDPI), Facundo Santomé (Sr. Marketing Manager, MDPI), and Evan Escamilla (Project Manager, MDPI Books) at 3rd World Forum Principles of Scientific Publications

Stefan Tochev
Chief Executive Officer
MDPI AG

23 May 2024
Transfer Service in MDPI

We are pleased to announce MDPI’s Transfer Service.

This service provides a convenient method of transferring your manuscript file, along with any reviewer comments, to another journal within our publishing portfolio.

We are committed to helping authors find the right home for their research, and we will provide authors with guidance and technical support through all stages of the transfer process. Authors will be able to choose to transfer in the following two situations:

1. Select alternative journals on submission.

2. Authors are encouraged to transfer manuscripts to other MDPI journals.

More details about the Transfer Service can be found at the following link:

https://www.mdpi.com/authors/transfer-service

17 May 2024
Tu Youyou Award—Open for Nominations

In acknowledgment of the groundbreaking achievements of Professor Tu Youyou, the Nobel laureate credited with the discovery of artemisinin, MDPI is proud to announce the Tu Youyou Award. This award, inaugurated in 2016, seeks to honor scholars who excel in the fields of natural products chemistry and medicinal chemistry.

Prize:

  • CHF 100,000 in total (If there is more than one winner, the prize will be divided equally amongst the winners);
  • An award medal for each winner.

Who should be nominated?

  • Scientists with outstanding achievements and contributions in the fields of natural products chemistry and medicinal chemistry.

Who can submit a nomination?

  • Academic research institutes
  • Universities
  • Academic societies

Any personal nominations are not accepted.

How do I submit a nomination?
Candidates’ institutional affiliations need to submit their nominations for final candidates to the Tu Youyou Award Team directly by email after internal screening, and each institution can only nominate a maximum of two candidates for each edition of the Tu Youyou Award. Please note that the nominations cannot be modified once they are submitted and confirmed by the Tu Youyou Award Team.

Required nomination materials:
Nomination Form (Download)

Schedule:
Nomination deadline: 31 December 2024;
Winner announcement: 30 April 2025.

Contact:
Tu Youyou Award Team ([email protected])

More information can be found on the Tu Youyou Award official website. For any inquiries, do not hesitate to contact the Tu Youyou Award Team.

16 May 2024
Current Oncology | Brain Tumor Awareness Month


May is brain tumor awareness month, although in some regions, it is celebrated in March. A brain tumor refers to an abnormal mass or growth of cells in the brain. It can be benign (non-cancerous) or malignant (cancerous). Brain tumors can cause a range of symptoms, including headaches, seizures, cognitive impairments, and neurological deficits. Treatment options include surgery, radiation therapy, and chemotherapy. Early detection, awareness, and research are vital in improving outcomes and supporting individuals affected by brain tumors. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings and a high-quality Special Issue in the field of brain tumor, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field.

“Classification of Brain Tumor from Magnetic Resonance Imaging Using Vision Transformers Ensembling”
by Sudhakar Tummala, Seifedine Kadry, Syed Ahmad Chan Bukhari and Hafiz Tayyab Rauf
Curr. Oncol. 202229(10), 7498-7511; https://doi.org/10.3390/curroncol29100590
Available online: https://www.mdpi.com/1718-7729/29/10/590

“Treatment of Older Adult Patients with Glioblastoma: Moving towards the Inclusion of a Comprehensive Geriatric Assessment for Guiding Management”
by Manik Chahal, Brian Thiessen and Caroline Mariano
Curr. Oncol. 2022, 29(1), 360-376; https://doi.org/10.3390/curroncol29010032
Available online:  https://www.mdpi.com/1718-7729/29/1/32

“Brain Metastases among Cancer Patients Diagnosed from 2010–2017 in Canada: Incidence Proportion at Diagnosis and Estimated Lifetime Incidence”
by Jiaqi L. Liu, Emily V. Walker, Yuba Raj Paudel, Faith G. Davis and Yan Yuan
Curr. Oncol. 202229(3), 2091-2105; https://doi.org/10.3390/curroncol29030169
Available online:  https://www.mdpi.com/1718-7729/29/3/169

“Focused Delivery of Chemotherapy to Augment Surgical Management of Brain Tumors”
by Yusuf Mehkri, Samuel Woodford, Kevin Pierre, Abeer Dagra, Jairo Hernandez, Mohammad Reza Hosseini Siyanaki, Mohammed Azab and Brandon Lucke-Wold
Curr. Oncol. 202229(11), 8846-8861; https://doi.org/10.3390/curroncol29110696
Available online:  https://www.mdpi.com/1718-7729/29/11/696

“Five-Fraction Stereotactic Radiotherapy for Brain Metastases—A Retrospective Analysis”
by Julian P. Layer, Katharina Layer, Gustavo R. Sarria, Fred Röhner, Cas S. Dejonckheere, Lea L. Friker, Thomas Zeyen, David Koch, Davide Scafa, Christina Leitzen et al.
Curr. Oncol. 202330(2), 1300-1313; https://doi.org/10.3390/curroncol30020101
Available online:  https://www.mdpi.com/1718-7729/30/2/101

“Leptomeningeal Metastasis: A Review of the Pathophysiology, Diagnostic Methodology, and Therapeutic Landscape”
by Andrew Nguyen, Alexander Nguyen, Oluwaferanmi T. Dada, Persis D. Desai, Jacob C. Ricci, Nikhil B. Godbole, Kevin Pierre and Brandon Lucke-Wold
Curr. Oncol. 202330(6), 5906-5931; https://doi.org/10.3390/curroncol30060442
Available online:  https://www.mdpi.com/1718-7729/30/6/442

Relevant Special Issue:

“Psychosocial Effects of Head and Neck Cancer”
Guest Editor: Dr. Soichi Oya
Available online: https://www.mdpi.com/si/curroncol/Surgical_Treatment_Brain_Tumors

You are welcome to submit relevant papers to the journal Current Oncology. For any questions, feel free to contact us.

Current Oncology Editorial Office

16 May 2024
MDPI Romania Author Training Academic Events in April

MDPI Romania sponsored four events over the month of April, contributing author training sessions to each event.

The NutriSciLabs 2024 conference was held at the Carol Davila University of Medicine and Pharmacy on 12 April 2024. Organized by the Association of Students from the Faculty of Pharmacy Studies, the conference aimed to enhance students’ academic writing and research skills, and bolster their confidence in participating in the academic world. Ioana Paunescu, journal relations specialist for MDPI Romania, led the training session. Paunescu first outlined MDPI’s history and core values, then explained academic writing techniques, ethics, and similarity percentages. The presentation covered the entire editorial process, highlighting the amount of attention paid to details throughout manuscript processing. Paunescu also discussed common errors that authors make while writing, and how to avoid such errors.


On 13 April 2024, the NextGEN 2.0 Student Conference took place at the Babes-Bolyai University of Cluj-Napoca. NextGen Healthcare organized this event with the university’s European Students’ Society to discuss European and international current affairs. MDPI Romania contributed an author training session called Steps of the Publication Process. Irina Codruta Zaharia, journal relations specialist, began the session with a general introduction of MDPI before diving into different article types, different layout formats, possible journals to submit to, the MDPI submission checklist, and the MDPI editorial process. By explaining the fundamentals of writing and publishing academic papers, Zaharia imparted valuable industry knowledge to the curious minds present. Participants were eager to engage with Zaharia in the subsequent Q&A session.


Celebrating its 20th anniversary this year, the International Conference “Students for Students” has long been a gathering place for undergraduate and postgraduate students of all nationalities to present their work and exchange ideas with each other. This year’s conference was held on 18 April 2024, with MDPI Romania contributing an author training session called The World of Open Access. Key speakers included Dr. Norbert Kiss from MDPI Romania and Prof. Dragos Horvath from Strasbourg University. Dr. Kiss discussed the history of open access, differences between open access publishing and traditional publishing, and implications for open access in the future. Attendees expressed keen interest in the subject, approaching Dr. Kiss with questions about academic publishing as well as his career trajectory.


Most recently, on 26 April 2024, MDPI Romania sponsored the National Symposium of Students from Geology and Geophysics Faculties. The AAPG Students Chapter at the Babes-Bolyai University organized this event as an opportunity for geology students from all Romanian universities to present their work and confer with other researchers. Dr. Kiss gave his lecture The World of Open Access at this event as well.


MDPI is thankful to all the participants, speakers, and organizers who attended these events. Through their enthusiasm and dedication, these events were great successes.

2 May 2024
MDPI Insights: The CEO's Letter #11 - 2023 Annual Report, MDPI Awards, STM

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

2023 Annual Report

This is an exciting time of year at MDPI, as we have just released our annual report 2023, recapping the past year and sharing the progress and changes that took place during it.


Stefan Tochev (CEO, MDPI)

Reflecting on 2023, I can't help but think of the changes that have occurred not only at MDPI but also within our industry as a whole. In light of this, I’m reminded that change is the only constant, and that for a publishing enterprise that has experienced rapid growth, adapting to change becomes not only a necessity but also a catalyst for sustained success.

Looking back on the significant ground we covered in 2023, I am pleased to report that the year was marked by a rise in paper submissions, along with a range of initiatives aimed at improving our internal processes and delivering top services to our scientists.

2023 Top-line MDPI Numbers

An important priority for 2023 was to strengthen our editorial policies. Despite a notable increase in the number of papers submitted from 603,000 to 655,000 (+8.6%), there was a decrease in the number of papers published from 303,000 to 285,000 (-5.9%), consistent with the overall trend in the scholarly publishing market. MDPI’s market share in gold open access articles published reached 17% in 2023 (according to Dimensions data).

2023 Open Access Numbers

For over two decades, MDPI has been at the forefront of reshaping the academic publishing landscape, with OA surpassing subscription-based publishing in 2020. This trajectory is deeply rooted in our history and reflects our unwavering commitment to, and vision for, an open future. This momentum continued in 2023, with 39% of the 4.16 million articles and reviews published as gold full-OA, 15% as gold hybrid-OA, 8% as bronze-OA, and 3% as green-OA, relative to 35% behind a paywall. In terms of gold OA (full or hybrid) articles and reviews published, MDPI leads the way in terms of total articles published in 2023.

MDPI is the trusted and preferred OA publisher for the scholarly community

However, in 2023, we saw a downward trend in publication numbers compared to 2022. This trend was also seen in total OA publications. While the number of submissions increased, the decline in MDPI publications can be attributed to several factors, such as improved scrutiny in our peer-review process, including the evaluation of content scope and higher rejection rates, and a post-pandemic decrease in research related to COVID-19 papers.

Download 2023 MDPI Annual Report.
Access 2023 Digital Report.

Impactful Research

Recognizing Scholars – MDPI Awards

MDPI is committed to empowering young researchers as they embark on their careers. In 2023, our journals hosted a total of 400 awards, receiving 8,839 applications and nominations. The evaluation committees selected 959 winners, with the total budget for these awards amounting to CHF 546,500.

For more information about MDPI awards, applications, and winners, please click here

The following awards recognize scholars and the impact of their research, including Young Investigator Awards, Best PhD Thesis Awards, and Travel Awards for junior researchers.

MDPI Awards – The following awards require an application or a nomination.

Young Investigator Award (CHF 1000–2000 for each winner)
This award acknowledges the achievements of young investigators in research areas relevant to the journal’s scope. Candidates must have received their PhD no more than 10 years prior to the award announcement date and must be nominated.

Best PhD Thesis Award (CHF 500–800 for each winner)
This award recognizes young scholars who have completed outstanding PhD theses in research areas relevant to the journal’s scope. It aims to encourage them to continue their excellent work and make further contributions to their field.

Travel Award (CHF 500–800 for each winner)
This award encourages junior scientists to present their latest research at academic conferences relevant to the journal’s scope, thereby increasing their impact.

Distinguished Scholars
Additionally, 220 awards were granted to the most distinguished authors and reviewers in our journals through Best Paper Awards and Outstanding Reviewer Awards. The following awards are selected by the editorial staff of the journal and do not require an application or a nomination. They exemplify the excellent contributions made by our authors, reviewers, and editors.

These awards exemplify the excellent contributions made by our authors, reviewers, and editors

Best Paper Award (CHF 200–500 for each winner)
This award is granted annually to highlight publications of high quality, scientific significance, and extensive influence.

Outstanding Reviewer Award (CHF 500 for partial winners)
This award is given annually to recognize reviewers who generously contribute their time to reviewing papers and demonstrate thoroughness, professionalism, and timeliness in their reviews.

MDPI also offers awards for specific topics in various research fields:

Carbon Neutrality Award (CHF 500–800 for each winner)
Sponsored by MDPI journal Sustainability, this award recognizes applicants who have made exceptional academic or societal contributions to carbon neutrality, either in general or in relation to a specific carbon-neutrality-related issue.

Intelligent Manufacturing Award (CHF 500–800 for each winner)
Administered by MDPI journal Machines, this award is presented to an individual who has made outstanding academic or societal contributions to the field of intelligent manufacturing.

Granted: World Sustainability Awards

Inside MDPI

MDPI Opens Office in Seoul, Korea and Appoints Claude Seo as Office Manager

As CEO of the world’s leading OA publisher, I am pleased to announce the official opening of our Korean branch office. With this addition, MDPI now operates 21 offices in 12 countries worldwide, improving on our position as a truly global publisher. This expansion represents more than just an increase in our physical footprint; it is a pivotal step in our ongoing commitment to making scientific knowledge more accessible across the globe.

MDPI now operates 21 offices in 12 countries worldwide, improving on our position as a truly global publisher


Claude Seo (MDPI Korea Office Manager, Seoul)

Claude Seo, who has over 15 years of experience in the academic publishing industry, has been appointed as the Office Manager of the Seoul office. The launch of our Seoul office allows us to better support the Korean scientific community and to further promote the publication of OA journals in the region.

Reflecting on his role, Claude shared that he is:

“Delighted to have been entrusted with this position within MDPI, the no. 1 scholarly OA publisher. As we establish our presence in Korea, we are dedicated to integrating ourselves into the local community and contributing to its vibrant culture. Our commitment goes beyond business growth; it is about creating a more informed and innovative society by embracing and promoting diversity within the scientific community.”

Sungkyunkwan University Joins MDPI’s Institutional Open Access Program

Additionally, I am pleased to share that Sungkyunkwan University has joined MDPI’s Institutional Open Access Program (IOAP). This program offers free access to MDP’s online submission system for institutions and provides APC discounts to affiliated authors. Thirteen major Korean universities, including Sungkyunkwan University, Kyunghee University, Chung-Ang University, and the Catholic University of Korea, have adopted IOAP in Korea.

Learn more about MDPI’s collaboration in Korea in my previous CEO Letter, in which I recap our visit to Seoul, South Korea.

Coming Together for Science

4th MMCS: Harnessing the Power of New Drug Modalities

Our conference team successfully managed the 4th Molecules Medicinal Chemistry Symposium, held from 24–26 April in Barcelona, Spain. It was chaired by Prof. Dr. Diego Muñoz-Torrero from the Institute of Biomedicine (IBUB), University of Barcelona, Spain, and Prof. Dr. Simona Collina from the University of Pavia, Italy. In total, there were 84 accepted abstracts and 102 conference attendees from 22 different countries.


From left to right: Prof. Dr. Rino Ragno (Scientific Committee), Dr. Maria Emilia Sousa (Scientific Committee), Prof. Dr. Claudio Viegas Jr. (Scientific Committee), Prof. Dr. Simona Collina (Chair), Prof. Dr. Diego Muñoz-Torrero (Chair), Alvina Wu (Managing Editor, MDPI), Prof. Dr. Roman Dembinski (Scientific Committee), Prof. Dr. Mariana Spetea (Scientific Committee).

The event comprised 12 Invited Speakers, 35 Selected Talks, 10 Flash Poster Presentations, and 39 Posters. The overarching topic of the conference was the impact of the emergence of new drug modalities on drug discovery, with thematic sessions covering topics such as photoactivatable drugs, candidates targeting RNA and epigenetic targets, covalent modifiers, and the development of new anti-cancer agents, among other medicinal chemistry projects.

We are pleased to have received feedback from attendees highlighting the professional approach of the conference chairs and participants, the high quality of the talks, and the overall outstanding organization on the part of the MDPI conference team.

Thank you to the conference sponsors, Fluorochem and IBUB, and to our partnering societies, The Spanish Society for Biochemistry and Molecular Biology (SEBBM), and the Spanish Society of Medicinal Chemistry (SEQT).

Upcoming In-Person Event

28–31 May, 2024
Polymers 2024 – Polymers for a Safe and Sustainable Future
Location:
Athens, Greece
Conference Chairs: Prof. Dr. Dimitrios Bikiaris, Prof. Dr. Konstantinos Triantafyllidis, Dr. Ioanna Deligkiozi
We look forward to welcoming experts Prof. Damià Barceló, Prof. Minna Hakkareinen, and Prof. Armando J. D. Silvestre to this event.

Find more upcoming MDPI events here.

Organize Your Event with MDPI’s Sciforum

Sciforum is MDPI’s platform dedicated to the organization of scientific events. In line with our mission to promote science, Sciforum supports scholars, societies, research networks, and universities at all stages of organizing in-person events, virtual events and webinars. Our platforms are efficient, user-friendly, and cost-effective. We handle all steps related to event management. Contact us for details.

Closing Thoughts

A Report from the Future – STM US Annual Conference 2024


Stefan Tochev (CEO, MDPI), Dr. Giulia Stefenelli and Dr. Ioana Craciun from MDPI’s Scientific Office Board.

MDPI has for a long time been a sponsor of the STM Annual Conferences, held yearly in the US and Frankfurt, and is a trusted partner and supporter of the STM organization. While I have attended the Frankfurt conference for the past three years, this was my first time visiting the Washington, DC session, and I am glad I did.

Although it was a brief trip, I greatly appreciated the opportunity to attend in the company of my colleagues Dr. Giulia Stefenelli and Dr. Ioana Craciun from MDPI’s Scientific Office Board. They always help map some of the new industry trends against MDPI’s operational framework and guidelines. It’s a great group for kicking ideas back and forth on what we can apply at MDPI.

In my experience, STM never fails to deliver. It’s always a great conference for reconnecting with fellow publishers, industry friends, and vendors. As usual, STM this year curated a diverse range of speakers and panels, who proferred valuable knowledge and insights from outside our industry, delivering thought-provoking insights into our field. An example of this was the ‘Trust Panel’ session, which included Alan Schiffres (Managing Director, InfoLinx), who shared a number of the learnings about fraud and risk management from his 40 years in financial services, to help address some of the challenges we are currently facing in the area of publishing integrity.

Launch of STM Trends 2028 Panel

I particularly enjoyed the ‘Launch of STM Trends 2028 Panel’, which presented a report focused on the integration of humans and machines in scholarly publishing. The session highlighted themes such as AI, digitization, and the evolving research ecosystem. The report envisions a future where technology blurs the lines between human and machine involvement in research processes, with significant implications for trust, reputation, and equity. While this presents opportunities for connectivity and knowledge dissemination, it also poses challenges such as disinformation, fragmentation, and geopolitical tensions. We must rely on a wise combination of technology and human agency to navigate this complex landscape and will have to carefully examine its potential impacts on communication and scholarly publishing.

MDPI has joined the STM Integrity Hub. Click here to learn more.

While every presenter brought their own knowledge and personal touch, I was particularly pleased to encounter new speakers such as Heather Whitney (Research Assistant Professor, Radiology, University of Chicago) and Igor Grossmann (Professor of Psychology, University of Waterloo, Canada). Having studied Sociology at the University of Guelph, I have a soft spot for fellow social scientists from Canada, and I was very impressed by Igor’s presentation on ‘The Social Scientist: A View from the Future’ and his participation in the panel session ‘The Future Beyond the Article,’ which was one of my favourites from the conference, given the diversity of perspectives from the panel speakers.

Memorial Park in Washington, DC

On a personal note, this was my first-time visiting Washington, DC, and I’m glad we took an afternoon to visit the Memorial Park, with its incredible monuments to figures ranging from Martin Luther King, Jr. to Abraham Lincoln. The magnitude of the monuments is deeply impressive. I particularly appreciated the Thomas Jefferson memorial and the following quote, which I think speaks to the importance of change and adaptation. It’s something we can apply not only in our industry but also in our personal lives.

"I am not an advocate for frequent changes in laws and constitutions, but laws and institutions must go hand in hand with the progress of the human mind. As that becomes more developed, more enlightened, as new discoveries are made, new truths discovered and manners and opinions change, with the change of circumstances, institutions must advance also to keep pace with the times. We might as well require a man to wear still the coat which fitted him when a boy as a civilized society to remain ever under the regimen of their barbarous ancestors."

– Excerpted from a letter to Samuel Kercheval, July 12, 1816.

Stefan Tochev
Chief Executive Officer
MDPI AG

30 April 2024
MDPI Opens Office in Seoul, Korea and Appoints Claude Seo as Office Manager

MDPI, the leading Open Access (OA) publisher, announced on Monday that it opened its Korean branch office on 29th April 2024. With this addition, MDPI now operates 21 offices in 12 countries worldwide. Claude Seo, with over 20 years of experience in the academic journal publishing industry, including Nature Publishing Group (NPG), has been appointed as the Office Manager of the Seoul office.

With the establishment of a Seoul office, MDPI aims to actively support Korea scientific communities to further promote the publication of OA journals in the region. As of the end of 2023, Korea ranked sixth worldwide in both submissions and publications of MDPI research papers. MDPI is the number one OA publisher in Korea.


Sungkyunkwan University Joins MDPI’s Institutional Open Access Program

In addition, MDPI announced that Sungkyunkwan University joined MDPI’s Institutional Open Access Program (IOAP). This program offers free access to MDPI online submission system for the institutions and APC discounts to affiliated authors. Thirteen major Korean universities, including Sungkyunkwan University, Kyung Hee University, Chung-Ang University and Catholic University of Korea, have adopted IOAP in Korea.

OA aims to break down barriers that have traditionally restricted access to science, ensuring that knowledge is available to all, regardless of financial situation or institutional affiliations. Authors, academia, and scientific communities are rapidly moving toward OA. MDPI has been at the forefront of reshaping the academic publishing landscape, with OA surpassing subscription-based publishing in 2020.


MDPI CEO Visits Seoul, Korea

In March, Stefan Tochev, Chief Executive Officer (CEO) of MDPI, visited Korea and met with various stakeholders including government agencies, research and academic institutions, universities. During his visit, Stefan highlighted that MDPI continues to pave the way for a world where science is accessible to all, supporting a global community of inclusive innovation and collaborative solutions.

Stefan expressed excitement about the new venture, stating, "Today marks a significant milestone for MDPI as we celebrate the opening of our new office in Seoul, Korea. This expansion is more than just an increase in our physical footprint, it is a pivotal step in our ongoing commitment to making scientific knowledge more accessible, participatory, and inclusive across the globe."

Claude Seo, reflecting on his new role, commented, "I am delighted to have been offered this position of trust within MDPI, the no. 1 scholarly OA publisher. As we establish our presence in Korea, we are dedicated to integrating into the local community and contributing to its vibrant culture. Our commitment goes beyond business growth; it is about creating a more informed and innovative society by embracing and promoting diversity within the scientific community.”

For further inquiries, please contact our Seoul office directly.


About MDPI

A pioneer in scholarly, open access publishing, MDPI has supported academic communities since 1996. MDPI is leading the transition to open science by making more research free and accessible to everyone. Over 3.3 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of 6000 diligent, well-trained staff members, and an in-house article submission platform that was designed to ensure efficient processes within its 430 fully OA titles.

12 April 2024
Prof. Dr. Katrin Scheinemann Appointed Section Editor-in-Chief of Section “Childhood, Adolescent and Young Adult Oncology” in Current Oncology

We are pleased to announce that Prof. Dr. Katrin Scheinemann has been appointed Section Editor-in-Chief of the Section “Childhood, Adolescent and Young Adult Oncology” in Current Oncology (ISSN: 1718-7729). Prof. Dr. med. Katrin Scheinemann is a pediatric oncologist/hematologist from Switzerland. She is the division head of oncology/hematology at the Children’s Hospital of Eastern Switzerland in St. Gallen and a professor at the Faculty of Health Sciences and Medicine at the University of Lucerne, Switzerland. The focus of her research lies in the area of survivorship care in pediatric oncology and pediatric neuro-oncology. She has published over 100 papers in peer-reviewed journals so far and has edited two textbooks. She also holds many national and international positions as the treasurer and a board member of SIOPE (European Society for Pediatric Oncology), the chair of the SIOPE BTG (brain tumor group), and the chair of PanCare (multidisciplinary pan-European network of professionals, survivors, and their families working on long-term follow-up care for European childhood cancer survivors).

The following is a short Q&A with Prof. Dr. Katrin Scheinemann, who has shared her vision for the journal's advancement and impact, the promising future of oncology research, and her positive view on the development of open access in the publishing field:

1. What appealed to you about the journal that made you want to take the role as its Section Editor-in-Chief?
The journey with Current Oncology: from just submitting a manuscript as an author to becoming an Editor of a Special Issue and now Section Editor-in-Chief in the field that I am so passionate about. But clearly also your support—thank you!

2. What is your vision for the journal?
Overall, to increase the impact factor and develop it into one of the top journals in the oncology field. But also to give adolescent and young adult (AYA) cancer other publication options, as there are not so many dedicated ones (we have only three journals focusing on pediatric cancer to my knowledge).

3. What does the future of this field of childhood, adolescent and young adult oncology look like?
From my point of view, very promising. Within 50 years, the survival rate of a few percent is now long-term well over 80% in high-income countries. I hope that we can improve survival rates in developing countries as well, and that with newer treatments (immunotherapy, targeted therapy) we will see less disabling long-term late effects.

4. What do you think of the development of open access in the publishing field?
As only 20% of all pediatric and adolescent cancer diagnoses are made in high-income countries with all the resources available, open access can help a lot to improve survival rates and care in developing countries. The downside (in my view as a submitting author) is the fees, which are challenging to get covered from any research funding.

We wish Prof. Dr. Katrin Scheinemann every success in her position as Section Editor-in-Chief, and we look forward to her future contributions to the journal.

8 April 2024
Meet Us at the 2024 ASCO Annual Meeting, 31 May–4 June 2024, Chicago, IL, USA


The 2024 ASCO Annual Meeting will take you to discover state-of-the-art research, groundbreaking treatments, and visionary insights, igniting your passion for oncology. This year's program will feature over 200 sessions, complementing Dr. Lynn Schuchter’s Presidential theme “The Art and Science of Cancer Care: From Comfort to Cure”.

The following MDPI journals will be represented:

If you are attending this conference, please feel free to start an online conversation with us. Our delegates look forward to meeting you in person at the booth at the conference and answering any questions you may have. For more information regarding the conference, please visit the following link: https://conferences.asco.org/am/attend.

7 April 2024
Current Oncology | National Oral, Head, and Neck Cancer Awareness Month


National Oral, Head, and Neck Cancer Awareness Month in April is a dedicated period to raise awareness about the risks, prevention, and early detection of oral, head, and neck cancers. Throughout this month, various educational campaigns, screenings, and initiatives are organized to promote understanding, encourage regular check-ups, and emphasize the importance of timely intervention in combating these potentially life-threatening diseases. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings and a high-quality Special Issue in the field of oral, head, and neck cancer, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field. The list of relevant papers can be seen below:

“A Qualitative Study of Patient and Healthcare Provider Perspectives on Building Multiphasic Exercise Prehabilitation into the Surgical Care Pathway for Head and Neck Cancer”

by Julia T. Daun, Rosie Twomey, Joseph C. Dort, Lauren C. Capozzi, Trafford Crump, George J. Francis, T. Wayne Matthews, Shamir P. Chandarana, Robert D. Hart, Christiaan Schrag et al.

Curr. Oncol. 2022, 29(8), 5942-5954; https://doi.org/10.3390/curroncol29080469

Available online: https://www.mdpi.com/1718-7729/29/8/469

“Interventions for the Prevention of Oral Mucositis in Patients Receiving Cancer Treatment: Evidence from Randomised Controlled Trials”

by Giuseppe Colella, Ciro Emiliano Boschetti, Rita Vitagliano, Chiara Colella, Lebei Jiao, Natalie King-Smith, Chong Li, Yii Nuoh Lau, Zacchaeus Lai, Ali Ibrahim Mohammed et al.

Curr. Oncol. 2023, 30(1), 967-980; https://doi.org/10.3390/curroncol30010074

Available online:  https://www.mdpi.com/1718-7729/30/1/74

“Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada”

by Jean Lachaine, Kimberly Guinan, Andrew Aw, Versha Banerji, Isabelle Fleury and Carolyn Owen

Curr. Oncol. 2023, 30(5), 4483-4498; https://doi.org/10.3390/curroncol30050339

Available online:  https://www.mdpi.com/1718-7729/30/5/339

“Biopsychosocial Markers of Body Image Concerns in Patients with Head and Neck Cancer: A Prospective Longitudinal Study”

by Justine G. Albert, Christopher Lo, Zeev Rosberger, Saul Frenkiel, Michael Hier, Anthony Zeitouni, Karen Kost, Alex Mlynarek, Martin Black, Christina MacDonald et al.

Curr. Oncol. 2022, 29(7), 4438-4454; https://doi.org/10.3390/curroncol29070353

Available online:  https://www.mdpi.com/1718-7729/29/7/353

“Rates of Smoking Cessation at 6 and 12 Months after a Clinical Tobacco Smoking Cessation Intervention in Head and Neck Cancer Patients in Northern Ontario, Canada”

by Stacey A. Santi, Michael S. C. Conlon, Margaret L. Meigs, Stacey M. Davidson, Kyle Mispel-Beyer and Deborah P. Saunders

Curr. Oncol. 2022, 29(3), 1544-1558; https://doi.org/10.3390/curroncol29030130

Available online:  https://www.mdpi.com/1718-7729/29/3/130

“Extra-Nodal Lymphomas of the Head and Neck and Oral Cavity: A Retrospective Study”

by Alfonso Sorrentino, Francesco Ferragina, Ida Barca, Antonella Arrotta and Maria Giulia Cristofaro

Curr. Oncol. 2022, 29(10), 7189-7197; https://doi.org/10.3390/curroncol29100566

Available online:  https://www.mdpi.com/1718-7729/29/10/566

“Clinicopathological Risk Factors for Contralateral Lymph Node Metastases in Intraoral Squamous Cell Carcinoma: A Study of 331 Cases”

by Christian Flörke, Aydin Gülses, Christina-Randi Altmann, Jörg Wiltfang, Henning Wieker and Hendrik Naujokat

Curr. Oncol. 2021, 28(3), 1886-1898; https://doi.org/10.3390/curroncol28030175

Available online:  https://www.mdpi.com/1718-7729/28/3/175

“Outcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy (CRT) in High-Risk Resected Oral Cavity Squamous Cell Carcinoma (OCSCC): A Multi-Institutional Collaboration”

by Arslan Babar, Neil M. Woody, Ahmed I. Ghanem, Jillian Tsai, Neal E. Dunlap, Matthew Schymick, Howard Y. Liu, Brian B. Burkey, Eric D. Lamarre, Jamie A. Ku et al.

Curr. Oncol. 2021, 28(4), 2409-2419; https://doi.org/10.3390/curroncol28040221

Available online:  https://www.mdpi.com/1718-7729/28/4/221

Relevant Special Issues:

“Advances in Squamous Cell Carcinoma of the Head and Neck”

Guest Editor: Dr. Dimitra P. Vageli

Available online: https://www.mdpi.com/journal/curroncol/special_issues/advances_hnscc

“New Frontiers in Head and Neck Oncology”

Guest Editors: Dr. George Shenouda, Prof. Dr. Denis Soulieres and Dr. Houda Bahig

Available online: https://www.mdpi.com/journal/curroncol/special_issues/New_Frontiers_Head_Neck_Oncology

“Psychosocial Effects of Head and Neck Cancer”

Guest Editor: Dr. Melissa Henry

Available online: https://www.mdpi.com/journal/curroncol/special_issues/mr_pshychosocial_effects_head_and_neck_cancer

You are welcome to submit relevant papers to the journal Current Oncology. If you have any questions, feel free to contact us.

Current Oncology Editorial Office

2 April 2024
Join Us for the 2024 Annual Congress of the European Association for Cancer Research (EACR 2024), 10–13 June 2024, Rotterdam, the Netherlands


The 2024 Annual Congress of the European Association for Cancer Research (EACR 2024) is a four-day congress engaged in basic, preclinical and translational cancer research across a myriad of topics that is aiming to spotlight, inspire and unite the cancer research community to innovate, build knowledge, and create collaborations.

The following MDPI journals will be represented:

If you are attending this conference, please feel free to contact us online. Our delegates look forward to meeting you in person and answering any questions you may have. For more information about the conference, please visit the following link: https://2024.eacr.org/.

2 April 2024
MDPI Insights: The CEO's Letter #10 - South Korea, IWD, U2A, Japan

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts


Left to right: Dr. Jisuk Kang (Scientific Officer, MDPI), Stefan Tochev (CEO, MDPI), and Dr. Giulia Stefenelli (Chair of Scientific Office Board, MDPI), during media meetings at Prain Agency office in Seoul, South Korea.

Visit to Seoul, South Korea

During my recent visit to South Korea, I had the privilege of meeting various stakeholders, including representatives of government, research institutions, and academia, to understand their needs and communicate MDPI’s commitment to accessible science. Accompanied by my colleagues Dr. Giulia Stefenelli and Dr. Jisuk Kang, I engaged with the Korean scientific community, which is increasingly embracing open access (OA).

As the leading OA publisher in South Korea, MDPI is trusted by local authors and in 2023 enjoyed an approximately 30% share of the OA market. South Korea ranks sixth globally for MDPI in terms of research papers submitted and published.

MDPI and South Korea by Numbers

As at 30 March, over 76,000 MDPI articles have been authored by individuals affiliated with Korean institutions. We have over 1,800 active editorial board members (EBMs) from South Korea, with more than 880 EBMs having an H-index between 26 and 50, including 10 serving as Chief Editors.

“South Korea is the sixth-largest contributor to our total publications”

Over the past five years (2019–2023), nearly 120,000 authors affiliated with South Korean institutes have published with MDPI. Specifically in 2023, we received approximately 25,000 submissions from South Korean authors, publishing close to 13,000 articles, resulting in a rejection rate of 47.4%, which is not far below MDPI’s overall rejection rate of 56.4% in 2023.

Institutional Partnerships with South Korea

I am pleased to share that MDPI has more than 825 institutional partnerships worldwide, with 12 in South Korea, including Kyunghee University, Chung-Ang University, and Inha University, among others.


Left to right: Dr. Jisuk Kang (Scientific Officer, MDPI), Dr. Giulia Stefenelli (Chair of Scientific Office Board, MDPI), and Stefan Tochev (CEO, MDPI) fielding media questions at Prain PR Agency office in Seoul, South Korea.

Over the past three years (2021–2023), we have had some of the most prestigious academic universities ranked among the top 10 Korean institutions publishing with MDPI. Seoul National University had the highest number of publications with MDPI during those three years, publishing nearly 6,000 papers. Universities such as Korea University and Yonsei University also rank among the top 10 Korean institutions publishing with MDPI.

MDPI Hosts Seminar for Academia and Media

As the world’s leading OA publisher, MDPI is actively democratizing science. This is reflected in the seminars we hosted on 21 March to address questions about our editorial processes and ethical standards. The visit garnered media coverage, reflecting our mission to providing high-quality services and fostering open dialogue in the community.

“MDPI is actively democratizing science”

MDPI in the News


Stefan Tochev (CEO, MDPI) leading a seminar on OA and MDPI at Prain PR Agency office in Seoul, South Korea.

Media coverage generated by our visit to Seoul included the following stories:

“Open access is an unstoppable trend…it will lead the development of the knowledge ecosystem.”

“Papers that the public needs, anyone can use quickly… low-quality publishing is a misunderstanding.”

I greatly appreciate the contributions of everyone who took the time to meet with us, share their stories, and hold us accountable for continuing to provide high-quality publishing services while identifying areas for improvement. I am also excited to announce that we have opened an MDPI office in Seoul and will release a press release on MDPI.com, with details, by the end April 2024. The purpose of the office is to establish a local presence to connect with and support the South Korean academic community through institutional partnerships, conferences, author workshops, stakeholder communications, and more.

Impactful Research

Featured Articles on Women’s Leadership and Healthcare

In celebration of International Women’s Day (8 March 2024), MDPI curated a collection of research articles on various topics, including women’s leadership, reproductive health, preventive healthcare, and a selection of articles from our journal Women.

Women’s Leadership

Women’s Reproductive Health

Women’s Preventive Healthcare

Featured Articles in MDPI Journal Women

Below are a few articles from Women, our journal focused on women’s health, the social determinants of health, and the healthcare system that serves women. The aim of Women is to encourage academics to publish their experimental and theoretical results in detail, to aid reproducibility, and in an engaging style, to aid comprehensibility.

Inside MDPI

 

Championing Women’s Healthcare and Access to Healthcare Information

MDPI colleagues from our offices joined in celebrating #IWD2024. In doing so, we emphasized key missions that encompass:

  • Empowering women to assume leadership and decision-making roles in both business and science.
  • Helping women and girls make informed decisions about their health.
  • Recruiting and developing female talent and fostering inclusive workplace environments.

“We are thrilled to recognize the accomplishments of women scientists”

I am proud to see our colleagues enthusiastically supporting the International Women’s Day call to ‘Inspire Inclusion!’ The heart-hands in the collage below symbolize our appreciation of the achievements of women researchers and the recognition of the trailblazers who have courageously made a mark on societies past and present.

We are thrilled to recognize the accomplishments of women scientists through our many MDPI awards and by highlighting success stories. As inspirational figures, female scientists are paving the way for the next generation of women aspiring to pursue careers in engineering, life sciences, computing, and various other STEM fields.

“I consider myself lucky because I work with incredibly talented women who inspire me every day.”
– Dr. Alessandra Pasut, Winner of MDPI's ‘Biology 2023 Young Investigator Award’

“It’s really important to find a supportive and enabling environment in which to do your science; it would have a big impact on you as a person and on your scientific outputs.”
– Dr. Rhea Longley, Winner of the ‘Pathogens 2023 Young Investigator Award’

Open-access publishing, in particular, allows early-career women researchers to share their work more widely, potentially attracting mentorship opportunities and collaborations. This support is crucial for career development and advancement.

Coming Together for Science

MDPI Joins United2Act in Collective Fight to Stop Paper Mills

In my February 2024 CEO Letter, I highlighted some of our recent initiatives aimed at bolstering our commitment to research integrity, including joining the STM Integrity Hub and expanding our Research Integrity and Publication Ethics team (RIPE). Continuing our efforts in coming together for science, I am pleased to share our participation in the United2Act initiative.

The text below is taken from our official announcement:

United2Act represents an international group of stakeholders in the publishing industry committed to addressing the collective challenge posed to research integrity by paper mills.

Scientists and academic publishers have increasingly noted the alarming proliferation of paper mills, recognized as fraudulent entities seeking to manipulate the publication process for financial profit. These entities engage in fraudulent practices such as falsifying or fabricating data, selling co-authorship of fake papers, manipulating peer review, and including inappropriate citations. These actions pose a significant threat to the integrity of the scholarly record, prompting widespread concern among those involved in the academic community.

MDPI has been actively contributing to combat the undermining of the scientific record. Our editors employ a set of tools to detect potential ethical breaches within a manuscript and to tackle the issue of fake papers.

United2Act’s consensus statement is the outcome of a virtual summit held in May 2023. It involved the participation of research bodies, publishers, researchers/sleuths, universities, and publishing infrastructure from 15 countries and resulted in a Consensus Statement outlining five key areas of action for all stakeholders:

  • Education and awareness
  • Improve post-publication corrections
  • Facilitate and organise research on paper mills
  • Enable the development of trust markers
  • Facilitate dialogue between stakeholders

MDPI is committed to promoting transparency and integrity in scholarly publishing and is continuing to work closely with the scientific community toward this goal.

Closing Thoughts


Left to right: Ryo Hirayama (Marketing Specialist, MDPI), Takashi Sasabe (Marketing Specialist, MDPI), Dr. Giulia Stefenelli (Chair of Scientific Office Board, MDPI), Dr. Izumi Yamamoto (Marketing Manager, MDPI), and Stefan Tochev (CEO, MDPI), at MDPI’s office in Tokyo, Japan.

Visit to Tokyo and Kyoto, Japan

In March, I had the opportunity to visit our Tokyo office and engage with stakeholders in Tokyo and Kyoto. During the visit, I also recorded a video message to welcome Japanese scholars working with MDPI and to highlight our operations in Japan.

We held meetings with Editors-in-Chief, librarians, scholars, and external consultants to gather feedback on our efforts to enhance our reputation and explore additional steps we can take in that direction. Japan's rich cultural heritage, characterized by tradition, respect, and formality, provided valuable insights into meeting the publishing needs specific to Japan.

Japan’s Open Access statistics

Over the years, we have seen a shift from subscription-only to gold OA publishing in Japan, despite the lack of an official mandate. Here are some statistics:

  • 2012: 68% of articles were subscription-only, 6% were green Open Access, and 8% were gold Open Access.
  • 2016: 55% of articles were subscription-only, 6% were green Open Access, and 20% were gold Open Access.
  • 2022: 43% of articles were subscription-only, 7% were green Open Access, and 39% were gold Open Access.

To learn more about the history of OA in Japan as well as about future trends, please read this blog post.

“Japan is the ninth-largest contributor to our total publications”


Left to right: Stefan Tochev (CEO, MDPI), Dr. Izumi Yamamoto (Marketing Manager, MDPI), and Dr. Giulia Stefenelli (Chair of Scientific Office Board, MDPI) visiting Kyoto University in Kyoto, Japan.

MDPI and Japan by Numbers

As at 1 April, over 50,000 MDPI articles have been authored by scholars affiliated with Japanese institutions, making the country the ninth-largest contributor to our total publications. Over the past three years (2020–2023), nearly 90,000 authors affiliated with Japanese institutes have published with MDPI, and we have collaborated with over 4,600 Guest Editors from Japan.

In 2023, we published over 8,200 papers from authors associated with Japanese institutions. MDPI collaborates with 41 institutional partnerships in Japan, including the University of Tokyo, Hokkaido University, and Nagoya University. We have over 2,100 active EBMs from Japan, more than 1,050 EBMs having an H-index between 26 and 50, including 13 serving as Editors-in-Chief.

General Feedback – a side note

A general takeaway from our discussions with stakeholders from around the world is that negative perceptions of MDPI often stem from misinformation, misconceptions, or misunderstandings about MDPI and our practices. While we acknowledge our mistakes and work diligently to address them, maintaining a strong editorial procedure and robust peer-review process, I find that educating stakeholders about our how we do what we do and our ongoing improvements tends to help shift opinions.

That said, we recognize the importance of addressing individual concerns. We take feedback seriously and are continuously working to get better while not compromising the core principles that millions of authors appreciate about MDPI.

Stefan Tochev
Chief Executive Officer
MDPI AG

27 March 2024
Prof. Dr. Matthias May Appointed Section Editor-in-Chief of Section “Genitourinary Oncology” in Current Oncology

We are pleased to announce that Prof. Dr. Matthias May has been appointed Section Editor-in-Chief of the Section “Genitourinary Oncology” in Current Oncology (ISSN: 1718-7729). Prof. Dr. Matthias May, born in Berlin (Germany), is a Professor of Urology at St. Elisabeth Hospital Straubing (Bavaria, Germany). Additionally, he holds a teaching position at the Department of Urology, University of Regensburg (Bavaria, Germany). His primary professional focus is operative urologic oncology surgery, including robot-assisted procedures. He maintains a broad scientific interest in urology, particularly in developing prognostic prediction models (including biomarker-based) for various urologic cancers across diverse clinical settings. In recent years, his research has increasingly focused on translational projects involving penile, prostate, and bladder cancer. Prof. Dr. May has secured multiple grants for his research endeavors and has initiated/founded more than 30 multicenter studies. He has authored over 250 peer-reviewed articles, serving as the first or senior author for most of them. Presently, his h-index stands at 39, with 5,802 citations to his work (i10-index: 137).

The following is a short Q&A with Prof. Dr. Matthias May, who has shared his vision for the journal's advancement and impact, the promising future of genitourinary oncology research, and his positive view on the development of open access in the publishing field:

1. What appealed to you about the journal that made you want to take the role of its Section Editor-in-Chief?
Current Oncology has always stood out to me as a beacon of excellence and innovation in the landscape of medical research publishing. Its long-standing tradition of fostering rigorous scientific inquiry and disseminating cutting-edge findings in oncology resonated deeply with my professional ethos and aspirations. Serving as the Section Editor-in-Chief for “Genitourinary Oncology” is not just an honor; it represents a unique opportunity to contribute to the advancement of a field that is at the cusp of transformative breakthroughs. I was particularly drawn to the journal's commitment to integrity, inclusivity, and the promotion of multidisciplinary collaboration, which aligns perfectly with my vision of pushing the boundaries of genitourinary oncology research.

2. What is your vision for the journal?
My vision for Current Oncology is its elevation to unprecedented levels of influence and innovation in the field of genitourinary oncology. In my role, I aim to champion the integration of multidisciplinary research approaches, bridging the gap between basic science, clinical research, and patient care. By doing so, we can provide a holistic perspective on the complexities of cancer diagnosis and treatment, fostering innovations that are both scientifically profound and clinically applicable. Furthermore, I am committed to enhancing the journal's accessibility and global reach, ensuring that cutting-edge research is available to a wide audience, thereby accelerating the translation of research discoveries into clinical practice.

3. What does the future of this field of genitourinary oncology look like?
The future of genitourinary (GU) oncology is incredibly promising, marked by rapid advancements in precision and interventional medicine, as well as personalized treatment plans. We are on the cusp of a paradigm shift where molecular genetics and biomarker research will significantly enhance our understanding of GU cancers and improve their treatment. Furthermore, the integration of artificial intelligence and machine learning in diagnostics and treatment planning holds tremendous potential to revolutionize patient care. As these technologies evolve, we will see a more tailored approach to oncology, prioritizing the patient’s and tumor’s unique genetic profile, patient lifestyle, and quality of life, as well as treatment preferences. In the coming years, I anticipate a more collaborative and interdisciplinary approach to research, driving innovations that will substantially improve outcomes for patients with GU cancers.

4. What do you think of the development of open access in the publishing field?
The development of open access in the publishing field is a transformative movement that democratizes knowledge and accelerates scientific discovery. By making research findings freely available, open access enhances the visibility and impact of scholarly work, facilitating greater collaboration and innovation across disciplines. This model encourages a more inclusive scholarly community, where valuable insights are not hidden behind paywalls, but shared widely, contributing to the collective advancement of science. While there are challenges to navigate, particularly regarding sustainable funding models and ensuring the quality of published work, the benefits of open access in fostering a more informed and engaged global research community are undeniable. As Section Editor-in-Chief, I am committed to supporting and advancing open access initiatives, recognizing their critical role in the future of academic publishing.

We wish Prof. Dr. Matthias May every success in his position as Section Editor-in-Chief, and we look forward to his future contributions to the journal.

26 March 2024
Current Oncology | Kidney Cancer Awareness Month

Kidney cancer, also known as renal cell carcinoma, is a type of cancer that forms in the kidneys. It typically originates in the cells lining the small tubes within the organ. Treatment options include surgery, targeted therapy, and immunotherapy. March is the Kidney Cancer Awareness Month. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings and a high-quality Special Issue in the field of kidney cancer, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field. The list of relevant papers is presented below.

“Prospective Evaluation of Kidney Function in Long-Term Survivors of Pediatric CNS Tumors”
by Natalia Stepien, Viktoria Handler, Johannes Gojo, Amedeo A. Azizi, Lisa Mayr, Chryssa Grylli, Daniela Schwarz, Monika Chocholous, Irene Slavc, Michael Boehm et al.
Curr. Oncol. 2022, 29(8), 5306–5315; https://doi.org/10.3390/curroncol29080421
Available online:  https://www.mdpi.com/1718-7729/29/8/421 

“Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma”
by Luisa M. Cardenas, Jasna E. Deluce, Shahrukh Khan, Omar Gulam, Saman Maleki Vareki, Ricardo Fernandes and Aly-Khan A. Lalani
Curr. Oncol. 2022, 29(8), 5426–5441; https://doi.org/10.3390/curroncol29080429
Available online:  https://www.mdpi.com/1718-7729/29/8/429

“Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature”
by Alexius John, Lavinia Spain and Anis A. Hamid
Curr. Oncol. 2023, 30(1), 923–937; https://doi.org/10.3390/curroncol30010070
Available online:  https://www.mdpi.com/1718-7729/30/1/70

“Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists”
by Irena Druce, Karine Tawagi, Julie L. V. Shaw, Andrea Ibrahim, Heather Lochnan and Michael Ong
Curr. Oncol. 2022, 29(7), 4665–4677; https://doi.org/10.3390/curroncol29070370
Available online: https://www.mdpi.com/1718-7729/29/7/370

“Virtual Resection: A New Tool for Preparing for Nephron-Sparing Surgery in Wilms Tumor Patients”
by Jasper M. van der Zee, Matthijs Fitski, Frank F. J. Simonis, Cornelis P. van de Ven, Aart J. Klijn, Marc H. W. A. Wijnen and Alida F. W. van der Steeg
Curr. Oncol. 2022, 29(2), 777–784; https://doi.org/10.3390/curroncol29020066
Available online:  https://www.mdpi.com/1718-7729/29/2/66

“Trop-2 in Upper Tract Urothelial Carcinoma”
by Eisuke Tomiyama, Kazutoshi Fujita, Kosuke Nakano, Ken Kuwahara, Takafumi Minami, Taigo Kato, Koji Hatano, Atsunari Kawashima, Motohide Uemura, Tetsuya Takao et al.
Curr. Oncol. 2022, 29(6), 3911–3921; https://doi.org/10.3390/curroncol29060312
Available online:  https://www.mdpi.com/1718-7729/29/6/312

“Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art”
by Gianluigi Califano, Idir Ouzaid, Paul Laine-Caroff, Arthur Peyrottes, Claudia Collà Ruvolo, Benjamin Pradère, Vincent Elalouf, Vincent Misrai, Jean-François Hermieu, Shahrokh F. Shariat et al.
Curr. Oncol. 2022, 29(2), 687–697; https://doi.org/10.3390/curroncol29020060
Available online:  https://www.mdpi.com/1718-7729/29/2/60

“Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies”
by Ioannis A. Voutsadakis
Curr. Oncol. 2022, 29(3), 1390–1407; https://doi.org/10.3390/curroncol29030117
Available online:  https://www.mdpi.com/1718-7729/29/3/117

Relevant Special Issue:
Current Advances in Clinical Genomics and Treatment of Urothelial Carcinoma
Guest Editor: Dr. Panagiotis J. Vlachostergios

You are welcome to submit relevant papers to the journal Current Oncology. For any questions, feel free to contact us.

Current Oncology Editorial Office

12 March 2024
Current Oncology | National Colorectal Cancer Awareness Month

Colorectal cancer is the third most common cancer worldwide, originating in the colon or rectum and characterized by uncontrolled cell growth in their lining.  Early detection through screenings is vital for successful treatment and improved survival rates. March is the National Colorectal Cancer Awareness Month. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings in the field of colorectal cancer, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field. The list of relevant papers is presented below.

“Colorectal Cancer and Onset of Anxiety and Depression: A Systematic Review and Meta-Analysis”
by Vicki Cheng, Niki Oveisi, Helen McTaggart-Cowan, Jonathan M. Loree, Rachel A. Murphy and Mary A. De Vera
Curr. Oncol. 2022, 29(11), 8751–8766; https://doi.org/10.3390/curroncol29110689
Available online:  https://www.mdpi.com/1718-7729/29/11/689

“Tumor Stroma Ratio and Its Significance in Locally Advanced Colorectal Cancer”
by Luz Sullivan, Richard R. Pacheco, Michel Kmeid, Anne Chen and Hwajeong Lee
Curr. Oncol. 2022, 29(5), 3232–3241; https://doi.org/10.3390/curroncol29050263
Available online: https://www.mdpi.com/1718-7729/29/5/263

“COVID-19 Impact on Diagnosis and Staging of Colorectal Cancer: A Single Tertiary Canadian Oncology Center Experience”
by Mathias Castonguay, Rola El Sayed, Corentin Richard, Marie-France Vachon, Rami Nassabein, Danielle Charpentier and Mustapha Tehfé
Curr. Oncol. 2022, 29(5), 3282–3290; https://doi.org/10.3390/curroncol29050268
Available online:  https://www.mdpi.com/1718-7729/29/5/268

“Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes”
by Nicolas Voizard, Tiffany Ni, Alex Kiss, Robyn Pugash, Michael Jonathon Raphael, Natalie Coburn and Elizabeth David
Curr. Oncol. 2022, 29(1), 209–220; https://doi.org/10.3390/curroncol29010020
Available online: https://www.mdpi.com/1718-7729/29/1/20

“Predictive Factors for Anastomotic Leakage Following Colorectal Cancer Surgery: Where Are We and Where Are We Going?”
by Christos Tsalikidis, Athanasia Mitsala, Vasileios I. Mentonis, Konstantinos Romanidis, George Pappas-Gogos, Alexandra K. Tsaroucha and Michail Pitiakoudis
Curr. Oncol. 2023, 30(3), 3111–3137; https://doi.org/10.3390/curroncol30030236
Available online:  https://www.mdpi.com/1718-7729/30/3/236

“Persisting Deficits in Health-Related Quality of Life of Colorectal Cancer Survivors 14–24 Years Post-Diagnosis: A Population-Based Study”
by Melissa S. Y. Thong, Daniela Doege, Linda Weißer, Lena Koch-Gallenkamp, Lina Jansen, Heike Bertram, Andrea Eberle, Bernd Holleczek, Alice Nennecke, Annika Waldmann et al.
Curr. Oncol. 2023, 30(3), 3373–3390; https://doi.org/10.3390/curroncol30030257
Available online:  https://www.mdpi.com/1718-7729/30/3/257

“Clinical Delays and Comparative Outcomes in Younger and Older Adults with Colorectal Cancer: A Systematic Review”
by Matthew Castelo, Colin Sue-Chue-Lam, Lawrence Paszat, Adena S. Scheer, Bettina E. Hansen, Teruko Kishibe and Nancy N. Baxter
Curr. Oncol. 2022, 29(11), 8609–8625; https://doi.org/10.3390/curroncol29110679
Available online:  https://www.mdpi.com/1718-7729/29/11/679

“Real-Life Effectivity of Dose Intensity Reduction of First-Line mFOLFIRI-Based Treatment of Metastatic Colorectal Cancers: Sometimes Less Is More”
by Balázs Pécsi and László Mangel
Curr. Oncol. 2023, 30(1), 908–922; https://doi.org/10.3390/curroncol30010069
Available online:  https://www.mdpi.com/1718-7729/30/1/69

You are welcome to submit relevant papers to the journal Current Oncology. For any questions, feel free to contact us.

Current Oncology Editorial Office

4 March 2024
MDPI Insights: The CEO's Letter #9 - Romania, Research Integrity, Viruses

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts


Reka Kovacs (Deputy Office Manager, MDPI), Stefan Tochev (CEO, MDPI), and Sandra Ana Spatariu (Office Manager, MDPI) at the MDPI office in Cluj, Romania.

MDPI’s Impact on Romania

In February, I visited our office in Cluj, Romania. I worked closely with our senior office managers and various teams, including the departments of training, marketing and conferences, as well as our journal relationship specialists, reviewing our service to the local scholarly community. During the visit, I also met with representatives from Babes-Bolyai University and the Technical University of Cluj-Napoca. Our multifunctional Romanian office plays an important role in supporting our collaborations with the local market as well as helping to meet MDPI’s overall business needs.


Feedback and strategy meeting with a group of MDPI’s Journal Relationship Specialists at the MDPI office in Cluj, Romania.

With 22,436 articles, Romania ranks as a top 20 contributing country to MDPI’s total number of papers published as at 28 February 2024. This highlights the importance of our collaboration with Romanian-affiliated authors and the growing opportunity to support their publishing needs. MDPI is one of the few academic publishers with a significant presence in Romania, boasting over 360 colleagues across our offices in Bucharest and Cluj. We are also proud to hire colleagues from local institutions to launch their careers within publishing.

Romania ranks as a top 20 contributing country.

The Numbers: 2019–2023

MDPI has seen a healthy increase in submissions from Romanian authors over the past three years, from 8,439 in 2021 to 11,866 by end of 2023, with most submissions going to journals such as Sustainability, Medicina, Diagnostics, IJMS, Applied Sciences, and JCM. From 2019 to 2023, MDPI published articles from 32,145 authors affiliated with Romanian institutions. Over those years, we have worked with Romanian Guest Editors on nearly 3,000 occasions to support their Special Issue and Topical collections.

With more than 300 Editorial Board Members from Romania, 34 appear on the board of Mathematics, 27 on Materials, 19 on Polymers, 18 on Coatings, and 16 on Molecules, while three serve as Section Editors-in-Chief (SEiC) on our journals Coatings (3.4 IF, 4.6 Citescore), Magnetochemistry (2.7 IF, 3.5 Citescore), and Chemosensors (4.2 IF, 3.9 Citescore).

Institutional Open Access Programs

Our commitment to working with institutions is evident in Romania, where we have established eight Institutional Open Access Programs (IOAP) with esteemed institutions such as the University of Bucharest, the University of Medicine and Pharmacy Cluj-Napoca, and most recently the National Institute for Laser, Plasma and Radiation Physics.

Our growth and presence in Romania are a true testament.

We also have IOAP agreements with Babes-Bolyai University and the Technical University of Cluj-Napoca, where I had the opportunity to meet senior stakeholders during my visit. Below are a few photos capturing our meeting with Prof. Radu Silaghi-Dumitrescu (Head of Faculty of Chemistry, Babes-Bolyai University) at the MDPI office in Cluj, Romania, along with a photo from our meeting with Vice Deans Nicoleta Cobarzan, Nicoleta Ilies, and Hoda Gavril, from the faculty of Civil Engineering at the Technical University of Cluj, Romania.


Our growth and presence in Romania are a true testament to the service we provide to the scholarly community and the relationships we foster in that region. We look forward to continuing to support Romanian scholars and institutions by providing a valuable and trusted experience with MDPI, the leader in open access publishing.

Impactful Research

MDPI Joins the STM Integrity Hub

MDPI has long been a supporter and partner of STM, with our involvement ranging from sponsoring and attending events to helping organize event programs. By joining the STM Integrity Hub, we aim to further our commitment to STM initiatives aimed at safeguarding the integrity of science.

“We are pleased to welcome MDPI as the 35th organisation participating in the Hub. This expansion is critical, as every new member enhances our capacity to prevent fraudulent submissions from entering the academic record.”

Joris van Rossum, Director of Research Integrity, STM

MDPI operates in full alignment with STM Integrity Hub's values of shared data and experiences. We strongly believe in collaboration and open exchange for the purposes of creating a holistic approach to support research integrity at MDPI itself and across the entire academic publishing industry. The Integrity Hub is an excellent example of how publishers can come together to jointly address industry-wide challenges related to research integrity, such as manuscripts that breach research integrity standards and paper-mills.

I look forward to our Research Integrity and Publication Ethics Team (RIPE) team immersing themselves in this initiative, exchanging information, best practices, and tools for the benefit of the entire scholarly ecosystem. We believe that ethical publishing standards should be implemented across the board, and we aim to be rigorous in our approach, addressing research integrity issues and improving the impact of published research.

Inside MDPI

MDPI Expands Research Integrity and Publication Ethics Team (RIPE)

In addition to external collaborations and joint initiatives aimed at further strengthening our commitment to research integrity, we are also enhancing our internal efforts. This includes improving our processes and guidelines and expanding our teams and departments to ensure quality assurance throughout our publishing process.

We are pleased to announce the expansion of our Research Integrity and Publication Ethics Team (RIPE) at MDPI. The RIPE team has recently welcomed new colleagues, each bringing unique skills and a personal commitment to prioritize ethical considerations in all our work.

The demand for research integrity and high ethical standards in academic publishing is steadily rising across our industry. Our expanded RIPE team will work to enhance and align our practices with industry best practices, ensuring excellence in research integrity and publication ethics.


Stefan Tochev (CEO, MDPI) introduces Dr. Tim Tait-Jamieson (Research Integrity Lead, MDPI) for his presentation on MDPI’s Retraction and Approval Process to a group of Journal Relationship Specialists at the MDPI office in Cluj, Romania: “The demand for research integrity and publication ethics is steadily rising across our industry.”

Introducing our Research Integrity and Publication Ethics Team

Led by Dr. Tim Tait-Jamieson (Research Integrity Lead), the RIPE team comprises Dr. Ivana Resanovic (Research Integrity Manager), Dr. Lavinia Rogojina (Research Integrity Manager), Ms. Diana Apodaritei (Research Integrity Specialist), Dr. Zoltan Mihaly (Research Integrity Specialist), Mr. Aleksandar Đukić (Research Integrity Specialist), Ms. Ana Stankovic (Research Integrity Specialist), and Ms. Anna Pena (Publication Ethics Assistant).

Please click here to access everything that you need to know about MDPI’s Research and Publication Ethics.

With this span of complementary roles, the RIPE team collaborates directly with journal editorial teams and works closely with various departments, including our Scientific Office Board and our Journal Relationship Specialists. The team’s primary objectives are to help prevent issues regarding research integrity and publication ethics during peer review, uphold MDPI’s ethics policies, adhere to industry standards, and resolve publication ethics and research integrity issues and complaints.

Quality Updates to Special Issues Oversight

At MDPI, we are committed to reviewing policies pertaining to the quality of research. In this blog post, Shaheena Patel (Communications Associate, MDPI), outlines two recent updates to MDPI journal processes. These updates pertain to Special Issue (SI) quality guidelines, in line with criteria provided by COPE and DOAJ. Alongside the SI updates, details regarding the new minor corrections policy introduced in 2024 are provided in the blog.

The two updates we implemented include greater oversight and the verification of Guest Editor credentials. These guidelines require that Editors-in-Chief (EiCs) and Editorial Board Members (EBMs) take responsibility for overseeing SIs.

PS. Thank you, James Butcher, for featuring this up in your 67th issue of the Journalogy newsletter.

Read more:

Coming Together for Science

Viruses 2024 – A World of Viruses

I am pleased to share the success of our MDPI conference Viruses 2024 – A World of Viruses, held 14-16 February, in Barcelona. With 240 registrations, this event brought together top scientists, researchers, and industry experts from 40 countries to share their findings on the latest developments in viral pathogenesis and immune responses.

Attendees gathered for the 5th edition of the Viruses’ conference, where we hosted influential keynote speeches from Nobel Prize laureate Dr. Charles M. Rice and ‘Distinguished Senior Virologist’ Prof. Luis Enjuanes, along with 14 invited speakers, 47 selected speakers, and nine flash poster presenters, to discuss the most significant issues in virology today.

Recap on the #Viruses2024 Conference

Take a look at the key moments from MDPI’s Viruses event and please join us in commemorating a gathering for global knowledge and cooperation. A heartfelt thank-you to all attendees; their passion and engagement played a crucial role in making this event an engaging success!

Below are calls to action from the keynote speakers encouraging collaboration and communication:

“There’s never been a better time than now to really take the power that we have both in terms of basic research and also in biotech and pharma to develop antiviral agents.” - Dr. Charles M. Rice, The Rockefeller University, New York, USA

“The collaboration between labs is absolutely essential. Improving initial detection and improving communication is a must for all of us working in science.” - Prof. Dr. Luis Enjuanes, National Center of Biotechnology (CNB-CSIC), Madrid, Spain

Our thanks go to our sponsors and partnering societies, our Viruses journal and editorial team, our Barcelona colleagues, and the social media, conference and other MDPI teams for making this event a memorable occasion. View the event gallery here.

Upcoming In-Person Event

24–26 April, 2024
4th MMCS – Harnessing the Power of New Drug Modalities
Location: Barcelona, Spain

Esteemed speakers at MMCS 2024 include Prof. Arun K. Ghosh, the mind behind the Darunavir molecule, and Prof. Paul Brennan, CSO of Alzheimer's Research UK Oxford Drug Discovery Institute.

Find more upcoming MDPI events here.


Organize Your Event with MDPI’s Sciforum

Sciforum is MDPI’s platform dedicated to the organization of scientific events. In line with our mission to promote science, Sciforum supports scholars, societies, research networks, and universities at all stages of organizing in-person events, virtual events and webinars. Our platforms are efficient, user-friendly, and cost-effective. We handle all steps related to event management. Contact us for details.

Closing Thoughts

Researcher to Reader (R2R) Conference

From 20–21 February 2024, I had the pleasure of attending the Researcher to Reader (R2R) conference in London, which MDPI has proudly sponsored over the years. The conference programme offered a variety of session formats, including workshops, panel discussions, debates, interviews, presentations, and lightning talks, with opportunities to discuss relevant topics.

We take pride in supporting the scientific community, bringing researchers across the world together to network, exchange ideas and share the latest in science and publishing. In 2023, MDPI invested close to 2 million CHF in sponsoring over 2,000 scientific and publishing-related conferences worldwide.

R2R Peer Review Innovations Workshop

I found the R2R conference to be engaging, with the workshops being particularly enjoyable. My colleague Giulia Stefenelli (Chair of Scientific Office Board) and I participated in the “Peer Review Innovations” workshop, which spanned four sessions over the two days. These sessions explored the future of peer review and how we can improve the peer review process for everyone involved. Notably, the large majority of attendees expressed their opinion that peer review, as currently practiced, requires significant improvement. Together, we collaborated on potential immediate and long-term improvements and innovative processes, aiming to create an ecosystem beneficial to all stakeholders by strengthening submission systems with the aim of reducing threats and making authors more responsible for their work. We also discussed the opportunity for academic institutions to better scrutinize the quality of the work produced and submitted to journals.

Our group comprised publishers, software providers, librarians, and more, bringing diverse perspectives to the discussions. These interactions were relevant to MDPI’s ongoing conversations, providing insights to our efforts. The session also made me appreciate that MDPI is doing well, as the group discussions included the subject of various quality checks that we have already embedded in our processes, ensuring that we keep abreast of industry standards.

The need for an optimized system to incentivize the activities of editors and reviewers was also a focus of discussion, as well as the support that reviewers need from publishers via the provision of strong reports through fixed forms, questionnaires and training.

At MDPI, we are currently auditing our reviewer program to improve reviewer recognition, guidelines, and methods for identifying suitable reviewers, while maintaining our commitment to quality and timeliness.

Congratulations to Mark Carden, Conference Director, and the R2R team for organizing a productive and successful event. PS: The break times were greatly appreciated as well!

Stefan Tochev
Chief Executive Officer
MDPI AG

29 February 2024
Current Oncology | Collaboration with The Canadian Centre for Applied Research in Cancer Control (ARCC)

In January 2024, Current Oncology (ISSN: 1718-7729) began to cooperate with the Canadian Centre for Applied Research in Cancer Control (ARCC). As part of this collaboration, all the members of ARCC will enjoy a discount on the Article Processing Charge (APC) when submitting articles to Current Oncology. The collaboration goes beyond the discount offered to members and includes other services, as well as cross promotion.

The Canadian Centre for Applied Research in Cancer Control (ARCC) is an innovative pan-Canadian research center whose mission is to improve cancer control and the delivery of care through interdisciplinary leadership in health economics, services, policy, and ethics research, education and knowledge translation.

We achieve our mission by making improvements across the cancer control spectrum, from prevention, screening and diagnosis to treatment, rehabilitation, survivorship or palliative care. We accomplish this through our dynamic network. The ARCC has provincial representation across Canada.

The ARCC is a professional organization whose functions are highly relevant to the scope of Current Oncology. We look forward to collaborating with the ARCC and publishing state-of-the-art research from its members.

For more information about societies cooperated with Current Oncology, please visit the following link: https://www.mdpi.com/journal/curroncol/societies.

7 February 2024
Current Oncology | International Childhood Cancer Day

International Childhood Cancer Day (15 February) is a global collaborative effort to deepen the understanding of the difficulties faced by children and adolescents with cancer, as well as by survivors and their families, and to raise awareness of these issues. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings in the field of childhood cancers, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field.

The list of relevant papers can be seen below:

  1. “Peer Support Needs and Preferences for Digital Peer Navigation among Adolescent and Young Adults with Cancer: A Canadian Cross-Sectional Survey”
    by Jacqueline L. Bender, Natasha Puri, Sarah Salih, Norma M. D’Agostino, Argerie Tsimicalis, A. Fuchsia Howard, Sheila N. Garland, Karine Chalifour, Emily K. Drake, Anthony Marrato et al.
    Curr. Oncol. 2022, 29(2), 1163–1175; https://doi.org/10.3390/curroncol29020099
    Available online: https://www.mdpi.com/1718-7729/29/2/99
  2. “The Chemo-Gut Pilot Study: Associations between Gut Microbiota, Gastrointestinal Symptoms, and Psychosocial Health Outcomes in a Cross-Sectional Sample of Young Adult Cancer Survivors”
    by Julie M. Deleemans, Faye Chleilat, Raylene A. Reimer, Mohamad Baydoun, Katherine-Ann Piedalue, Dana E. Lowry, Jan-Willem Henning and Linda E. Carlson
    Curr. Oncol. 2022, 29(5), 2973–2994; https://doi.org/10.3390/curroncol29050243
    Available online: https://www.mdpi.com/1718-7729/29/5/243
  3. “The Impact of Exercise on Cardiotoxicity in Pediatric and Adolescent Cancer Survivors: A Scoping Review”
    by Stephanie J. Kendall, Jodi E. Langley, Mohsen Aghdam, Bruce N. Crooks, Nicholas Giacomantonio, Stefan Heinze-Milne, Will J. Johnston, Melanie R. Keats, Sharon L. Mulvagh and Scott A. Grandy
    Curr. Oncol. 2022, 29(9), 6350–6363; https://doi.org/10.3390/curroncol29090500
    Available online: https://www.mdpi.com/1718-7729/29/9/500
  4. “The Transformation of Adolescent and Young Adult Oncological and Supportive Care in Canada: A Mixed Methods Study”
    by Jonathan Avery, Emily Wong, Christine Harris, Stacy Chapman, Serena Uppal, Shaayini Shanawaz, Annemarie Edwards, Laura Burnett, Tushar Vora and Abha A. Gupta
    Curr. Oncol. 2022, 29(7), 5126–5138; https://doi.org/10.3390/curroncol29070406
    Available online: https://www.mdpi.com/1718-7729/29/7/406
  5. “Recruiting Adolescent and Young Adult Cancer Survivors for Patient-Reported Outcome Research: Experiences and Sample Characteristics of the SURVAYA Study”
    by Carla Vlooswijk, Lonneke V. van de Poll-Franse, Silvie H. M. Janssen, Esther Derksen, Milou J. P. Reuvers, Rhodé Bijlsma, Suzanne E. J. Kaal, Jan Martijn Kerst, Jacqueline M. Tromp, Monique E. M. M. Bos et al.
    Curr. Oncol. 2022, 29(8), 5407–5425; https://doi.org/10.3390/curroncol29080428
    Available online: https://www.mdpi.com/1718-7729/29/8/428 
  6. “Utilization, Delivery, and Outcomes of Dance/Movement Therapy for Pediatric Oncology Patients and their Caregivers: A Retrospective Chart Review”
    by Karolina Bryl, Suzi Tortora, Jennifer Whitley, Soo-Dam Kim, Nirupa J. Raghunathan, Jun J. Mao and Susan Chimonas
    Curr. Oncol. 2023, 30(7), 6497–6507; https://doi.org/10.3390/curroncol30070477
    Available online: https://www.mdpi.com/1718-7729/30/7/477
  7. “Adherence to Oral Chemotherapy in Acute Lymphoblastic Leukemia during Maintenance Therapy in Children, Adolescents, and Young Adults: A Systematic Review”
    by Xiaopei L. Zeng, Mallorie B. Heneghan and Sherif M. Badawy
    Curr. Oncol. 2023, 30(1), 720–748; https://doi.org/10.3390/curroncol30010056
    Available online: https://www.mdpi.com/1718-7729/30/1/56
  8. “Setting Priorities for a Provincial Adolescent and Young Adult Oncology Program”
    by Julian Surujballi, Grace Chan, Caron Strahlendorf and Amirrtha Srikanthan
    Curr. Oncol. 2022, 29(6), 4034–4053; https://doi.org/10.3390/curroncol29060322
    Available online: https://www.mdpi.com/1718-7729/29/6/322

You are welcome to submit relevant papers to the journal Current Oncology. If you have any questions, feel free to contact us.

Current Oncology Editorial Office

1 February 2024
Acknowledgment of the Reviewers of Current Oncology in 2023

In recognizing the exceptional efforts of our reviewers in 2023, we express our sincere gratitude for upholding the high standards of Current Oncology. Their commitment ensured the rigorous peer review that is integral to quality academic publishing.

In 2023, Current Oncology received 2833 review reports, from 2094 reviewers. This past year, we worked with reviewers from 67 countries and regions, reflecting the diversity in our collaboration with research communities. Their dedication shapes scholarly discourse and advances global research. The editorial team expresses gratitude for the vital role played by each reviewer in the Current Oncology family throughout 2023, and we look forward to their continued support in 2024.

The following are the reviewers who have consented to show their names:

Jeffrey S. Hoch Tao Li
Jeffrey Velotta Tatiana Simao
Jen-Chih Tseng Tatsuji Mizukami
Jennifer Pursley Terry Lichtor
Jenny Drott Theodoros Tokas
Joanna Zawitkowska Tianjie Pu
Joaquim Carreras Tiberiu Augustin Georgescu
Joaquim Soares do Brito Tijana Išić Denčić
Joel L. Schwartz Tito Brambullo
Joel Nitzkin Tomasz Banas
John Amson Capitman Tommaso Greco
John Mack Tracey Madgett
John Ward Tunc Eren
Jörg Weimer Uhi Toh
Jorge Feito Uros Bumbasirevic
Jose Carlos Vilches Jimenez Valeria Dionisi
José López Castro Varun Monga
José Maria Lasso Vasyl Vasko
Joshua Jue Vellone Gaetano
Jr. Tivadar Bara Venkata Satya Vivek Tammineedi
Julia Kaal Vera Damuzzo
Julie Townsend Veronica Rivi
Junaid Rafi Vicki Butenschoen
Junwei Shi Victor Seledtsov
Juozas Lazutka Vignesh Sundararajan
Jyotindra Narayan Vikas Kuma Somani
Kacper Nijakowski Vinícius Simão
Kamil Nelke Vitor Parola
Kanakaraju Manupati Vittorio Aprile
Kari Nielsen Vlad David
Karim Hamesch Vladimir Bilim
Kate Anderson Vladimir Jurisic
Katsuhiro Ito Wael Mansy
Kazi Abdul Mannan Wei Shi
Kazuki Ide Wei Zhou
Ke Cong Weichung Shia
Keeren Sundara Rajoo Wei-Fan Hsu
Kendra Ratnapradipa Weiren Luo
Kenji Hayashida Wi-Young So
Keren Dopelt Wojciech Skrobot
Keun-Yeong Jeong Wojciech Szlasa
Kirthiram Sivakumar Xenophon Sinopidis
Kishor Pant Xiang-Yu Hou
Klaus-Henning Kahl Xiaodong Wang
Klazien Matter-Walstra Xiaomo Xiong
Koji Ichihara Xing Wei
Koki Nakanishi Xinyuan Lei
Konstantinos Arvanitakis Yaoxiang Li
Konstantinos Perivoliotis Yari Longobucco
Konstantinos Seretis Yasuo Imai
Koroknai Viktória Yavuz Samanci
Kristijan Skok Yi Huang
Kristin Nieman Yoichi Kobayashi
Kubilay Gürünlüoğlu Yong-Moon Lee
Kui Zhang Yoshihito Kano
Kurubaran Ganasegeran Young Zoon Kim
Lakshmi Vineela Nalla Yuan-Ming Tsai
Laura Grunewald Yutaka Endo
Laura Tack Zachary Mccaw
Lauren Zimmaro Zhaoqing Cong
Laurentiu Simion Zheng Chen
Lei Huang Zhijun Zhou
Leila Allahqoli Zoltan Herold
Leny Jose Zorana Dobrijević
Leonardo Tariciotti

31 January 2024
MDPI Insights: The CEO's Letter #8 - Altmetric and Flat Fee Agreement

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

MDPI and Digital Science Meeting

At MDPI, we are committed to providing our authors with the essential tools to publish, promote, and track their research. In line with this commitment, we have established a longstanding collaboration with Digital Science, a company specializing in research data and analytical insights for the research community. Our collaboration integrates their Altmetric tool, offering us and our authors the ability to track a variety of sources that monitor and report attention surrounding publications.

As part of our collaboration, we recently hosted Cathy Holland, Director of Global Publisher Business Development, and Helen Cooke, Managing Director of Publisher Sales, from Digital Science, at our MDPI headquarters in Basel, Switzerland.


Left to right: Facundo Santomé (Senior Marketing Manager, MDPI), Constanze Shelhorn (Indexing Manager, MDPI), Cathy Holland (Director of Global Publisher Business Development, Digital Science), Helen Cooke (Managing Director of Publisher Sales, Digital Science), and Stefan Tochev (CEO, MDPI) in front of MDPI headquarters in Basel, Switzerland.

During our meeting, we discussed MDPI’s publishing philosophy and explored further avenues for collaboration. We look forward to continuing our partnership with Digital Science, aiming to improve our services yet further and meet the needs of our authors more closely than ever.

What is Altmetric?

You will notice that MDPI articles feature an Altmetric score, a colourful doughnut capturing the score in the upper right corner of the article page. This score represents ‘alternative metrics,’ as distinct from traditional metrics such as Impact Factor, CiteScore, and Scimago Journal Rank.

Altmetrics complement traditional citation-based metrics by capturing online discussions related to a specific research topic. By analyzing both sets of data, we can obtain a comprehensive understanding of the attention a particular research output receives and the sources in which it is mentioned.

“Almetric provides visual insights into where research is being discussed”

Sources Tracked by Altmetric


Altmetric badge showing the Altmetric score and colour-coded mention sources.

Altmetric monitors various sources, categorizing them into segments such as policy documents, peer reviews, Wikipedia, news and blogs, and social media, among other sources. Each category is identifiable by a specific colour.

The Altmetric badge provides visual insights into where the research is being discussed. A more colourful badge indicates broader mentions across multiple platforms. Such tracking enables us to gauge the extent of an article’s online dissemination, noting that increased visibility may correlate with higher citation rates.

Read more:

Impactful Research

Ten High-Altmetric Articles Published by MDPI

As at 30 January 2024, Altmetric has tracked 670,500 MDPI research outputs from MDPI, resulting in over 4.3 million mentions. This includes over 71,894 mentions in policy and patents and 294,714 mentions in news and blogs, with some achieving an Altmetric score as high as 28,754.

So, what is a good Altmetric score? There are various ways to put this score into context. You can find out more about the score in context and how to evaluate your work by this means.

Here are ten MDPI papers ranking in the top 5% of all research outputs scored by Altmetric.

“Accuracy in Wrist-Worn, Sensor-Based Measurements of Heart Rate and Energy Expenditure in a Diverse Cohort”

J. Pers. Med. 2017, 7(2), 3; https://doi.org/10.3390/jpm7020003

Altmetric page: https://mdpi.altmetric.com/details/20477344

Altmetric shows that this article appeared in 253 news stories from 209 outlets including Forbes, BBC, and Fox News.

“Daylight Saving Time and Acute Myocardial Infarction: A Meta-Analysis”

J. Clin. Med. 2019, 8(3), 404; https://doi.org/10.3390/jcm8030404

Altmetric page: https://mdpi.altmetric.com/details/57654628

Altmetric shows that this article appeared in 295 news stories from 207 outlets including Forbes, The Atlantic, and New York Times.

“The Preliminary Analysis of Cave Lion Cubs Panthera spelaea (Goldfuss, 1810) from the Permafrost of Siberia”

Quaternary 2021, 4(3), 24; https://doi.org/10.3390/quat4030024

Altmetric page: https://mdpi.altmetric.com/details/111086701

Altmetric shows that this article appeared in 182 news stories from 134 outlets including CBC News, CNN, and National Geographic.

“Not the Cat’s Meow? The Impact of Posing with Cats on Female Perceptions of Male Dateability”

Animals 2020, 10(6), 1007; https://doi.org/10.3390/ani10061007

Altmetric page: https://mdpi.altmetric.com/details/83796184

Altmetric shows that this article appeared in 124 news stories from 98 outlets including VICE, CNN and The Guardian.

“Behaviour and Welfare Impacts of Releasing Elephants from Overnight Tethers: A Zimbabwean Case Study”

Animals 2022, 12(15), 1933; https://doi.org/10.3390/ani12151933

Altmetric page: https://mdpi.altmetric.com/details/133463915

Altmetric shows that this article appeared in 192 news stories from 186 outlets.

How do I use altmetrics?

Altmetric Explorer provides a detailed step-by-step guide and instruction video for first-time users of the tool. The guide includes useful diagrams that make it easy to get started.

Sharing Research Online

For research to be tracked across different sources, Altmetric needs a research output with a persistent identifier: a DOI, ISBN, PubMed ID, handle ID, etc. When sharing research, it is important to include a link to the original research output.

“An Update on Eukaryotic Viruses Revived from Ancient Permafrost”

Viruses 2023, 15(2), 564; https://doi.org/10.3390/v15020564

Altmetric page: https://mdpi.altmetric.com/details/142929875

Altmetric shows that this article appeared in 250 news stories from 180 outlets including CTV, Fox News, and CNN.

“The Global Problem of Insufficient Sleep and Its Serious Public Health Implications”

Healthcare 2019, 7(1), 1; https://doi.org/10.3390/healthcare7010001

Altmetric page: https://mdpi.altmetric.com/details/53406248

Altmetric shows that this article appeared in 252 news stories from 168 outlets including BBC, Harvard Business Review, and Forbes.

“A Detailed Review Study on Potential Effects of Microplastics and Additives of Concern on Human Health”

Int. J. Environ. Res. Public Health 2020, 17(4), 1212; https://doi.org/10.3390/ijerph17041212

Altmetric page: https://mdpi.altmetric.com/details/86529137

Altmetric shows that this article appeared in 197 news stories from 150 outlets including BBC, The Tribune, and World Economic Forum.

“An Empirical Study of Chronic Diseases in the United States: A Visual Analytics Approach to Public Health”

Int. J. Environ. Res. Public Health 2018, 15(3), 431; https://doi.org/10.3390/ijerph15030431

Altmetric page: https://mdpi.altmetric.com/details/34714141

Altmetric shows that this article appeared in 232 news stories from 149 outlets including Forbes, New York Times, and Harvard Business Review.

“Garden Scraps: Agonistic Interactions between Hedgehogs and Sympatric Mammals in Urban Gardens”

Animals 2023, 13(4), 590; https://doi.org/10.3390/ani13040590

Altmetric page: https://mdpi.altmetric.com/details/142934305

Altmetric shows that this article appeared in 172 news stories from 168 outlets including BBC.

Inside MDPI

MDPI Annual Meeting Celebrations in China

On Thursday 25 January, over 1,300 MDPI colleagues from our two offices in Beijing gathered to kick off MDPI’s traditional ‘Annual Meetings.’ These celebrations take place in MDPI’s offices across China, including Dalian, Tianjin, Wuhan, and Nanjing.

The evenings include performances, informative talks and presentations, awards, and entertainment, providing an ideal platform to recognize our colleagues, celebrate their achievements, and set our sights on the future.

“It is essential that we stay connected and share best practices”

I sent a video congratulating everyone on their work and sharing our vision of building MDPI into the most trusted OA publisher, highlighting the roles each of us has to play in achieving that goal.

Unfortunately I could not join in person, but you may recall my recent trip, when I visited our offices in Beijing and Wuhan, which I look forward to visiting again this year.

Although our headquarters are in Basel, Switzerland, and we are expanding throughout Europe and North America, the majority of MDPI’s workforce is in China and throughout the Asia-Pacific region, including offices in Singapore, Thailand, Japan, and newly opened office in South Korea. It is essential that as a global organization, we stay connected and share best practices in order to grow collectively and continue providing the exceptional service to our authors.

The Annual Meeting is a moment to reflect and enjoy the year’s hard work and dedication.

I extend our best wishes to all for the Chinese New Year (Xīnnián kuàilè)!

Coming Together for Science

MDPI and TU Delft Adopt Flat Fee Model in Extended Partnership

We are excited to announce a renewed three-year partnership with Delft University of Technology (TU Delft) in the Netherlands. This collaboration introduces a fixed lump-sum fee, covering publishing costs from 2024 to 2026.

“This initiative reflects our dedication to transparent and inclusive publishing”

TU Delft-affiliated authors will enjoy cost-free publishing in any MDPI journal during this period, aligning with our commitment to removing barriers for open access publishing. The agreement supports Plan S compliance and facilitates a seamless publishing process for TU Delft corresponding authors. This initiative reflects our dedication to transparent and inclusive publishing, providing stability and predictability both for authors and for institutions.

For further details on our Institutional Open Access Program (IOAP), please contact us.

Benefits to MDPI’s IOAP

At MDPI we have a long tradition of partnerships, including our Institutional Open Access Program (IOAP). IOAP supports institutions through simplification, access, transparency, APC discounts, and institutional repository deposits. The program simplifies administrative processes, offers central payment, and allows easy opting in and out. Participants gain free access to Susy, MDPI’s online submission system, with extensive article metadata and exportable data. APC discounts and Book Processing Charge discounts are available for affiliated authors. Automated deposits to institutional repositories and streamlined matching of papers to IOAP participants enhance the overall experience.

For further information, see our IOAP FAQ.

Closing Thoughts

Reflections on the 2024 APE Conference

MDPI was proud to co-sponsor the Academic Publishing in Europe (APE) 2024 Conference that took place in Berlin, Germany, from 9–10 January 2024.

The conference theme, ‘Keep the Conversation Going!’, explored the evolving landscape of scholarly communication. APE is one of the key conferences I make a point to attend each year. January offers a valuable opportunity to engage with new contacts, reconnect with familiar faces, and participate in impactful discussions and presentations among professionals, scholars, and practitioners in the field.

“It's fascinating to see how other publishers are leveraging AI”

Highlights

Some of the standout panels for me include: the role of the UN Sustainable Development Goals (SDGs) within the publishing industry. It was encouraging to hear the current status quo, though I was eager also to learn about the exciting projects planned for 2024 and beyond. These will allow us to track progress in subsequent years. At MDPI, we remain committed to promoting Open–Access (OA) content on SDGs through scientific articles and books. Furthermore, we extend our commitment to sustainability by financially supporting researchers through initiatives such as the World Sustainability Award and the Emerging Sustainability Leader Award, as well as waiving the APC for feature papers on each SDG.

In recent years, discussions on AI have become increasingly prominent at such conferences. It’s fascinating to see how other publishers are leveraging AI to meet the evolving needs of their audiences while at the same time using it to safeguard the scientific process. Other engaging panels that I enjoyed included updates on transformation beyond transformative agreements, the principles of lean change, incentive structures related to research integrity, and the panel on reviewer incentives.

“We can share best practices and lessons learned”

Incorporating MDPI’s Insights into Conferences

I must confess that I sometimes feel overlooked when MDPI is not invited to participate in crucial industry discussions. As the leading open access publisher and the third-largest publisher overall, we possess extensive experience in many of these areas and can offer valuable contributions to these discussions. We can share best practices, lessons learned, and our thinking about future trajectories. For instance, in panels discussing reviewer incentives, at MDPI we offer a discount voucher to reviewers for future submissions, reflecting our commitment to fostering a robust peer review process. In 2022 alone, MDPI collected over 1.4 million peer review reports, informing the decision-making processes of our editors. Given our expertise in these areas, it would be natural to include MDPI in such discussions. I therefore extend an invitation to future conference organizers to consider MDPI for speaking engagements and collaborative opportunities.

Stefan Tochev
Chief Executive Officer
MDPI AG

9 January 2024
Meet Us at the 7th Symposium on Primary Breast Cancer in Older Women, 1 March 2024, Nottingham, UK


MDPI will attend the 7th Symposium on Primary Breast Cancer in Older Women as an exhibitor. This conference will be held in Nottingham, UK, on 1 March 2024.

The 7th Symposium on Primary Breast Cancer in Older Women aims to develop an in-depth understanding around the biology and treatment options, explore the specific physical and psychosocial needs and consideration including the patient perspective, and gain insight into the development of a holistic and multidisciplinary management approach and the importance of supporting research in the field of breast cancer.

The following MDPI journals will be represented:

If you are attending this conference, please feel free to start a conversation with us at our booth. Our delegates look forward to meeting you in person and answering any questions that you may have.

For more information about the conference, please visit https://www.nottingham.ac.uk/conference/fac-mhs/medicine/symposia-on-primary-breast-cancer-in-older-women/index.aspx

5 January 2024
Current Oncology | Top 10 Most Cited Papers in 2023

As Current Oncology (ISSN: 1718-7729) has an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2023 top cited papers listed below:

1. “Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems”
by George Doumat, Darine Daher, Morgan Bou Zerdan, Nasri Nasra, Hisham F. Bahmad, Monica Recine and Robert Poppiti
Curr. Oncol. 2023, 30(1), 704-719; https://doi.org/10.3390/curroncol30010055
Available online: https://www.mdpi.com/1718-7729/30/1/55

2. “Underlying Features of Prostate Cancer—Statistics, Risk Factors, and Emerging Methods for Its Diagnosis”
by Cristina V. Berenguer, Ferdinando Pereira, José S. Câmara and Jorge A. M. Pereira
Curr. Oncol. 2023, 30(2), 2300-2321; https://doi.org/10.3390/curroncol30020178
Available online: https://www.mdpi.com/1718-7729/30/2/178

3. “Current Overview of Treatment for Metastatic Bone Disease”
by Mohammed Badwelan, Hasan Muaddi, Abeer Ahmed, Kyungjun T. Lee and Simon D. Tran
Curr. Oncol. 2023, 30(4), 3721-3734; https://doi.org/10.3390/curroncol30040283
Available online: https://www.mdpi.com/1718-7729/30/4/283

4. “Machine Learning Approaches with Textural Features to Calculate Breast Density on Mammography”
by Mario Sansone, Roberta Fusco, Francesca Grassi, Gianluca Gatta, Maria Paola Belfiore, Francesca Angelone, Carlo Ricciardi, Alfonso Maria Ponsiglione, Francesco Amato, Roberta Galdiero et al.
Curr. Oncol. 2023, 30(1), 839-853; https://doi.org/10.3390/curroncol30010064
Available online: https://www.mdpi.com/1718-7729/30/1/64

5. “Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea”
by Han-Sang Baek, Jeonghoon Ha, Seunggyun Ha, Ja Seong Bae, Chan Kwon Jung and Dong-Jun Lim
Curr. Oncol. 2023, 30(3), 3020-3031; https://doi.org/10.3390/curroncol30030229
Available online: https://www.mdpi.com/1718-7729/30/3/229

6. “Harnessing Real-World Evidence to Advance Cancer Research”
by Monica Tang, Sallie-Anne Pearson, Robert J. Simes and Boon H. Chua
Curr. Oncol. 2023, 30(2), 1844-1859; https://doi.org/10.3390/curroncol30020143
Available online: https://www.mdpi.com/1718-7729/30/2/143

7. “Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers”
by Marco Russano, Giulia La Cava, Alessio Cortellini, Fabrizio Citarella, Alessandro Galletti, Giuseppina Rita Di Fazio, Valentina Santo, Leonardo Brunetti, Alessia Vendittelli, Iacopo Fioroni et al.
Curr. Oncol. 2023, 30(2), 2366-2387; https://doi.org/10.3390/curroncol30020181
Available online: https://www.mdpi.com/1718-7729/30/2/181

8. “Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients”
by Roberta Rosso, Marta D’Alonzo, Valentina Elisabetta Bounous, Silvia Actis, Isabella Cipullo, Elena Salerno and Nicoletta Biglia
Curr. Oncol. 2023, 30(2), 1461-1472; https://doi.org/10.3390/curroncol30020112
Available online: https://www.mdpi.com/1718-7729/30/2/112

9. “The Effects of Lack of Awareness in Age-Related Quality of Life, Coping with Stress, and Depression among Patients with Malignant Melanoma”
by Ana-Olivia Toma, Estera Boeriu, Luminita Decean, Vlad Bloanca, Felix Bratosin, Mihaela Codrina Levai, Neeharika Gayatri Vasamsetti, Satish Alambaram, Andrada Licinia Oprisoni, Bogdan Miutescu et al.
Curr. Oncol. 2023, 30(2), 1516-1528; https://doi.org/10.3390/curroncol30020116
Available online: https://www.mdpi.com/1718-7729/30/2/116

10. “Artificial Intelligence for Cancer Detection—A Bibliometric Analysis and Avenues for Future Research”
by Erik Karger and Marko Kureljusic
Curr. Oncol. 2023, 30(2), 1626-1647; https://doi.org/10.3390/curroncol30020125
Available online: https://www.mdpi.com/1718-7729/30/2/125

2 January 2024
MDPI Insights: The CEO's Letter #7 - Nobel Laureates Entrust MDPI with Their Research

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

Nobel Prize Laureates Entrust MDPI with Their Research

The Nobel Prize stands as a hallmark of distinction, honouring ground-breaking research across disciplines. Annually, the Nobel Prizes are awarded in six categories: Physics, Chemistry, Medicine or Physiology, Literature, Peace, and Economic Sciences.

Through the years, renowned scholars have entrusted MDPI with their work. As at December 2023, 26 Nobel laureates have contributed to more than 75 articles across 25 MDPI journals, including: Antibiotics, Applied Sciences, Biology, Biomedicines, Cancers, Catalysts, Cells, Crystals, Entropy, Games, IJMS, Life, Materials, Micromachines, Molecules, Pharmaceuticals, PharmaceuticsPhotonics, Quantum Beam Science, Remote Sensing, Sensors, Solids, Universe, Vaccines, and Viruses.

The best of the best trust us with their work.

Nobel Prize Laureates Who Have Published with MDPI

We are proud to list the names of Pierre Agostini, Hiroshi Amano, Werner Arber, Aaron Ciechanover, Robert H. Grubbs, Oliver Hart, Gerard ‘t Hooft, Michael Houghton, Harald zur Hausen, Katalin Karikó, Jean-Marie Lehn, Gérard Mourou, Ferid Murad, Shuji Nakamura, William Nordhaus, Kostya S. Novoselov, Giorgio Parisi, Charles M. Rice, Alvin E. Roth, Donna Strickland, K. Barry Sharpless, George F. Smoot, Anne L’Huillier, Drew Weissman, Kurt Wüthrich, Ada Yonath.

The privilege of hosting such contributors resonates deeply with our editorial teams. For instance, in this interview, the Editor-in-Chief (EiC) of Universe speaks on the significance of publishing a paper by Nobel laureate Gerard ’t Hooft within the journal.

2023 Nobel Prize Winners Published by MDPI

Nobel Prize Winners, 2023: Katalin Karikó, Drew Weissman, Anne L’Huillier (Ill. Niklas Elmehed © Nobel Prize Outreach)

Three laureates from the 2023 Nobel Prize cohort have trusted MDPI as their publishing platform. Notably, in a 2022 Pharmaceutics paper, molecular biologist Katalin Karikó and her team presented a methodology for evaluating mRNA capping efficiency, pivotal for therapeutic applications. Pharmaceutics had previously dedicated a Special Issue to “mRNA Therapeutics: A Themed Issue in Honor of Professor Katalin Karikó”, spotlighting ten articles from August 2021 to February 2022.

In the journal Vaccines, Professor Drew Weissman, collaborating with scholars from Pennsylvania University and George Mason University, contributed an influential review titled “Nanomaterial Delivery Systems for mRNA Vaccines”. His collaborative efforts spanned five papers across MDPI journals between 2021 and 2023.

Furthermore, Anne L'Huillier of Lund University, only the fifth female recipient of the Physics Prize, co-authored an article in Applied Sciences focusing on "Advanced EUV and X-Ray Optics". Similarly, Pierre Agostini, an Emeritus Professor from Ohio State University, co-authored an article featured in the special issue "Attosecond Science and Technology: Principles and Applications".

We extend heartfelt congratulations to all Nobel Prize laureates and express sincere gratitude for their confidence in MDPI as a platform for their scholarly contributions.

Read more:

Impactful Research

MDPI Journals Newly Indexed in 2023

The aim of indexing is to enhance the quality and credibility of published research, ensuring that researchers access the most credible resources available. While the principle behind citation indexing is straightforward, it remains one of the most dependable methods for tracking an idea's evolution across various scientific disciplines.

Throughout the year, MDPI works to expand the reach of our publications across premier multidisciplinary databases like Web of Science, Scopus, EBSCO, and ProQuest. This initiative is spearheaded by MDPI's Indexing team, under the leadership of Dr. Constanze Schelhorn.

In 2023, MDPI achieved 54 new acceptances in Scopus, 29 in Web of Science, 52 in EBSCO, and 83 in DOAJ: Directory of Open Access Journals.

The team prioritizes ensuring that our journals feature in numerous specialized databases, including PMC, PubMed, MEDLINE, Inspec, CAS, and FSTA, among others. Currently, MDPI collaborates with over 65 renowned international databases, consistently enhancing our database affiliations annually.

MDPI’s journals are indexed in all major global databases.

Furthermore, we collaborate with universities and government organizations to list our journals in country-specific ranking lists and relevant institutional repositories. This ensures compliance with requirements often set by funders or institutions for authors to publish in specific journals.

Web of Science Adds 24 MDPI Journals to Emerging Sources Citation Index (ESCI)

Clarivate recently analysed MDPI’s new journals, resulting in 24 journals, mainly established in 2020, being added to the ESCI in November and December 2023. Additionally, five journals passed this assessment earlier in the year. For a complete list of our journals in Web of Science, refer here. Journals in the ESCI meet 24 quality criteria, ensuring editorial rigor. They may be considered for inclusion in broader indices like the Science Citation Index Expanded (SCIE), the Social Sciences Citation Index (SSCI), or the Arts and Humanities Citation Index (AHCI), based on four impact criteria.

Read more:

Inside MDPI

MDPI Appoints New Chief Operating Officer (COO)

Alistair Freeland returned to MDPI and assumed the role of Chief Operating Officer in November 2023, a position he previously held from 2013 to 2019. He succeeds Dr. Yu Lin, who will remain a member of MDPI’s Board of Directors, overseeing significant financial decisions for the company. I would like to express my sincere thanks to Dr. Yu Lin for his service as COO.

Alistair brings extensive experience not only in scholarly publishing but also in technology and business management. Prior to rejoining MDPI, he was associated with SIX Group, the entity responsible for Switzerland's financial market infrastructure. There, he played a pivotal role in developing the blockchain-based platform SDX (SIX Digital Exchange), which has gained traction among major Swiss banks and the Swiss National Bank.

As COO, Alistair will collaborate with the MDPI management team to improve the practices and services we offer to scholarly communities. I am pleased to welcome Alistair back to MDPI and look forward to his contributions going forward.

Coming Together for Science

MDPI’s 2024 In-Person Academic Events Schedule

MDPI's Conference Team is dedicated to organizing and hosting in-person academic events across Europe, Asia-Pacific, and North America. We recognize conferences as invaluable platforms for scientific collaboration, scholarly exchange, discussions on contemporary topics, networking, and forging collaborations.

Here's a glimpse of the notable events we currently have scheduled for 2024:

14–16 February, 2024
Viruses 2024 – A World of Viruses
Location: Barcelona, Spain
We are honoured to feature Nobel Prize laureate Dr. Charles M. Rice and ‘Distinguished Senior Virologist’ Prof. Luis Enjuanes as keynote speakers for this 5th edition.
Event details

24–26 April, 2024
4th MMCS – Harnessing the Power of New Drug Modalities 
Location: Barcelona, Spain
Esteemed speakers include Prof. Arun K. Ghosh, the mind behind the Darunavir molecule, and Prof. Paul Brennan, CSO of Alzheimer's Research UK Oxford Drug Discovery Institute.
Event details

28–31 May, 2024
Polymers 2024 – Polymers for a Safe and Sustainable Future
Location:
Athens, Greece
We look forward to welcoming renowned experts like Prof. Damià Barceló, Prof. Minna Hakkareinen, and Prof. Armando J. D. Silvestre to this event.
Event details

1–4 August, 2024
The 1st International Conference on AI Sensors & The 10th International Symposium on Sensor Science
Location: Singapore
The AI Sensors 2024 Conference will unite innovators and experts in the realms of sensors, sensing technology, and artificial intelligence.
Event details

Upcoming events with details to be announced:

  • September 2024, Materials 2024 – Basel, Switzerland
  • 1921 September 2024, International Conference on Nanomaterials Sciences 2024 – Beijing, China
  • October 2024, ncRNA 2024 – Basel, Switzerland
  • November 2024, Pharmaceuticals 2024 – Barcelona, Spain
  • 2226 November 2024, International Conference on Science of Electronics – Wuhan, China
  • Stay tuned for more details on the Sustainable Publishing Forum 2024.

Click here for all upcoming MDPI events.

Organize Your Event with MDPI’s Sciforum

Sciforum is MDPI’s platform dedicated to the organization of scientific events. In line with our mission to promote science, Sciforum supports scholars, societies, research networks, and universities at all stages of organizing in-person events, virtual events and webinars. Our platforms are efficient, user-friendly, and cost-effective. We handle all steps related to event management. Contact us for details.

Closing Thoughts

Reflecting on 2023 and Looking Ahead to 2024

As we approach 2024, I reflect on the incredible journey we’ve had together at MDPI this year. The past 12 months have been marked by ambitious projects and initiatives to improve our internal processes, and a commitment to continue delivering top-notch services to our stakeholders. I’d like to thank each and every one of our staff members for contributing to the positive experiences our stakeholders have reported in our surveys. Your dedication to speed, efficiency, and effective communication with our stakeholders is very much recognized and appreciated.

Becoming a stronger organisation

While we have encountered challenges in 2023, it’s important to understand that these are a part of our growth process. Difficulties provide us with opportunities to reflect, address problems at their roots, and ultimately evolve into a stronger organization. Our stakeholders expect us to overcome tough times, and it’s an expectation that we have for ourselves.

I extend my sincere appreciation to every MDPI employee, from our editorial office and IT department to marketing, indexing, IOAP, societies, Scientific Office board, products, production, conferences, finance, operations, admin, and beyond. To our newest team members, a warm welcome; to our longstanding colleagues, your dedication is invaluable.

“I am committed to taking MDPI to a new level of excellence.”

Interacting with many of you during my visits to our offices and representing MDPI at external events has been a personal highlight. I am deeply grateful to Dr. Lin for entrusting me with the role of CEO of MDPI. Looking forward, I am committed to working closely with our management team to lead MDPI and take it to a new level of excellence, aiming to establish it as the most trusted publisher in open access worldwide. This is a collective endeavour, with each of us shaping MDPI’s reputation. I therefore encourage us to take pride in our work, as it represents not only our craft but also MDPI as a whole.

Accountability and communication

As we look forward to 2024, there’s a lot to be excited about. Together, we’ll navigate challenges, seize growth opportunities, and refine our practices. To solidify MDPI’s position as the premier open access publisher globally, we must bolster accountability, improve stakeholder communication, share MDPI’s best practices, champion the open access philosophy, and educate stakeholders about our mission, methodologies, and motivations.

Thank you for engaging with the CEO Letter over the past six months of 2023. I will continue to release this newsletter as a method of sharing the great work being done at MDPI. Please feel free to connect directly with any insights or questions.

Here’s to a joyous and prosperous 2024!

Stefan Tochev
Chief Executive Officer
MDPI AG

11 December 2023
Current Oncology | Top 10 Most Cited Papers in 2021

As Current Oncology (ISSN: 1718-7729) has an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers listed below:

1. “Synovial Sarcoma: A Clinical Review”
by Aaron M. Gazendam, Snezana Popovic, Sohaib Munir, Naveen Parasu, David Wilson and Michelle Ghert
Curr. Oncol. 2021, 28(3), 1909–1920; https://doi.org/10.3390/curroncol28030177
Available online: https://www.mdpi.com/1718-7729/28/3/177

2. “The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review”
by Nicolas Iragorri, Claire de Oliveira, Natalie Fitzgerald and Beverley Essue
Curr. Oncol. 2021, 28(2), 1216–1248; https://doi.org/10.3390/curroncol28020117
Available online: https://www.mdpi.com/1718-7729/28/2/117

3. “Current Overview of Treatment for Metastatic Bone Disease”
by Shinji Tsukamoto, Akira Kido, Yasuhito Tanaka, Giancarlo Facchini, Giuliano Peta, Giuseppe Rossi and Andreas F. Mavrogenis
Curr. Oncol. 2021, 28(5), 3347–3372; https://doi.org/10.3390/curroncol28050290
Available online: https://www.mdpi.com/1718-7729/28/5/290

4. “Pathological Features and Prognostication in Colorectal Cancer”
by Kabytto Chen, Geoffrey Collins, Henry Wang and James Wei Tatt Toh
Curr. Oncol. 2021, 28(6), 5356–5383; https://doi.org/10.3390/curroncol28060447
Available online: https://www.mdpi.com/1718-7729/28/6/447

5. “Extramammary Paget’s Disease: Diagnosis, Pathogenesis, and Treatment with Focus on Recent Developments”
by Shoichiro Ishizuki and Yoshiyuki Nakamura
Curr. Oncol. 2021, 28(4), 2969–2986; https://doi.org/10.3390/curroncol28040260
Available online: https://www.mdpi.com/1718-7729/28/4/260

6. “The Feasibility and Effects of a Telehealth-Delivered Home-Based Prehabilitation Program for Cancer Patients during the Pandemic”
by Fiona Wu, Oloruntobi Rotimi, Roberto Laza-Cagigas and Tarannum Rampal
Curr. Oncol. 2021, 28(3), 2248–2259; https://doi.org/10.3390/curroncol28030207
Available online: https://www.mdpi.com/1718-7729/28/3/207

7. “Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults †”
by D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika Krzyzanowska et al.
Curr. Oncol. 2021, 28(1), 523–548; https://doi.org/10.3390/curroncol28010053
Available online: https://www.mdpi.com/1718-7729/28/1/53

8. “Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma”
by Yuji Eso, Haruhiko Takeda, Kojiro Taura, Atsushi Takai, Ken Takahashi and Hiroshi Seno
Curr. Oncol. 2021, 28(5), 4157–4166; https://doi.org/10.3390/curroncol28050352
Available online: https://www.mdpi.com/1718-7729/28/5/352

9. “Recent Radiomics Advancements in Breast Cancer: Lessons and Pitfalls for the Next Future”
by Filippo Pesapane, Anna Rotili, Giorgio Maria Agazzi, Francesca Botta, Sara Raimondi, Silvia Penco, Valeria Dominelli, Marta Cremonesi, Barbara Alicja Jereczek-Fossa, Gianpaolo Carrafiello et al.
Curr. Oncol. 2021, 28(4), 2351–2372; https://doi.org/10.3390/curroncol28040217
Available online: https://www.mdpi.com/1718-7729/28/4/217

10. “Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects”
by Grace Lassiter, Cole Bergeron, Ryan Guedry, Julia Cucarola, Adam M. Kaye, Elyse M. Cornett, Alan D. Kaye, Giustino Varrassi, Omar Viswanath and Ivan Urits
Curr. Oncol. 2021, 28(1), 640–660; https://doi.org/10.3390/curroncol28010063
Available online: https://www.mdpi.com/1718-7729/28/1/63

30 November 2023
MDPI Insights: The CEO's Letter #6 - MDPI Spain Summit and ResearchGate

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

MDPI Spain Summit


Stefan Tochev (CEO, MDPI) gives the opening speech at the MDPI Spain Summit.

On Friday 10 November 2023 I was in Barcelona, Spain, to deliver the opening presentation and participate in a panel at MDPI’s Spain Summit, a two-day event, inspired by our salon events in China.

With 16 Editors-in-Chief (EiCs) and 20 Editorial Board Members (EBMs) in attendance, the event, organized by our conference team and Barcelona office, featured presentations on open access (OA), MDPI, and publishing market trends in Spain.

The event provided a great opportunity to engage with stakeholders from various MDPI journals, including Nutrients, Vaccines, Buildings, IJMS, and others. We were able to gather feedback and have open conversations around manuscript quality, the peer-review process, and journal development, as well as accreditation agencies.

The main objective of this Summit was to bring together Editors representing MDPI journals across various disciplines within Spanish universities and research centers, primarily from the Barcelona area. The aim was to facilitate an open and fruitful discussion regarding the development of their journals, the future of OA in Spain, and to provide meaningful interactions and networking opportunities.

Connecting with Editorial Board Members


Stefan Tochev in conversation with Summit participants: "Our EBMs are passionate about the journals they serve."

Interacting with our EBMs in person provides a valuable opportunity to show how important it is to us to connect with them, hear their perspectives on their journals and learn more about their own experience collaborating with MDPI.

From my conversations, it was clear that our EBMs are passionate about the journals they serve. I know the advice they provide may sometimes involve just small tweaks, but these can lead to important improvements. As the saying goes, small hinges swing open big doors.

As at November 2023, MDPI has over 6,300 EBMs affiliated with Spanish institutions, with more than 30 of them serving as EiCs or section EiCs. Furthermore, over 68,000 Spanish scholars have contributed as reviewers in MDPI journals.

Open Access in Spain

In 2023, Spain implemented legislation mandating immediate OA for all publicly funded research, aligning with the EU’s Plan S initiative to expedite the transition to OA. The Spanish government also approved a four-year, €23.8 million annual budget for the first national OA strategy, aiming to make publicly funded research freely accessible upon publication. This strategy aims to strengthen the quality and transparency of research in Spain, and to help promote movement towards a digital, low-carbon economy.

For further details of Spain's OA policy and the history of government mandates, click here.

Spain has already seen a notable decline in subscription-only articles, decreasing by 62% over a 10-year period, while gold OA increased by 42%. Green OA slightly decreased, suggesting a shift towards publishing in gold OA journals rather than traditional subscription-based ones. Here are some statistics from Scopus. 

A big thank-you to the various MDPI teams, including our conference team and the Barcelona office, for organizing this very successful event!


MDPI colleagues from various offices gathered to host and support the first MDPI Spain Summit, in Barcelona, Spain.

I think this type of gathering has the potential to become an annual event in various locations. For example, Manchester could be an option, as we have over 30 EiCs and over 3,000 EBMs in the UK, a top market for MDPI that publishes high-quality research.

Impactful Research

769 Editorial Board Members of MDPI Journals Recognized as Highly Cited Researchers in 2023

Congratulations to our 769 Editorial Board Members from 40 countries/territories who have been awarded Highly Cited Researcher status for 2023 by Clarivate. This recognition is based on their outstanding scientific research contributions and significant influence in various fields, as evidenced by Web of Science data.

Click here to view the full list of 769 Editorial Board Members.

Clarivate's Highly Cited ResearchersTM list identifies individuals with exceptional impact in scientific and social science domains over the past decade. Their papers rank in the top 1% of citations in 21 fields analysed in ‘Essential Science Indicators,’ showcasing their substantial influence.

This year, 7,125 Highly Cited Researcher 2023 designations were issued to 6,849 individuals from 67 countries, representing just 1 in 1,000 researchers worldwide.

These researchers demonstrate exceptional influence, representing a small fraction of contributors pushing the boundaries of knowledge, contributing to global well-being, sustainability, and security.

Congratulations to these scholars for their remarkable achievement: we are honoured to have them on board with our journals!

Inside MDPI

Corporate Marketing and Communications Strategy Session


Members of MDPI’s Corporate Marketing & Communications team.

For the past few years, I have led the Corporate Marketing & Communications department in our annual strategy session.

This typically involves 2–3 days of focused sessions covering key topics including budgeting, hiring targets, campaign reviews, and planning for the upcoming year, department strategy, and structure.

We are constantly exploring ways to optimize the Corporate Marketing & Communications department to support MDPI’s primary objectives and better convey the MDPI story while serving the scholarly community.

The strategy session also serves as a team-building activity, during which the team voted on bowling!

Strategy Session

In this strategy session, we looked at how to align our teams in order to better streamline our content with our campaigns, build a dedicated marketing team to strategically support our core MDPI products, expand our communications teams and functionalities to focus on company-critical campaigns and press releases, align our new brand design system with our marketing initiatives, set up a community and engagement team to support various teams with their outreach and communication efforts, and increase our use of data in the evaluation of campaign performance.

To grow in these areas, we will be hiring for various positions, including those of Public Relations Manager, Communications Manager, Internal Communications Manager, Campaign Manager, Marketing Associate, and Editorial Engagement Manager.

I am grateful for the way our Corporate Marketing & Communications department has grown and gelled over the years, and I look forward to supporting the department teams and their ideas for the future.

Coming Together for Science

ResearchGate and MDPI Partner to Boost the Visibility of Open Access Content through Journal Home


Stefan Tochev (CEO, MDPI) and Sören Hofmayer (Co-Founder and Chief Strategy Officer, ResearchGate) meet in Berlin, Germany to take their ongoing discussion further.

When I assumed the role of CEO at MDPI, my primary focus was to initiate the building of essential partnerships and collaborations within our industry. After all, I am a firm believer in achieving our goals by helping others achieve theirs and focusing on co-opetition wherever there is an opportunity. I first touched on the notion of co-opetition in MDPI Insights: The CEO's Letter #3, particularly when discussing collaborations with Elsevier.

In light of this, Sören Hofmayer (Co-Founder and Chief Strategy Officer at ResearchGate) and I connected recently to continue a discussion that had been ongoing for months. I was quickly brought up to speed and felt there was an opportunity for MDPI journals to pilot the Journal Home service that ResearchGate had launched. This would provide a new way for MDPI to engage with authors and readers and amplify the visibility of our journals.

While I receive many offers and opportunities for discussions with vendors, I am a firm believer that timing is everything, and in this case, the time for us is now. Sören and I met in person during my recent visit to Berlin and decided to proceed with piloting ten MDPI journals with the Journal Home service.

The press release below provides further details.

Press Release: Berlin (Germany) and Basel (Switzerland), 15 November 2023

ResearchGate, the professional network for researchers, and MDPI, the largest open access publisher in the world and a pioneer in open access publishing, today announced a partnership that will see ten of MDPI’s open access journals benefit from an enhanced presence on ResearchGate through its innovative Journal Home offering.  

This new partnership will expand the reach and visibility of MDPI’s participating flagship journals with ResearchGate’s highly relevant community of more than 25 million researchers globally.

Around 210,000 version-of-record articles from these 10 titles will be readily available on ResearchGate, including the full archive material and all new articles as they are published. These journals also benefit from enhanced brand visibility, with dedicated journal profiles, prominent representation on all associated article pages and all relevant touchpoints across the ResearchGate network – keeping the journals top-of-mind with their reader and author audiences. All articles covered by the new partnership will automatically be added to the authors’ publication records in ResearchGate. This not only reduces MDPI authors’ needs for direct management but also offers them valuable insights into the impact of their work, including data about readership and citations.

Closing Thoughts

November is Men’s Health Awareness Month


Stefan Tochev (CEO, MDPI) listening to music as he writes at a coffee shop in Basel, Switzerland.

November is dedicated to raising awareness of various men’s health issues. I have been fortunate to have positive male role models in my life, and I strive to share my experiences with others.

I used to take part in Movember, growing my moustache throughout November to raise awareness and funds and to help “change the face of men’s health.” With male family and friends impacted by physical and mental health issues, I have recently become more interested in men’s overall well-being.

Men often face stigma involving the perceived need always to be strong and have things figured out. Recently, I’ve had meaningful conversations with male friends and colleagues about issues we rarely discuss, and it was a positive experience.

Various factors impact men’s health and well-being, all too easily leading to risky health behaviours including a lack of health awareness, poor health education, and negative, culturally induced, behaviour patterns in our work and personal lives. I hope we can break down these barriers in our work environment.

Healthy men help build healthy families and a healthy society

Men are less likely than women to seek help with their physical and mental health struggles. This is a reminder to prioritize your overall well-being. I hope that as men, we will continue to open up to one another, becoming vulnerable in order to share what we are going through. By sharing and by supporting each other, we can learn and grow together. You are not alone, and when you fall, you can still get up and stand tall.

From one broski to another, you are loved and appreciated. I hope this mindset carries into December and beyond.

Mindfulness

Our content team recently released a handful of articles on mindfulness, a practice that I believe provides a good opportunity for stress release and self-reflection:

Stefan Tochev
Chief Executive Officer
MDPI AG

21 November 2023
769 Editorial Board Members of MDPI Journals Achieve Highly Cited Researcher Recognition in 2023


We extend our sincere congratulations to the 769 Editorial Board Members of our journals – from 40 different countries/territories – who have been recognized as Highly Cited Researchers for the year 2023 by Clarivate. They are being recognized for their high-quality scientific research achievements and outstanding contributions to their professional fields, as indicated by Web of Science data.

Clarivate's annual list of Highly Cited ResearchersTM identifies the most highly cited scientists for the past decade who stand out for their significant and broad influence in various scientific and social science domains. Their impactful papers are among the top 1 per cent in the citation distribution of one or more of 21 fields analyzed in the "Essential Science Indicators", distinguishing them as hugely influential among their peers.

This year, 7,125 Highly Cited Researcher 2023 designations were issued to 6,849 individuals from 67 countries, representing just 1 in 1,000 researchers worldwide.

This means that these researchers have demonstrated an incredible level of significant and broad influence in their chosen field or fields over the last decade. They represent a small fraction of the researcher population whose contributions disproportionately push the boundaries of knowledge, enhancing global well-being, sustainability, and security.

Congratulations to the scholars for their noteworthy achievement – we are honored to have them on board with our journals!


Abate, Antonio
Aguilera, Ruth V.
Ahmed, Warish
Ahn, Myung-Ju
An, Qiaoshi
Anasori, Babak
Andersson, Dan I.
Angeletti, Silvia
Annabi, Nasim
Antinori, Spinello
Ariga, Katsuhiko
Asa, Sylvia L.
Astruc, Didier
Atala, Anthony
Atanasov, Atanas G.
Balsamo, Gianpaolo
Bandodkar, Amay J.
Banks, William A.
Bao, Yan-Ping
Barba, Francisco J.
Barnes, Peter J.
Barnholtz-Sloan, Jill S.
Barrow, Colin J.
Bashir, Ali Kashif
Basit, Abdul W.
Bassetti, Matteo
Batley, Jacqueline
Battino, Maurizio
Behnood, Ali
Benediktsson, Jon Atli
Biondi, Antonio
Bjarnsholt, Thomas
Blaschke, Thomas
Blay, Jean-Yves
Blumwald, Eduardo
Blunt, John W.
Boczkaj, Grzegorz
Bogers, Marcel
Bonomo, Robert A.
Boyd, Robert W.
Boyer, Cyrille
Braeckmans, Kevin
Bragazzi, Nicola Luigi
Bu, Wenbo
Bursać Kovačević, Danijela
Bush, Ashley I.
Byrd, John C.
Cabeza, Luisa F.
Cai, Xingjuan
Cambria, Erik
Cao, Guozhong
Cao, Xingzhong
Capasso, Raffaele
Carvalho, Andre F.
Casper, Jonathan
Castellanos-Gomez, Andres
Cavalli, Giacomo
Chai, Siang-Piao
Chan, Jasper Fuk-Woo
Chan, Timothy A.
Chang, Chih-Hao
Chang, Guoqing
Chao, Dongliang
Chen, Bo
Chen, Chaoji
Chen, Fahu
Chen, Gang
Chen, Jianmin
Chen, Jun
Chen, Jun
Chen, Jun
Chen, Lidong
Chen, Lingxin
Chen, Min
Chen, Mou
Chen, Peng
Chen, Qian
Chen, Qianwang
Chen, Shaowei
Chen, Shuangming
Chen, Wei
Chen, Xiaobo
Chen, Yimin
Chen, Yu
Chen, Yulin
Chen, Zhong
Chen, Zonghai
Cheng, Gong
Cheng, Huanyu
Cheng, Laifei
Cheng, Qiang
Chew, Kit Wayne
Chiclana, Francisco
Choi, Wonyong
Choi, Young Hae
Chowdhary, Anuradha
Cichocki, Andrzej
Clevers, Hans
Coops, Nicholas C.
Cortes, Javier
Cortes, Jorge
Costanza, Robert
Creutzig, Felix
Crommie, Michael F.
Cuadrado, Antonio
Cui, Haiying
Cui, Yi
Curigliano, Giuseppe
Dai, Sheng
Dai, Shifeng
Daiber, Andreas
Davies, Michael J.
Davis, Thomas P.
Dawson, Ted M.
de la Fuente-Nunez, Cesar
Delord, Jean-Pierre
Demaria, Marco
Deng, Xiangzheng
Desneux, Nicolas
Dikic, Ivan
Dimopoulos, Meletios-Athanasios
Ding, Aijun
Ding, Jianxun
Dokmeci, Mehmet Remzi
Dolgui, Alexandre
Dong, Chung-Li
Dou, Shi Xue
Dragicevic, Tomislav
Du, Bo
Du, Qian
Du, Yonghua
Duan, Xidong
Dufresne, Alain
Dummer, Reinhard
Edwards, David
Elaissari, Abdelhamid
ElMasry, Gamal
Enjuanes, Luis
Fabbro, Doriano
Facchetti, Antonio
Fan, Junliang
Fan, Kelong
Fan, Xiulin
Fan, Zhanxi
Fang, Baizeng
Fang, Chuanglin
Fang, Yongjin
Fasano, Alessio
Feng, Liangzhu
Feng, Xuning
Fensholt, Rasmus
Ferdinandy, Péter
Fernandez-Lafuente, Roberto
Filippi, Massimo
Flavian, Carlos
Fortino, Giancarlo
Fowler, Michael
Franceschi, Claudio
Frattini, Federico
Friston, Karl J.
Fu, Gengtao
Gai, Francesco
Gaisford, Simon
Galanakis, Charis M.
Galluzzi, Lorenzo
Galvano, Fabio
Gan, Ren-You
Gao, Feng
Gao, Huijun
Gao, Huile
Gao, Peng
Gao, Wei
Garbe, Claus
Garg, Abhishek D.
Gasbarrini, Antonio
Gastaldelli, Amalia
Gautier, Emmanuel L.
Genevet, Patrice
Geng, Yong
Gerdts, Gunnar
Geschwind, Daniel H.
Ghaffari, Roozbeh
Ghamisi, Pedram
Giacobbe, Daniele Roberto
Giampieri, Francesca
Gillies, Robert J.
Godos, Justyna
Gogotsi, Yury
Golding, Nick
Gong, Jinlong
Gong, Peng
Gong, Yongji
Govindan, Kannan
Gozal, David
Grancini, Giulia
Grant, William B.
Graus, Francesc
Green, Douglas R.
Grosso, Giuseppe
Gu, Meng
Gu, Zhanjun
Guan, Cao
Gueimonde, Miguel
Gui, Guan
Guigo, Roderic
Guo, Hengyu
Guo, Jianping
Guo, Lin
Guo, Song
Guo, Yan
Guo, Zaiping
Gupta, Rangan
Gutzmer, Ralf
Haase, Dagmar
Hagger, Martin S.
Hall, C. Michael
Han, Fudong
Han, Heesup
Hanes, Justin
Hartung, Hans-Peter
He, Bao-Jie  
He, Debiao
He, Hongwen
He, Jiaqing
He, Jie
He, Jr-Hau
He, Qiong
He, Xiangming
He, Xijun
He, Zhili
Heneka, Michael T.
Herrera, Francisco
Herrera-Estrella, Luis
Herrera-Viedma, Enrique
Hetz, Claudio
Holick, Michael F.
Hong, Danfeng
Hong, Xuechuan
Hsueh, Po-Ren
Hu, Bin
Hu, Enyuan
Hu, Jin-Song
Hu, Weida
Hu, Wenbin
Hu, Xiaosong
Huang, Baibiao
Huang, Hongwei
Huang, Jianliang
Huang, Jianping
Huang, Peng
Huang, Xin
Hubacek, Klaus
Hussain, Saddam
Italiano, Antoine
Iwata, Hiroji
Jaeschke, Hartmut
Jain, Atul

Jaiswal, Amit K.
Jankovic, Joseph
Janssens, Ivan A.
Jelezko, Fedor
Jeon, Byong-Hun
Ji, Guangbin
Ji, Qiang
Ji, Wei
Ji, Xiaobo
Ji, Xiaoyuan
Jiang, Bin
Jiang, Hong
Jiang, Junjun
Jiang, Lianzhou
Jiang, Qing
Jiang, Shibo
Jiang, Yuyan
Jiang, Zhongyi
Jiao, Licheng
Jin, Shi
Jin, Zhong
Kalantar-zadeh, Kourosh
Kamal, Mohammad Amjad
Kaner, Richard B.
Kaneti, Yusuf Valentino
Kang, Zhenhui
Karagiannidis, George K.
Karniadakis, George Em
Karp, Peter D.
Kataoka, Kazunori
Katritch, Vsevolod
Kawi, Sibudjing
Kepp, Oliver
Khademhosseini, Ali
Khan, Nafees A.
Kiessling, Fabian
Kildishev, Alexander V.
Kim, Haegyeom
Kim, Jeonghun
Kim, Jin-Hoi
Kim, Jong Seung
Kim, Ki-Hyun
Kirkwood, John M.
Kivshar, Yuri
Klenk, Hans-Peter
Ko, Wen-Chien
Kong, Baohua
Kontoyiannis, Dimitrios P.
Koonin, Eugene V.
Kroemer, Guido
Kuang, Dai-Bin
Kudo, Masatoshi
Kuhn, Jens H.
Kumar, Prashant
Kumar, Sudhir
Kurths, Juergen
Kurzrock, Razelle
Kuzyakov, Yakov
Kyrpides, Nikos C.
La Vecchia, Carlo
Lai, Yuekun
Lan, Ke
Lancellotti, Patrizio
Landi, Francesco
Lavie, Carl J.
Laxminarayan, Ramanan
Lee, Chengkuo
Lee, Jechan
Lee, Jin-Wook
Lee, Pooi See
Lee, Sang Soo
Lehmann, Johannes
Lei, Yaguo
Li, Bin
Li, Chunzhong
Li, Dongsheng
Li, Feng
Li, Hai
Li, Heng
Li, Hongyi
Li, Hui
Li, Jinghong
Li, Jun
Li, Li
Li, Linlin
Li, Neng
Li, Ning
Li, Shuai
Li, Shutao
Li, Wei
Li, Wentao
Li, Xiang
Li, Xuecao
Li, Xuelong
Li, Yat
Li, Yurui
Li, Zhijun
Liang, Chao
Liang, Shuquan
Liaw, Peter K.
Lin, Jun
Lin, Yuehe
Lippi, Giuseppe
Lister, Ryan
Liu, Chengmei
Liu, Gang
Liu, Hong
Liu, Hui
Liu, Jian
Liu, Jinyan
Liu, Jun
Liu, Meilin
Liu, Pan
Liu, Wei
Liu, Xianhu
Liu, Xiaoping
Liu, Xuejun
Liu, Yang
Liu, Yu
Liu, Yuan
Lonardo, Amedeo
Long, Hualou
Long, Ying
Lu, Bingan
Lu, Junling
Lu, Lu
Lu, Nanshu
Lu, Rongxing
Lucey, Brian
Lucieer, Arko
Lugato, Emanuele
Lund, Henrik
Luo, Yangchao
Luo, Yi
Luo, Zisheng
Lv, Wei
Lyons, Timothy W.
Ma, Haile
Ma, Jianmin
Ma, Jun
Ma, Tianyi
Ma, Wei
Ma, Yanming
Madabhushi, Anant
Mahmoudi, Morteza
Mai, Liqiang
Mai, Wenjie
Makridakis, Spyros
Mandala, Mario
Mantovani, Alberto
Mao, Jianfeng
Mao, Like
Mardani, Abbas
Mathivanan, Suresh
Matyjaszewski, Krzysztof
McCabe, Matthew F.
McCauley, Darren
McClements, David Julian
Mei, Lin
Melenhorst, Jan Joseph
Melero, Ignacio
Meyerholz, David K.
Van Mierlo, Joeri
Miroshnichenko, Andrey E.
Mittler, Ron
Mu, Shichun
Mubarak, Mohammad S.
Mueller, Lukas A.
Muhammad, Khan
Mumtaz, Shahid
Munekata, Paulo Eduardo Sichetti
Nakagawa, Shinichi
Nauen, Ralf
Newman, David J.
Niaura, Raymond S.
Nidheesh, P. V.
Niu, Ben
Nussinov, Ruth
O'Connor, David
Odintsov, Sergei D.
Omri, Anis
Orsini, Nicola
Ostrikov, Kostya (Ken)
Oswald, Isabelle P.
Oudard, Stephane
Ouyang, Minggao
Ozcan, Aydogan
Pan, Anlian
Pan, Anqiang
Pan, Caofeng
Pan, Genxing
Pan, Likun
Pan, Quan-Ke
Pan, Xiaoqing
Pandolfi, Pier Paolo
Parati, Gianfranco
Pateiro, Mirian
Peng, Qiang
Peng, Qing
Peng, Shushi
Perc, Matjaz
Perlin, David S.
Perlman, Stanley
Petruzzelli, Antonio Messeni
Pitt, Bertram
Pöhlmann, Stefan
Polasky, Stephen
Pommier, Yves
Poor, H. Vincent
Potenza, Marc N.
Preat, Veronique
Prinsep, Michele R.
Pu, Kanyi
Putnik, Predrag
Qin, Yuanwei
Qiu, Jieshan
Qu, Xiaogang
Ragauskas, Arthur J.
Ramakrishna, Seeram
Ramkissoon, Haywantee
Ran, Jingrun
Rao, Zhonghao
Recio, Isidra
Ren, Jinsong
Rengel, Zed
Rho, Junsuk
Riahi, Keywan
Ribeiro-Soriano, Domingo
Richardson, Paul G.
Robert, Caroline
Rocca, Maria A.
Rodriguez-Manas, Leocadio
Rojas, Orlando J.
Rojo, Teofilo
Roubaud, David
Saad, Fred
Saad, Walid
Sadorsky, Perry
Saliba, Michael
Sander, Chris
Sangaiah, Arun Kumar
Santamouris, Mattheos
Santoro, Gabriele
Scaldaferri, Franco
Schatzberg, Alan F.
Schwab, Matthias
Schweizer, Frank
Scolyer, Richard A.
Scott, Daniel
Serruys, Patrick W.
Setzer, William N.
Shahzad, Babar
Shao, Shuai
Shao, Zongping
Shen, Guozhen
Shen, Liyin

Shen, Zexiang
Shi, Peng
Shi, Yi
Siano, Pierluigi
Simões, Manuel
Sing, Swee Leong
Singh, Vijay P.
Smagghe, Guy
Smith, Lee
Soffietti, Riccardo
Song, Houbing
Song, Jibin
Song, Yu
Sood, Anil K.
Souto, Eliana B.
Stadler, Marc
Stanley, H. Eugene
Stephanopoulos, Gregory
Sternberg, Cora N.
Stoumpos, Constantinos C.
Stunnenberg, Hendrik G.
Su, Shiliang
Sun, Baoguo
Sun, Cuixia
Sun, Fengchun
Sun, Hongqi
Sun, Jie
Sun, Lijun
Sun, Litao
Sun, Runcang
Sun, Yanjuan
Sun, Zaicheng
Sun, Zhipei
Sureda, Antoni
Svenning, Jens-Christian
Tan, Chaoliang
Tan, Weihong
Tang, Chuan-He
Tang, Chuyang
Tang, Dianping
Tang, Yongbing
Tanzi, Rudolph E.
Terpos, Evangelos
Teschendorff, Andrew E.
Tian, He
Timsit, Jean-Francois
Tiwari, Aviral Kumar
Tohge, Takayuki
Tousoulis, Dimitris
Tran, Lam-Son Phan
Tress, Wolfgang
Trivedi, Pankaj
Tsao, Rong
Tully, Mark A.
Tung, Chen-Ho
Van der Bruggen, Bart
Vandenbroucke, Roosmarijn E.
Vangronsveld, Jaco
Varsani, Arvind
Vatanen, Tommi
Verbeke, Kristin
Vermote, Eric
Verpoorte, Robert
Vieta, Eduard
Vincent, Jean-Louis
Vita, Antonio
Wan, Jiafu
Wan, Shaohua
Wanek, Wolfgang
Wang, Bin
Wang, Bo
Wang, Chao
Wang, Chuanyi
Wang, Chunsheng
Wang, Dan
Wang, Feng
Wang, Gongming
Wang, Guoxiu
Wang, Haihui
Wang, Hao
Wang, Huanqing
Wang, Huanting
Wang, Hui
Wang, Jian
Wang, Jie
Wang, Jing
Wang, John
Wang, Joseph
Wang, Lianzhou
Wang, Lihui
Wang, Meng
Wang, Peng
Wang, Pengfei
Wang, Qi
Wang, Qi
Wang, Qiang
Wang, Qilin
Wang, Qin
Wang, Qing
Wang, Shaojian
Wang, Sibo
Wang, Tao
Wang, Ying
Wang, Yong
Wang, Zhen
Wang, Zhong Lin
Wang, Zhongrui
Wang, Zifa
Wang, Zuankai
Wei, Haotong
Wei, Leyi
Wei, Zhixiang
Wei, Zhongbao
Weissleder, Ralph
Weitschies, Werner
Wen, Guanghui
Wesemael, Bas van
Willerslev, Eske
Witlox, Frank
Wu, Haijun
Wu, Hao Bin
Wu, Hui
Wu, Jun
Wu, Qinglin
Wu, Shuilin
Wu, Xiaojun
Wu, Yongzhen
Wu, Yuping
Wu, Zheng-Guang
Wu, Zhong-Shuai
Xia, Jianguo (Jeff)
Xia, Meimei
Xia, Xinhui
Xia, Yongyao
Xia, Zhiguo
Xiang, Quanjun
Xiao, Fuyuan
Xiao, Jie
Xin, Sen
Xing, Baoshan
Xing, Wei
Xiong, Rui
Xu, Hui
Xu, Li Da
Xu, Ping
Xu, Yi-Jun
Xu, Zhenjiang Zech
Yan, Chong
Yan, He
Yan, Huaicheng
Yan, Kai
Yan, Ruqiang
Yang, Bing
Yang, Chenguang
Yang, Hongshun
Yang, Hui
Yang, Jian
Yang, Jianping
Yang, Jie
Yang, Jun
Yang, Kai
Yang, Shihe
Yang, Xiaofeng
Yang, Xinsong
Yang, Yun-Gui
Yao, Yonggang
Yigitcanlar, Tan
Yin, Shen
Yin, Shou-Wei
Yin, Yulong
Yin, Zongyou
Yokoya, Naoto
Young, Allan H.
Yu, Guihua
Yu, Jun
Yu, Le
Yu, Minghao
Yu, Shu-Hong
Yu, Wei
Yu, Wenwu
Yuan, Qiangqiang
Yuan, Yifei
Yuan, Yuan
Yuen, Chau
Zeadally, Sherali
Zhai, Tianyou
Zhang, Bing
Zhang, Dengsong
Zhang, Fan
Zhang, Fusuo
Zhang, Guangyu
Zhang, Guowen
Zhang, Hengjie
Zhang, Hongjie
Zhang, Hui
Zhang, Lai-Chang
Zhang, Lefei
Zhang, Lei
Zhang, Liangpei
Zhang, Lijun
Zhang, Min
Zhang, Peng
Zhang, Qiang
Zhang, Qiaobao
Zhang, Qichun
Zhang, Shicheng
Zhang, Shujun
Zhang, Tierui
Zhang, Wei
Zhang, Weili
Zhang, Xian-Ming
Zhang, Xiaodong
Zhang, Xiaogang
Zhang, Xiaoling
Zhang, Yang
Zhang, Yaobin
Zhang, Yi
Zhang, Yi-Zhou
Zhang, Yong
Zhang, Yu Shrike
Zhang, Yue-Jun
Zhang, Yuelin
Zhang, Zheng
Zhang, Zhicheng
Zhang, Zhien
Zhao, Guochun
Zhao, Jie
Zhao, Li-Dong
Zhao, Qing
Zhao, Yi
Zheng, Hao
Zheng, Weitao
Zheng, Yufeng
Zhong, Cheng
Zhou, Jie
Zhou, Jizhong
Zhou, Kun
Zhou, Liang
Zhou, Peng
Zhou, Qi
Zhou, Wei
Zhou, Weiqi
Zhu, Chengzhou
Zhu, Hongwei
Zhu, Junfa
Zhu, Jun-Jie
Zhu, Lei
Zhu, Mingshan
Zhu, Quanxin
Zhu, Yi
Zhu, Yongfa
Zhu, Zhe
Zhuang, Xiaodong
Zou, Quan
Zou, Ruqiang
Zuo, Chao

10 November 2023
Current Oncology | World Neuroendocrine Tumor Awareness Day (NET Cancer Day) 2023


World Neuroendocrine Tumor Awareness Day (NET Cancer Day) takes place annually on the 10 November and it is coordinated by the International Neuroendocrine Cancer Alliance (INCA). The main objectives of this event are to increase awareness about various types of neuroendocrine tumors (NETs), advocate for scientific progress by addressing unmet needs, and foster global collaboration to tackle the challenges faced by NET patients and the medical community in terms of timely diagnosis, optimal treatment, and support.

In celebration of NET Cancer Day 2023, Current Oncology (ISSN: 1718-7729) has curated a collection of open access scholarly research studies focused on neuroendocrine tumors. Our intention is to disseminate new scientific knowledge to the world on this significant occasion.

1. “Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study”
by Golmehr Sistani, Duncan E. K. Sutherland, Amol Mujoomdar, Daniele P. Wiseman, Alireza Khatami, Elena Tsvetkova, Robert H. Reid and David T. Laidley
Curr. Oncol. 2021, 28(1), 115–127; https://doi.org/10.3390/curroncol28010015
Available online: https://www.mdpi.com/1718-7729/28/1/15 

2. “Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors”
by Taymeyah Al-Toubah, Brian Morse and Jonathan Strosberg
Curr. Oncol. 2022, 29(2), 510–515; https://doi.org/10.3390/curroncol29020046
Available online: https://www.mdpi.com/1718-7729/29/2/46

3. “Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden”
by Nai-Wen Kang, Kien-Thiam Tan, Chien-Feng Li and Yu-Hsuan Kuo
Curr. Oncol. 2021, 28(6), 4587–4596; https://doi.org/10.3390/curroncol28060388
Available online: https://www.mdpi.com/1718-7729/28/6/388

4. “A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib”
by Chloe A. Lim, Norbert Banyi, Tracy Tucker, Diana N. Ionescu and Barbara Melosky
Curr. Oncol. 2022, 29(2), 848–852; https://doi.org/10.3390/curroncol29020072
Available online: https://www.mdpi.com/1718-7729/29/2/72

5. “Resection of Non-Functional Pancreatic Neuroendocrine Neoplasms—A Single-Center Retrospective Outcome Analysis”
by Kirsten Lindner, Daniel Binte, Jens Hoeppner, Ulrich F. Wellner, Dominik M. Schulte, Sebastian M. Schmid, Kim Luley, Inga Buchmann, Lars Tharun, Tobias Keck et al.
Curr. Oncol. 2021, 28(4), 3071–3080; https://doi.org/10.3390/curroncol28040268
Available online: https://www.mdpi.com/1718-7729/28/4/268

6. “Neuroendocrine Carcinomas of the Uterine Cervix, Endometrium, and Ovary Show Higher Tendencies for Bone, Brain, and Liver Organotrophic Metastases”
by Hyung Kyu Park
Curr. Oncol. 2022, 29(10), 7461–7469; https://doi.org/10.3390/curroncol29100587
Available online: https://www.mdpi.com/1718-7729/29/10/587

7. “Better Prognosis of Gastric Neuroendocrine Carcinoma Than Gastric Adenocarcinoma among Whites in the United States: A Propensity Score Matching Analysis Based on SEER”
by Zefeng Li, Hu Ren, Lulu Zhao, Xiaojie Zhang, Tongbo Wang, Chongyuan Sun, Penghui Niu, Wanqing Wang, He Fei, Chunguang Guo et al.
Curr. Oncol. 2022, 29(7), 4879–4892; https://doi.org/10.3390/curroncol29070387
Available online: https://www.mdpi.com/1718-7729/29/7/387

8. “The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases”
by Zainul-Abedin Kapacee, Jennifer Allison, Mohammed Dawod, Xin Wang, Melissa Frizziero, Bipasha Chakrabarty, Prakash Manoharan, Catherine McBain, Was Mansoor, Angela Lamarca et al.
Curr. Oncol. 2022, 29(7), 5110–5125; https://doi.org/10.3390/curroncol29070405
Available online: https://www.mdpi.com/1718-7729/29/7/405

9. “Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors”
by Nicole Brighi, Giuseppe Lamberti, Elisa Andrini, Cristina Mosconi, Lisa Manuzzi, Giada Donati, Andrea Lisotti and Davide Campana
Curr. Oncol. 2023, 30(2), 1381–1394; https://doi.org/10.3390/curroncol30020106
Available online: https://www.mdpi.com/1718-7729/30/2/106

10. “Comparison of Transarterial Bland and Chemoembolization for Neuroendocrine Tumours: A Systematic Review and Meta-Analysis”
by E. Tai, S. Kennedy, A. Farrell, A. Jaberi, J. Kachura and R. Beecroft
Curr. Oncol. 2020, 27(6), 537–546; https://doi.org/10.3747/co.27.6205
Available online: https://www.mdpi.com/1718-7729/27/6/6205

1 November 2023
MDPI Insights: The CEO's Letter #5 - OA Week, UK, and Strategy

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

Open Access Week 2023 – the Global Drive to Open Continues

As the world's largest open-access (OA) publisher, we believe that unrestricted access to research findings is the cornerstone of transparency, efficiency, and quality control across scientific disciplines. At MDPI, we provide free, immediate access to scientific papers, empowering scientists to examine, validate, replicate, and build upon existing results. This minimizes redundancy, optimizes resources, and fosters innovative approaches.

International OA Week, held from 23 to 29 October 2023, provided a unique opportunity to link the global movement toward open sharing and open science with the progress of policy changes at the local level. Our mission, during OA Week and all the year round, is to offer educational resources highlighting the benefits of open-access publishing. The MDPI Blog is a valuable resource for information on open access and open science.

Core principles of OA publishing

Accessibility, transparency, and collaboration are core principles of OA publishing. OA aims to break down barriers that have traditionally restricted research access, ensuring that knowledge is available to all, regardless of financial situation or institutional affiliations. Our commitment to diverse pathways for OA publishing worldwide includes discounts for researchers. You can learn more about how MDPI supports scientific communities here.

One of the key strengths of OA publishing is its ability to facilitate interdisciplinary research. By removing paywalls and promoting knowledge-sharing across disciplines, OA encourages collaboration and innovation. Researchers from various fields can access and build upon each others’ work, fostering a holistic approach to addressing complex global challenges.

OA holds the potential to democratize knowledge, advance science, and drive positive societal change.

Policy driving change

Governments, institutions, and funding agencies have recognized the transformative potential of OA and have implemented policies to promote it. These policies often require publicly funded research to be made openly accessible, accelerating the growth of OA repositories and journals. Check out our spotlights on OA policies in the USEU and China

OA publishing is continuously evolving, with community-driven models and technologies shaping its future. Initiatives such as “Plan S” and “cOAlition S” promote OA publishing from the perspective of national funders, requiring grantees to publish their research openly. A new policy announced by the US administration last year mandates that, with effect from January 2026, all US federally funded research should be freely and immediately available after publication.

Additionally, preprint servers such as MDPI's Preprints.org, which allow researchers to share their findings before formal peer review, have gained popularity, enhancing the speed at which new knowledge is disseminated. The rise of blockchain technology is also being explored to ensure transparency and authenticity in scholarly publishing.

For more than two decades, OA publishing has been revolutionizing academic publishing by promoting accessibility, transparency, and collaboration. Its support for interdisciplinary research, evolving policies, and innovative practices all contribute to its growing influence in the global research community. As OA continues to expand, it holds the potential to democratize knowledge, advance science, and drive positive societal change.

MDPI is proud to lead the transition to open access.

Read more:

Impactful Research

Spotlight on Smart Cities

Smart cities will serve as a cornerstone for future human development. Their implementation will help us tackle many of the significant challenges we are facing – climate change, ageing populations, waste management, public safety, travel, and so on. Recognising the importance of this multifaceted field, MDPI launched the inaugural issue of Smart Cities in 2018 to provide an advanced forum for research into smart technology and society. Here we take a look at how this journal has developed, and its impact in this exciting field.

As at 30 October, 2023, Smart Cities has published 421 papers and has an Impact Factor of 6.4. It also has a CiteScore of 8.5, and more than one quarter of its published papers – 124 – have been cited 10 times or more.

Highly cited papers in Smart Cities

Below are several highly cited papers recently published in Smart Cities. Citation metrics are current as at 31 October 2023.

1. “Introducing the “15-Minute City”: Sustainability, Resilience and Place Identity in Future Post-Pandemic Cities
Authors: Carlos Moreno, Zaheer Allam, Didier Chabaud, Catherine Gall and Florent Pratlong
Smart Cities 2021, 4(1), 93-111; https://doi.org/10.3390/smartcities4010006
Citations: Crossref (338), Scopus (366), Web of Science (270), Google Scholar (710)
The paper discusses the socio-economic impacts of the COVID-19 on cities, including increasing inequalities and rising unemployment. It introduces the concept of the "15-Minute City," a form of "chrono-urbanism," as a response to the challenges posed by the pandemic.

2. “A Review on Electric Vehicles: Technologies and Challenges
Authors: Julio A. Sanguesa, Vicente Torres-Sanz, Piedad Garrido, Francisco J. Martinez and Johann M. Marquez-Barja
Smart Cities 2021, 4(1), 372-404; https://doi.org/10.3390/smartcities4010022
Citations: Crossref (359), Scopus (363), Web of Science (268), Google Scholar (558)
This paper provides an overview of the progress in Electric Vehicles (EVs), focusing on battery technology, charging methods, and emerging research challenges. It also analyzes the global EV market and its future outlook.

3. “IoT in Smart Cities: A Survey of Technologies, Practices and Challenges
Authors: Abbas Shah Syed, Daniel Sierra-Sosa, Anup Kumar and Adel Elmaghraby
Smart Cities 2021, 4(2), 429-475; https://doi.org/10.3390/smartcities4020024
Citations: Crossref (121), Scopus (151), Web of Science (91), Google Scholar (215)
This paper gives an overview of the Internet of Things (IoT) in the context of Smart Cities, discussing the fundamental components, technologies, architectures, networking technologies, and artificial algorithms that underpin IoT-based Smart City systems.

4. “Artificial Intelligence Techniques in Smart Grid: A Survey
Authors: Olufemi A. Omitaomu and Haoran Niu
Smart Cities 2021, 4(2), 548-568; https://doi.org/10.3390/smartcities4020029
Citations: Crossref (76), Scopus (94), Web of Science (57), Google Scholar (120)
This survey paper reviews the utilization of artificial intelligence (AI) techniques in the context of the smart grid. It covers various applications of AI in load forecasting, power grid stability assessment, fault detection, and security issues in the smart grid and power systems.

5. “The Metaverse as a Virtual Form of Smart Cities: Opportunities and Challenges for Environmental, Economic, and Social Sustainability in Urban Futures
Authors: Zaheer Allam, Ayyoob Sharifi, Simon Elias Bibri, David Sydney Jones and John Krogstie
Smart Cities 2022, 5(3), 771-801; https://doi.org/10.3390/smartcities5030040
Citations: Crossref (72), Scopus (75), Web of Science (43), Google Scholar (176)
This paper discusses the concept of the Metaverse, a virtual world introduced by Meta (formerly Facebook), and its potential impact on urban life. It explores how emerging technologies such as AI, Big Data, IoT, and Digital Twins could reshape urban design and services in the context of the Metaverse.

Testimonial

“It was indeed a great and pleasant experience with MDPI regarding our recent publication. The submission process was very straightforward and less time-consuming than the norm. The review process was very fast compared to many other open access journals, which is praiseworthy. The support from the Editorial Office during the revision process was highly useful as well. We look forward to publishing with MDPI in the future, and I will most definitely recommend MDPI to my colleagues and collaborators. – Dr. Luís Rosa, University of Minho

Article in Smart Cities: Mobile Networks and Internet of Things Infrastructures to Characterize Smart Human Mobility

Inside MDPI

MDPI Manchester office, UK Visit


Allie Shi (Editorial Director, MDPI), Stefan Tochev (CEO, MDPI), Jamie Anderson (Manchester Office Manager, MDPI), Michael O’Sullivan (Senior Scientific Officer, MDPI), Hushneara Akhtar, and Becky Castellon (IOAP Team Lead, MDPI), dining out in Manchester, UK.

In October, I visited MDPI’s new office in Manchester. During the visit, I connected with our English Editing (EE) managers, Scientific Officer, members of the Editorial team, the Marketing team, and IOAP Team Lead.

Our Manchester office focuses primarily on EE services and provides local support for the UK market. Additionally, we regularly visit Editorial Board members and participate in local conferences.

I would like to thank Jamie Anderson, Manchester Office Manager, and her team, for their deep commitment to our Manchester staff and to MDPI’s impact on the UK market.

The UK by numbers

The UK is a hub for the world’s top universities, making it a key market for MDPI and the publishing world in general. It is home to two of the top-five-ranked universities globally, 11 in the top 100, and 15 in the top 200.

As a result, the UK plays a key role in MDPI’s global market. As at October 2023, it ranks as the seventh-largest contributor to the total number of papers published by MDPI. We have 3,500 Editorial Board members affiliated with UK institutions, including 34 serving as Editors-in-Chief (EiCs). Our commitment to collaboration with institutions is evident in the UK, where we have successfully established some 60 Institutional Open Access Program (IOAP) agreements with esteemed institutions, such as the University of Oxford, the University of Cambridge, Imperial College London, the University of Edinburgh, and more.

According to InCites Dataset + ESCI for the period 2018–2022, as at October 2023, nearly 65% of UK papers are now published as OA. Just over 10% of total OA publications are by UK authors. UK papers are known for their high quality, with an average of 11 citations per paper. Furthermore, 2.16% of UK papers are in the top 1% of cited papers, and 14.61% are in the top 10% of cited papers, showcasing their impact.

We are currently hiring EEs in various locations worldwide.

English Editing at MDPI

Our English Editing (EE) department consists of two main branches, Quality Control and Learning and Development, reflecting our priorities. We are continuously enhancing the quality of our English Editing services and have raised the relevant standards, which now extend to company-wide communications. English editors participate in international interviews, conduct English assessments, and provide colleagues with presentations on ways to improve their use of written and spoken English.

While expanding, the EE department has proactively refocused its efforts on the quality of our work and how the English Editing department can benefit the company more broadly. We currently have approximately 140 full-time English Editors based across five offices worldwide, supplemented by over 700 freelance English editors.

Our Manchester office serves as the hub for the EE Department, with EE Managers situated there, except for Kurtis Jackson, who serves as the Head of EE and is located in our Basel office. Manchester EEs play a critical role in establishing and developing EE teams in our other offices, overseeing management and recruitment. The EE department plays a vital role in MDPI’s operations, as it is the department that touches every published paper. If this work interests you, I encourage you to explore our available EE positions, whether you are seeking full-time or freelance opportunities.

Testimonials

“MDPI provides an excellent service compared to any other previously used services. It delivers fast and high-quality results but at an affordable price.” – Ardha Apriyanto, University of Potsdam

“In my role as a professor, I consider that MDPI Author Services offer an excellent quality in the editing of Western academic writing while maintaining the required standards of clarity, precision and rigor. Additionally, delivery times are fast compared to other available services.” – Jesus Insuasti, University of Nariño

Read more:

Coming Together for Science

STM and Frankfurt Book Fair

Attending STM

MDPI has been a proud sponsor of the STM Conference for several years. The STM Conference is a dynamic event featuring interactive sessions, expert panellists, idea-sharing, and ample networking opportunities. On 16 October, the event kicked off with arrival drinks, sponsored by MDPI, followed by a welcoming dinner, providing a great chance to connect and network with industry professionals. The following day was filled with speakers, sessions, and further opportunities to connect. STM exemplifies the collaborative spirit of the scientific community, with session topics including achieving open, visible, and impactful research at scale; maintaining research integrity in a rapidly changing world; and exploring the impact of ever-evolving technology in the scholarly community.

Meeting with Web of Science

On a personal note, one of the highlights of STM was a candid and productive conversation with Nandita Quaderi, Editor-in-Chief and SVP at Web of Science. During our discussion, we talked about MDPI, Web of Science, the IJERPH delisting, and ways of moving forward. This open conversation aimed at fostering better collaboration for the future.

“We discussed ways to improve our communication and collaboration.”

I appreciated our frank discussion and felt that Nandita wholeheartedly supports open access. She also expressed her appreciation for the monthly CEO Letter, which she sees as a way to add personality to the MDPI brand and provide insight into the great work we do at MDPI. While we highlighted the positives, we also discussed ways to improve our communication and collaboration moving forward. This meeting alone made the trip worthwhile, and I hope Nandita doesn’t mind my sharing that she found our chat to be “the most honest and constructive discussion” she’s had with someone from MDPI in recent years.

75th Frankfurt Book Fair


Jelena Milojevic (Book Editor, MDPI), Jovana Dubajic (Book Editor, MDPI), Evan Escamilla (Project Manager, MDPI), Laura Wagner (Head of Books, MDPI), and Jenny Knowles (Commissioning Editor, MDPI), at the Frankfurt Book Fair in Frankfurt am Main, Germany.

For the 75th time, the Frankfurter Buchmesse opened its doors in October to celebrate exciting stories and their authors. If you haven’t yet had the chance to visit the Frankfurt Book Fair, I highly recommend it. It’s the largest book fair in the world, attracting thousands of visitors from around the globe. This is the place to gain valuable industry insights from top-class publishing professionals, connect with publishers directly, and learn about the latest trends in publishing.

MDPI Books

Our Books team was also present at the Frankfurt Book Fair, networking and learning from various panels. Did you know that our MDPI Books department publishes OA Books?

The book publishing program includes monographs, book series, edited books and reprints of special issues and topical collections, among other book types.

If you have a book proposal you would like to discuss, please feel free to contact our Books team to understand the benefits and methods of publishing your next book with the OA model.

Closing Thoughts

MDPI Strategy Meeting

As the newly appointed CEO, this is my first year leading the MDPI Senior Management Strategy session. I saw it as an opportunity to explore what MDPI has the potential to become in the next five years. Guided by the vision of its founder and President, Dr. Shu-kun Lin, the company has accomplished remarkable feats over the past 27 years and currently holds the position as the world’s third-largest academic publisher, following Springer Nature and Elsevier.

Our primary objective is to build upon the milestones of the past decades and consolidate MDPI’s position as well-established publishing brand. The two-day meeting emphasized the importance of communicating MDPI’s values more actively via its brand and adopting a straightforward yet impactful approach to managing MDPI as a mature academic publisher.

“Our primary objective is to consolidate MDPI’s position as well-established publishing brand”

As the world’s number one open-access publisher, MDPI has long been a game-changer in the scholarly community, serving millions of authors. The challenge in being a trailblazer is the need to continuously improve and at the same time explore the next blue-ocean strategy, while also maintaining the smooth operation of the business. Our collection model, featuring guest-curated thematic topics in the form of Special Issues, has disrupted the industry. Other publishers closely study us and attempt to replicate our models. The future of this collection model is something we are actively addressing – while, of course, looking ahead to what comes next!

Stefan Tochev
Chief Executive Officer
MDPI AG

25 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Bone and Soft Tissue Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Bone and Soft Tissue Oncology” listed below:

1. “Synovial Sarcoma: A Clinical Review”
by Aaron M. Gazendam, Snezana Popovic, Sohaib Munir, Naveen Parasu, David Wilson and Michelle Ghert
Curr. Oncol. 2021, 28(3), 1909–1920; https://doi.org/10.3390/curroncol28030177
Available online: https://www.mdpi.com/1718-7729/28/3/177

2. “Current Overview of Treatment for Metastatic Bone Disease”
by Shinji Tsukamoto, Akira Kido, Yasuhito Tanaka, Giancarlo Facchini, Giuliano Peta, Giuseppe Rossi and Andreas F. Mavrogenis
Curr. Oncol. 2021, 28(5), 3347–3372; https://doi.org/10.3390/curroncol28050290
Available online: https://www.mdpi.com/1718-7729/28/5/290

3. “Emerging Concepts in the Surgical Management of Peri-Acetabular Metastatic Bone Disease”
by Aaron Gazendam, Daniel Axelrod, David Wilson and Michelle Ghert
Curr. Oncol. 2021, 28(4), 2731–2740; https://doi.org/10.3390/curroncol28040238
Available online: https://www.mdpi.com/1718-7729/28/4/238

4. “The Role of a Navigational Radiofrequency Ablation Device and Concurrent Vertebral Augmentation for Treatment of Difficult-to-Reach Spinal Metastases”
by Claudio Pusceddu, Davide De Francesco, Luca Melis, Nicola Ballicu and Alessandro Fancellu
Curr. Oncol. 2021, 28(5), 4004–4015; https://doi.org/10.3390/curroncol28050340
Available online: https://www.mdpi.com/1718-7729/28/5/340

5. “The Surgical Management of Proximal Femoral Metastases: A Narrative Review”
by Daniel Axelrod, Aaron M. Gazendam and Michelle Ghert
Curr. Oncol. 2021, 28(5), 3748–3757; https://doi.org/10.3390/curroncol28050320
Available online: https://www.mdpi.com/1718-7729/28/5/320

6. “We’re on a Merry-Go-Round”: Reflections of Patients and Carers after Completing Treatment for Sarcoma”
by Rhys Weaver, Moira O’Connor, Richard Carey Smith, Dianne Sheppard and Georgia K. B. Halkett
Curr. Oncol. 2021, 28(4), 3003–3014; https://doi.org/10.3390/curroncol28040263
Available online: https://www.mdpi.com/1718-7729/28/4/263

7. “Assessment of Risk of Bias in Osteosarcoma and Ewing’s Sarcoma Randomized Controlled Trials: A Systematic Review”
by Robert Koucheki, Aaron M. Gazendam, Jonathan R. Perera, Anthony Griffin, Peter Ferguson, Jay Wunder and Kim Tsoi
Curr. Oncol. 2021, 28(5), 3771–3794; https://doi.org/10.3390/curroncol28050322
Available online: https://www.mdpi.com/1718-7729/28/5/322

8. “Impact of an Augmented Reality Navigation System (SIRIO) on Bone Percutaneous Procedures: A Comparative Analysis with Standard CT-Guided Technique”
by Eliodoro Faiella, Gennaro Castiello, Caterina Bernetti, Giuseppina Pacella, Carlo Altomare, Flavio Andresciani, Bruno Beomonte Zobel and Rosario Francesco Grasso
Curr. Oncol. 2021, 28(3), 1751–1760; https://doi.org/10.3390/curroncol28030163
Available online: https://www.mdpi.com/1718-7729/28/3/163

9. “Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report”
by Thierry Alcindor, Sungmi Jung and Lucy Gilbert
Curr. Oncol. 2021, 28(3), 2146–2149; https://doi.org/10.3390/curroncol28030199
Available online: https://www.mdpi.com/1718-7729/28/3/199

10. “The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review”
by Abha Gupta, Lisa Durocher-Allen, Snezana Popovic, Richard Tozer, Xiaomei Yao and Michelle Ghert
Curr. Oncol. 2021, 28(2), 1302–1313; https://doi.org/10.3390/curroncol28020124
Available online: https://www.mdpi.com/1718-7729/28/2/124

24 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Breast Cancer”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Breast Cancer” listed below:

1. “Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors”
by Sonu S. Varghese, Will J. Johnston, Cameron R. Eekhoudt, Melanie R. Keats, Davinder S. Jassal and Scott A. Grandy
Curr. Oncol. 2021, 28(5), 4139–4156; https://doi.org/10.3390/curroncol28050351
Available online: https://www.mdpi.com/1718-7729/28/5/351

2. “Comparison of the Quality of Life of Patients with Breast or Colon Cancer with an Arm Vein Port (TIVAD) Versus a Peripherally Inserted Central Catheter (PICC)”
by Brent Burbridge, Hyun Lim, Lynn Dwernychuk, Ha Le, Tehmina Asif, Amer Sami and Shahid Ahmed
Curr. Oncol. 2021, 28(2), 1495–1506; https://doi.org/10.3390/curroncol28020141
Available online: https://www.mdpi.com/1718-7729/28/2/141

3. “The Challenge of Return to Work after Breast Cancer: The Role of Family Situation, CANTO Cohort”
by Elsa Caumette, Inès Vaz-Luis, Sandrine Pinto, Julie Havas, Thomas Bovagnet, Garazi Ruiz de Azua, Antonio Di Meglio, Anne-Laure Martin, Sibille Everhard, Paul Cottu et al.
Curr. Oncol. 2021, 28(5), 3866–3875; https://doi.org/10.3390/curroncol28050330
Available online: https://www.mdpi.com/1718-7729/28/5/330

4. “A Multidisciplinary Approach to Implement Personalized Breast Cancer Treatment and Care Plans”
by Rashida Haq, Amy Kong and Pauline Gulasingam
Curr. Oncol. 2021, 28(1), 767–782; https://doi.org/10.3390/curroncol28010075
Available online: https://www.mdpi.com/1718-7729/28/1/75

5. “Longitudinal Symptom Burden Trajectories in a Population-Based Cohort of Women with Metastatic Breast Cancer: A Group-Based Trajectory Modeling Analysis”
by Suman Budhwani, Rahim Moineddin, Walter P. Wodchis, Camilla Zimmermann and Doris Howell
Curr. Oncol. 2021, 28(1), 879–897; https://doi.org/10.3390/curroncol28010087
Available online: https://www.mdpi.com/1718-7729/28/1/87

6. “Cancer-Specific Outcomes in the Elderly with Triple-Negative Breast Cancer: A Systematic Review”
by Jenny Yoon, Gregory Knapp, May Lynn Quan and Antoine Bouchard-Fortier
Curr. Oncol. 2021, 28(4), 2337–2345; https://doi.org/10.3390/curroncol28040215
Available online: https://www.mdpi.com/1718-7729/28/4/215

7. “Narratives of Survivorship: A Study of Breast Cancer Pathographies and Their Place in Cancer Rehabilitation”
by Åsa Mohlin and Katarina Bernhardsson
Curr. Oncol. 2021, 28(4), 2840–2851; https://doi.org/10.3390/curroncol28040249
Available online: https://www.mdpi.com/1718-7729/28/4/249

8. “Factors Associated with “Survivor Identity” in Men with Breast Cancer”
by Kathryn L. Dalton, Sheila N. Garland, Peggy Miller, Bret Miller, Cheri Ambrose and Richard J. Wassersug
Curr. Oncol. 2021, 28(3), 1696–1705; https://doi.org/10.3390/curroncol28030158
Available online: https://www.mdpi.com/1718-7729/28/3/158 

9. “Results from a Theory-Guided Survey to Support Breast Cancer Trial Participation: Barriers, Enablers, and What to Do about them”
by Jamie C. Brehaut, Kelly Carroll, Jenn Gordon, Justin Presseau, Dawn P. Richards, Dean A. Fergusson, Ian D. Graham and Susan Marlin
Curr. Oncol. 2021, 28(3), 2014–2028; https://doi.org/10.3390/curroncol28030187
Available online: https://www.mdpi.com/1718-7729/28/3/187

10. “Acute Care Use by Breast Cancer Patients on Adjuvant Chemotherapy in Alberta: Demonstrating the Importance of Measurement to Improving Quality”
by Che Hsuan David Wu, May Lynn Quan, Shiying Kong, Yuan Xu, Jeffrey Q. Cao, Sasha Lupichuk and Lisa Barbera
Curr. Oncol. 2021, 28(6), 4420–4431; https://doi.org/10.3390/curroncol28060375
Available online: https://www.mdpi.com/1718-7729/28/6/375

24 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Gastrointestinal Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Gastrointestinal Oncology” listed below:

1. “Artificial Intelligence in Colorectal Cancer Screening, Diagnosis and Treatment. A New Era”
by Athanasia Mitsala, Christos Tsalikidis, Michail Pitiakoudis, Constantinos Simopoulos and Alexandra K. Tsaroucha
Curr. Oncol. 2021, 28(3), 1581–1607; https://doi.org/10.3390/curroncol28030149
Available online: https://www.mdpi.com/1718-7729/28/3/149

2. “Pathological Features and Prognostication in Colorectal Cancer”
by Kabytto Chen, Geoffrey Collins, Henry Wang and James Wei Tatt Toh
Curr. Oncol. 2021, 28(6), 5356–5383; https://doi.org/10.3390/curroncol28060447
Available online: https://www.mdpi.com/1718-7729/28/6/447

3. “Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma”
by Yuji Eso, Haruhiko Takeda, Kojiro Taura, Atsushi Takai, Ken Takahashi and Hiroshi Seno
Curr. Oncol. 2021, 28(5), 4157–4166; https://doi.org/10.3390/curroncol28050352
Available online: https://www.mdpi.com/1718-7729/28/5/352

4. “Higher Efficiency of Percutaneous Microwave (MWA) Than Radiofrequency Ablation (RFA) in Achieving Complete Response in Cirrhotic Patients with Early Hepatocellular Carcinoma”
by Silvia Gaia, Michela Ciruolo, Davide Giuseppe Ribaldone, Emanuela Rolle, Enrica Migliore, Elena Mosso, Simone Vola, Alessandra Risso, Sharmila Fagoonee, Giorgio Maria Saracco et al.
Curr. Oncol. 2021, 28(2), 1034–1044; https://doi.org/10.3390/curroncol28020101
Available online: https://www.mdpi.com/1718-7729/28/2/101

5. “Screening for Colorectal Cancer Leading into a New Decade: The “Roaring ‘20s” for Epigenetic Biomarkers?”
by Hélder Almeida-Lousada, André Mestre, Sara Ramalhete, Aryeh J. Price, Ramon Andrade de Mello, Ana D. Marreiros, Ricardo Pires das Neves and Pedro Castelo-Branco
Curr. Oncol. 2021, 28(6), 4874–4893; https://doi.org/10.3390/curroncol28060411
Available online: https://www.mdpi.com/1718-7729/28/6/411

6. “Geographic and Socioeconomic Disparity of Gastric Cancer Patients in Canada”
by Leila Cattelan, Feras M. Ghazawi, Michelle Le, François Lagacé, Elham Rahme, Andrei Zubarev, Denis Sasseville, Ivan V. Litvinov, Kevin A. Waschke and Elena Netchiporouk
Curr. Oncol. 2021, 28(3), 2052–2064; https://doi.org/10.3390/curroncol28030190
Available online: https://www.mdpi.com/1718-7729/28/3/190

7. “Quality of Colon Cancer Care in Patients Undergoing Emergency Surgery”
by Keegan Guidolin, Rebecca Withers, Farhana Shariff, Shady Ashamalla and Ashlie Nadler
Curr. Oncol. 2021, 28(3), 2079–2086; https://doi.org/10.3390/curroncol28030192
Available online: https://www.mdpi.com/1718-7729/28/3/192

8. “Resection of Non-Functional Pancreatic Neuroendocrine Neoplasms—A Single-Center Retrospective Outcome Analysis”
by Kirsten Lindner, Daniel Binte, Jens Hoeppner, Ulrich F. Wellner, Dominik M. Schulte, Sebastian M. Schmid, Kim Luley, Inga Buchmann, Lars Tharun, Tobias Keck et al.
Curr. Oncol. 2021, 28(4), 3071–3080; https://doi.org/10.3390/curroncol28040268
Available online: https://www.mdpi.com/1718-7729/28/4/268

9. “The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis”
by Suganija Lakkunarajah, Daniel A. Breadner, Hanbo Zhang, Ellen Yamanaka, Andrew Warner and Stephen Welch
Curr. Oncol. 2021, 28(5), 4031–4041; https://doi.org/10.3390/curroncol28050342
Available online: https://www.mdpi.com/1718-7729/28/5/342

10. “Recent Advances in Photodynamic Imaging and Therapy in Hepatobiliary Malignancies: Clinical and Experimental Aspects”
by Atsushi Nanashima, Masahide Hiyoshi, Naoya Imamura, Koichi Yano, Takeomi Hamada and Kengo Kai
Curr. Oncol. 2021, 28(5), 4067–4079; https://doi.org/10.3390/curroncol28050345
Available online: https://www.mdpi.com/1718-7729/28/5/345

23 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Genitourinary Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Genitourinary Oncology” listed below:

1. “Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making”
by Philipp Mandel, Mike Wenzel, Benedikt Hoeh, Maria N. Welte, Felix Preisser, Tahir Inam, Clarissa Wittler, Clara Humke, Jens Köllermann, Peter Wild et al.
Curr. Oncol. 2021, 28(3), 2123–2133; https://doi.org/10.3390/curroncol28030197
Available online: https://www.mdpi.com/1718-7729/28/3/197

2. “Correlation of Urine Loss after Catheter Removal and Early Continence in Men Undergoing Radical Prostatectomy”
by Benedikt Hoeh, Felix Preisser, Mike Wenzel, Clara Humke, Clarissa Wittler, Jan L. Hohenhorst, Maja Volckmann-Wilde, Jens Köllermann, Thomas Steuber, Markus Graefen et al.
Curr. Oncol. 2021, 28(6), 4738–4747; https://doi.org/10.3390/curroncol28060399
Available online: https://doi.org/10.3390/curroncol28060399

3. “The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging”
by Daiki Kato, Kaori Ozawa, Shinichi Takeuchi, Makoto Kawase, Kota Kawase, Chie Nakai, Manabu Takai, Koji Iinuma, Keita Nakane, Hiroki Kato et al.
Curr. Oncol. 2021, 28(2), 1294–1301; https://doi.org/10.3390/curroncol28020123
Available online: https://www.mdpi.com/1718-7729/28/2/123

4. “Extreme Hypofractionation with SBRT in Localized Prostate Cancer”
by Maria Antonia Gómez-Aparicio, Jeannette Valero, Begoña Caballero, Rafael García, Ovidio Hernando-Requejo, Ángel Montero, Alfonso Gómez-Iturriaga, Thomas Zilli, Piet Ost, Fernando López-Campos, et al.
Curr. Oncol. 2021, 28(4), 2933–2949; https://doi.org/10.3390/curroncol28040257
Available online: https://www.mdpi.com/1718-7729/28/4/257

5. “Spontaneous Regression of Metastatic Renal Cell Carcinoma after SARS-CoV-2 Infection: A Report of Two Cases”
by Tomas Buchler, Lukas Fiser, Jaroslava Benesova, Hana Jirickova and Jana Votrubova
Curr. Oncol. 2021, 28(5), 3403–3407; https://doi.org/10.3390/curroncol28050294
Available online: https://www.mdpi.com/1718-7729/28/5/294

6. “Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells”
by Hyunho Kim, Okran Kim, Myung Ah Lee, Ji Youl Lee, Sung-Hoo Hong, U-Syn Ha, Kwangil Yim and In-Ho Kim
Curr. Oncol. 2021, 28(3), 1652–1662; https://doi.org/10.3390/curroncol28030154
Available online: https://www.mdpi.com/1718-7729/28/3/154

7. “Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)”
by Ibon Gurruchaga Sotés, Ana Nuño Alves, Sandra Vicente Arregui and Carmen Santander Lobera
Curr. Oncol. 2021, 28(4), 2346–2350; https://doi.org/10.3390/curroncol28040216
Available online: https://www.mdpi.com/1718-7729/28/4/216

8. “Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer”
by Tim Wollenweber, Lucia Zisser, Elisabeth Kretschmer-Chott, Michael Weber, Bernhard Grubmüller, Gero Kramer, Shahrokh F. Shariat, Markus Mitterhauser, Stefan Schmitl, Chrysoula Vraka et al.
Curr. Oncol. 2021, 28(5), 3692–3704; https://doi.org/10.3390/curroncol28050315
Available online: https://www.mdpi.com/1718-7729/28/5/315

9. “Prostate Cancer Metastasis to the Pituitary Gland Manifesting as Corticosteroid Withdrawal, and the Impact of the Switch from Prednisone to Dexamethasone on Survival Time”
by Okeroghene Ataikiru, Mahmoud Abdelsalam, Mrudula Avileli and Trina Hynes
Curr. Oncol. 2021, 28(6), 4291–4297; https://doi.org/10.3390/curroncol28060365
Available online: https://www.mdpi.com/1718-7729/28/6/365

10. “Cost–Utility Analysis of Radiation Treatment Modalities for Intermediate-Risk Prostate Cancer”
by Najlaa Alyamani, Jiheon Song, Sasha van Katwyk, Kednapa Thavorn, Julie Renaud, Alain Haddad, Miller MacPherson and Marc Gaudet
Curr. Oncol. 2021, 28(4), 2385–2398; https://doi.org/10.3390/curroncol28040219
Available online: https://www.mdpi.com/1718-7729/28/4/219

20 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Childhood, Adolescent and Young Adult Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Childhood, Adolescent and Young Adult Oncology” listed below:

1. “A Cross-Sectional Survey Exploring the Impact of the COVID-19 Pandemic on the Cancer Care of Adolescents and Young Adults”
by Kaitlyn Howden, Camille Glidden, Razvan G. Romanescu, Andrew Hatala, Ian Scott, Julie Deleemans, Karine Chalifour, Geoff Eaton, Abha A. Gupta, James M. Bolton et al.
Curr. Oncol. 2021, 28(4), 3201–3213; https://doi.org/10.3390/curroncol28040278
Available online: https://www.mdpi.com/1718-7729/28/4/278

2. “The Role of PET in Supratentorial and Infratentorial Pediatric Brain Tumors”
by Angelina Cistaro, Domenico Albano, Pierpaolo Alongi, Riccardo Laudicella, Daniele Antonio Pizzuto, Giuseppe Formica, Cinzia Romagnolo, Federica Stracuzzi, Viviana Frantellizzi, Arnoldo Piccardo et al.
Curr. Oncol. 2021, 28(4), 2481–2495; https://doi.org/10.3390/curroncol28040226
Available online: https://www.mdpi.com/1718-7729/28/4/226

3. “The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors”
by Julian Kolorz, Salih Demir, Adrian Gottschlich, Iris Beirith, Matthias Ilmer, Daniel Lüthy, Christoph Walz, Mario M. Dorostkar, Thomas Magg, Fabian Hauck et al.
Curr. Oncol. 2022, 29(1), 94–110; https://doi.org/10.3390/curroncol29010008
Available online: https://www.mdpi.com/1718-7729/29/1/8

4. “A Retrospective Comparative Analysis of Outcomes and Prognostic Factors in Adult and Pediatric Patients with Osteosarcoma”
by Stefano Testa, Benjamin D. Hu, Natalie L. Saadeh, Allison Pribnow, Sheri L. Spunt, Gregory W. Charville, Nam Q. Bui and Kristen N. Ganjoo
Curr. Oncol. 2021, 28(6), 5304–5317; https://doi.org/10.3390/curroncol28060443
Available online: https://www.mdpi.com/1718-7729/28/6/443

5. “Parents’ Experiences with Home-Based Oral Chemotherapy Prescribed to a Child Diagnosed with Acute Lymphoblastic Leukemia: A Qualitative Study”
by Étienne Camiré-Bernier, Erwan Nidelet, Amel Baghdadli, Gabriel Demers, Marie-Christine Boulanger, Marie-Claude Brisson, Bruno Michon, Sophie Lauzier and Isabelle Laverdière
Curr. Oncol. 2021, 28(6), 4377–4391; https://doi.org/10.3390/curroncol28060372
Available online: https://www.mdpi.com/1718-7729/28/6/372

20 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Health Economics”

As Current Oncology (ISSN: 1718-7729) is of an open-access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Health Economics” listed below:

1. “Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients”
by Yuti P. Patel, Donald Husereau, Natasha B. Leighl, Barbara Melosky and Julian Nam
Curr. Oncol. 2021, 28(6), 5278–5294; https://doi.org/10.3390/curroncol28060441
Available online: https://www.mdpi.com/1718-7729/28/6/441

2. “Cost Analysis of Laparoscopic Low Anterior Resection vs. Transanal Endoscopic Microsurgery for Rectal Neoplasms”
by Katerina Neumann, Nirmal Randhawa, Jason Park and David J. Hochman
Curr. Oncol. 2021, 28(3), 1795–1802; https://doi.org/10.3390/curroncol28030167
Available online: https://www.mdpi.com/1718-7729/28/3/167

3. “The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review”
by Nicolas Iragorri, Claire de Oliveira, Natalie Fitzgerald and Beverley Essue
Curr. Oncol. 2021, 28(2), 1216–1248; https://doi.org/10.3390/curroncol28020117
Available online: https://www.mdpi.com/1718-7729/28/2/117

4. “Cost Minimization Analysis of Hypofractionated Radiotherapy”
by Hannah L.Yaremko, Gordon E. Locke, Ronald Chow, Michael Lock, Robert Dinniwell and Brian P. Yaremko
Curr. Oncol. 2021, 28(1), 716–725; https://doi.org/10.3390/curroncol28010070
Available online: https://www.mdpi.com/1718-7729/28/1/70

5. “Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care”
by Adam J. N. Raymakers, David Cameron, Scott Tyldesley and Dean A. Regier
Curr. Oncol. 2021, 28(3), 1857–1866; https://doi.org/10.3390/curroncol28030172
Available online: https://www.mdpi.com/1718-7729/28/3/172

6. “Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs”
by Ronak Saluja, Tina Jiao, Liza Koshy, Matthew Cheung and Kelvin K. W. Chan
Curr. Oncol. 2021, 28(1), 606–618; https://doi.org/10.3390/curroncol28010060
Available online: https://www.mdpi.com/1718-7729/28/1/60

7. “Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer”
by Megan M. Tu, Mark Clemons, Carol Stober, Ahwon Jeong, Lisa Vandermeer, Mihaela Mates, Phillip Blanchette, Anil Abraham Joy, Olexiy Aseyev, Gregory Pond et al.
Curr. Oncol. 2021, 28(3), 1847–1856; https://doi.org/10.3390/curroncol28030171
Available online: https://www.mdpi.com/1718-7729/28/3/171

8. “Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial”
by Anca Prica, Annette E. Hay, Michael Crump, Nicole Mittmann, Lois E. Shepherd, Ralph M. Meyer, Kevin I. Imrie, Nancy Risebrough, Marina Djurfeldt, Bingshu E. Chen et al.
Curr. Oncol. 2021, 28(2), 1256–1261; https://doi.org/10.3390/curroncol28020119
Available online: https://www.mdpi.com/1718-7729/28/2/119

19 October 2023
Open Access Week 2023 – the Global Drive to Open Continues


MDPI has been a strong proponent of the open access publishing model right from the beginning. As one of the pioneering fully open access publishers, we firmly believe that unrestricted access to research findings forms the foundation for better transparency, efficiency, and quality control across all scientific disciplines.

In December 2022, we reached a significant milestone by surpassing one million articles published. That is one million articles freely available to all, to circulate and build upon!

Offering free and immediate access to scientific papers empowers scientists to examine, validate, replicate, and expand upon existing results. This not only helps prevent redundancy and optimizes how resources are used but also paves the way for innovative new approaches.

The International Open Access Week takes place from 23 to 29 October 2023, providing a unique opportunity to connect the global movement towards open sharing and open science with the progress of policy transformations at the local level.

Our goal, during Open Access Week as well as throughout the year, is to offer resources for educating people about the benefits of open access publishing. The MDPI Blog offers a wealth of information around open access and open science.

Promoting the values of accessibility, transparency, and collaboration

Open access publishing embodies the fundamental values of democratizing knowledge and fostering global accessibility. It aims to break down barriers that have traditionally limited access to scholarly work, ensuring that knowledge is available to all, regardless of their financial or institutional affiliations. 

Discounts are part of our commitment to ensuring there are diverse pathways to Open Access publishing for researchers worldwide. MDPI supports scientific communities in several different ways. 

One of the key strengths of open access publishing lies in its ability to facilitate interdisciplinary research. By removing paywalls and promoting the sharing of knowledge across disciplines, OA encourages collaboration and innovation. Researchers from diverse fields can access and build upon each other's work, fostering a holistic approach to addressing complex global challenges. 

Funders' policies are getting aligned with open science

Governments, institutions, and funding agencies have recognized the transformative potential of open access and have implemented policies to promote it. These policies often mandate that publicly funded research should be made openly accessible. Such initiatives have accelerated the growth of open access repositories and journals, reinforcing the commitment to open access principles. Check our spotlights on OA policies in the USEU and China

Open access publishing is continually evolving, with innovative and community-driven models and technologies shaping its future. Initiatives like "Plan S" and "cOAlition S" promote the adoption of OA publishing from the national funders’ perspective by requiring grantees to publish their research openly. A new policy announced by the US administration last year requires that, as of January 2026, all US federally funded research be made freely and immediately available after publication. 

Additionally, preprint servers such as MDPI's Preprints.org, which allow researchers to share their findings before formal peer review, have gained popularity, enhancing the speed at which new knowledge is disseminated. The rise of blockchain technology is also being explored to ensure transparency and authenticity in scholarly publishing. 

For more than twenty years, open access scholarly publishing has been revolutionizing academia by promoting the values of accessibility, transparency, and collaboration. Its support for interdisciplinary research, evolving policies, and innovative practices all contribute to its growing influence in the global research community. As open access continues to expand, it holds the potential to democratize knowledge, advance science, and drive positive societal change. 

MDPI is proud to be a leader in the transition to open access.

19 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Thoracic Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Thoracic Oncology” listed below:

1. “The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Center: A Retrospective Chart Review”
by Goulnar Kasymjanova, Aksa Anwar, Victor Cohen, Khalil Sultanem, Carmela Pepe, Lama Sakr, Jennifer Friedmann and Jason S. Agulnik
Curr. Oncol. 2021, 28(6), 4247–4255; https://doi.org/10.3390/curroncol28060360
Available online: https://www.mdpi.com/1718-7729/28/6/360

2. “Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada”
by Dylan E. O’Sullivan, Winson Y. Cheung, Iqra A. Syed, Daniel Moldaver, Mary Kate Shanahan, D. Gwyn Bebb, Christina Sit, Darren R. Brenner and Devon J. Boyne
Curr. Oncol. 2021, 28(4), 3091–3103; https://doi.org/10.3390/curroncol28040270
Available online: https://www.mdpi.com/1718-7729/28/4/270

3. “Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer—A Cost-Efficient Strategy in a Public Healthcare System”
by Maisam Makarem, Doreen A. Ezeife, Adam C. Smith, Janice J. N. Li, Jennifer H. Law, Ming-Sound Tsao and Natasha B. Leighl
Curr. Oncol. 2021, 28(5), 3268–3279; https://doi.org/10.3390/curroncol28050284
Available online: https://www.mdpi.com/1718-7729/28/5/284

4. “Immunotherapy in Extensive-Stage Small Cell Lung Cancer”
by Rola El Sayed, and Normand Blais
Curr. Oncol. 2021, 28(5), 4093–4108; https://doi.org/10.3390/curroncol28050347
Available online: https://www.mdpi.com/1718-7729/28/5/347

5. “Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database”
by Heidi A. I. Grosjean, Samantha Dolter, Daniel E. Meyers, Philip Q. Ding, Igor Stukalin, Siddhartha Goutam, Shiying Kong, Quincy Chu, Daniel Y. C. Heng, D. Gwyn Bebb et al.
Curr. Oncol. 2021, 28(5), 4213–4222; https://doi.org/10.3390/curroncol28050357
Available online: https://www.mdpi.com/1718-7729/28/5/357

6. “Meta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer”
by Christopher Cao, Anthony Le, Matthew Bott, Chi-Fu Jeffrey Yang, Dominique Gossot, Franca Melfi, David H. Tian and Allen Guo
Curr. Oncol. 2021, 28(6), 4686–4701; https://doi.org/10.3390/curroncol28060395
Available online: https://www.mdpi.com/1718-7729/28/6/395

7. “Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes”
by Sarah Sharman Moser, Jair Bar, Inna Kan, Keren Ofek, Raanan Cohen, Nikhil Khandelwal, Varda Shalev, Gabriel Chodick and Nava Siegelmann-Danieli
Curr. Oncol. 2021, 28(1), 317–331; https://doi.org/10.3390/curroncol28010036
Available online: https://www.mdpi.com/1718-7729/28/1/36

8. “Contribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations”
by Constance Petiteau, Gwladys Robinet-Zimmermann, Adèle Riot, Marine Dorbeau, Nicolas Richard, Cécile Blanc-Fournier, Frédéric Bibeau, Simon Deshayes, Emmanuel Bergot, Radj Gervais et al.
Curr. Oncol. 2021, 28(6), 4432–4445; https://doi.org/10.3390/curroncol28060376
Available online: https://www.mdpi.com/1718-7729/28/6/376

9. “Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”
by Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Tsukasa Ohnishi and Hironori Sagara
Curr. Oncol. 2021, 28(2), 1094–1113; https://doi.org/10.3390/curroncol28020106
Available online: https://www.mdpi.com/1718-7729/28/2/106

10. “Health Resource and Cost Savings Achieved in a Multidisciplinary Lung Cancer Clinic”
by Christopher J. L. Stone, Ana P. Johnson, Danielle Robinson, Andriy Katyukha, Rylan Egan, Sophia Linton, Christopher Parker, Andrew Robinson and Geneviève C. Digby
Curr. Oncol. 2021, 28(3), 1681–1695; https://doi.org/10.3390/curroncol28030157
Available online: https://www.mdpi.com/1718-7729/28/3/157

18 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Surgical Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Surgical Oncology” listed below:

1. “Synovial Sarcoma: A Clinical Review”
by Aaron M. Gazendam, Snezana Popovic, Sohaib Munir, Naveen Parasu, David Wilson and Michelle Ghert
Curr. Oncol. 2021, 28(3), 1909–1920; https://doi.org/10.3390/curroncol28030177
Available online: https://www.mdpi.com/1718-7729/28/3/177

2. “Combined Exoscopic and Endoscopic Technique for Craniofacial Resection”
by Kenichiro Iwami, Tadashi Watanabe, Koji Osuka, Tetsuya Ogawa, Shigeru Miyachi and Yasushi Fujimoto
Curr. Oncol. 2021, 28(5), 3945–3958; https://doi.org/10.3390/curroncol28050336
Available online: https://www.mdpi.com/1718-7729/28/5/336

3. “Emerging Concepts in the Surgical Management of Peri-Acetabular Metastatic Bone Disease”
by Aaron Gazendam, Daniel Axelrod, David Wilson and Michelle Ghert
Curr. Oncol. 2021, 28(4), 2731–2740; https://doi.org/10.3390/curroncol28040238
Available online: https://www.mdpi.com/1718-7729/28/4/238

4. “The Surgical Management of Proximal Femoral Metastases: A Narrative Review”
by Daniel Axelrod, Aaron M. Gazendam and Michelle Ghert
Curr. Oncol. 2021, 28(5), 3748–3757; https://doi.org/10.3390/curroncol28050320
Available online: https://www.mdpi.com/1718-7729/28/5/320

5. “Incidence, Etiology, Prevention and Management of Ureteroenteric Strictures after Robot-Assisted Radical Cystectomy: A Review of Published Evidence and Personal Experience”
by Shintaro Narita, Mitsuru Saito, Kazuyuki Numakura and Tomonori Habuchi
Curr. Oncol. 2021, 28(5), 4109–4117; https://doi.org/10.3390/curroncol28050348
Available online: https://www.mdpi.com/1718-7729/28/5/348

6. “The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review”
by Abha Gupta, Lisa Durocher-Allen, Snezana Popovic, Richard Tozer, Xiaomei Yao and Michelle Ghert
Curr. Oncol. 2021, 28(2), 1302–1313; https://doi.org/10.3390/curroncol28020124
Available online: https://www.mdpi.com/1718-7729/28/2/124

7. “Do Preoperative Transfusions Impact Prognosis in Moderate to Severe Anaemic Surgical Patients with Colon Cancer?”
by Nicolò Tamini, Luca Gianotti, Shadya Darwish, Salvatore Petitto, Davide Bernasconi, Massimo Oldani, Fabio Uggeri, Marco Braga and Luca Nespoli
Curr. Oncol. 2021, 28(6), 4634–4644; https://doi.org/10.3390/curroncol28060391
Available online: https://www.mdpi.com/1718-7729/28/6/391

8. “Salvage Surgical Resection after Linac-Based Stereotactic Radiosurgery for Newly Diagnosed Brain Metastasis”
by Ryosuke Matsuda, Takayuki Morimoto, Tetsuro Tamamoto, Nobuyoshi Inooka, Tomoko Ochi, Toshiteru Miyasaka, Shigeto Hontsu, Kaori Yamaki, Sachiko Miura, Yasuhiro Takeshima et al.
Curr. Oncol. 2021, 28(6), 5255–5265; https://doi.org/10.3390/curroncol28060439
Available online: https://www.mdpi.com/1718-7729/28/6/439

9. “National Variations in the Work-Up, Investigation, and Surgical Management of Ductal Carcinoma In Situ of the Breast across Canadian Surgeons”
by Ryerson Seguin and Lashan Peiris
Curr. Oncol. 2021, 28(2), 1366–1375; https://doi.org/10.3390/curroncol28020130
Available online: https://www.mdpi.com/1718-7729/28/2/130

10. “Extent of Groin Dissection in Melanoma: A Mixed-Methods, Population-Based Study of Practice Patterns and Outcomes”
by Suzana Küpper, Janice L. Austin, Brittany Dingley, Yuan Xu, Kristine Kong, Mantaj Brar, Frances C. Wright, Carolyn Nessim, Antoine Bouchard-Fortier and May Lynn Quan
Curr. Oncol. 2021, 28(6), 5422–5433; https://doi.org/10.3390/curroncol28060452
Available online: https://www.mdpi.com/1718-7729/28/6/452

18 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Palliative and Supportive Care”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Palliative and Supportive Care” listed below:

1. “Virtual Care in Patients with Cancer: A Systematic Review”
by Simron Singh, Glenn G. Fletcher, Xiaomei Yao and Jonathan Sussman
Curr. Oncol. 2021, 28(5), 3488–3506; https://doi.org/10.3390/curroncol28050301
Available online: https://www.mdpi.com/1718-7729/28/5/301

2. “Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study”
by Agnese Paderi, Sara Fancelli, Enrico Caliman, Serena Pillozzi, Elisabetta Gambale, Marinella Micol Mela, Laura Doni, Francesca Mazzoni and Lorenzo Antonuzzo
Curr. Oncol. 2021, 28(5), 3259–3267; https://doi.org/10.3390/curroncol28050283
Available online: https://www.mdpi.com/1718-7729/28/5/283

3. “Risk-Stratified Pathways for Cancer Survivorship Care: Insights from a Deliberative Multi-Stakeholder Consultation”
by Dominique Tremblay, Nassera Touati, Karine Bilodeau, Catherine Prady, Susan Usher and Yves Leblanc
Curr. Oncol. 2021, 28(5), 3408–3419; https://doi.org/10.3390/curroncol28050295
Available online: https://www.mdpi.com/1718-7729/28/5/295

4. “RELIEF: A Digital Health Tool for the Remote Self-Reporting of Symptoms in Patients with Cancer to Address Palliative Care Needs and Minimize Emergency Department Visits”
by Ravi Bhargava, Bonnie Keating, Sarina R. Isenberg, Saranjah Subramaniam, Pete Wegier and Martin Chasen
Curr. Oncol. 2021, 28(6), 4273–4280; https://doi.org/10.3390/curroncol28060363
Available online: https://www.mdpi.com/1718-7729/28/6/363

5. “Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada”
by Kristina Jenei, Stuart Peacock, Michael Burgess and Craig Mitton
Curr. Oncol. 2021, 28(4), 2708–2719; https://doi.org/10.3390/curroncol28040236
Available online: https://www.mdpi.com/1718-7729/28/4/236

6. “Post-Treatment Adverse Health Correlates among Prostate Cancer Survivors in a Sample of Men Residing in Atlantic Canada”
by Gabriela Ilie, Robert Rutledge and Ellen Sweeney
Curr. Oncol. 2021, 28(4), 2812–2822; https://doi.org/10.3390/curroncol28040246
Available online: https://www.mdpi.com/1718-7729/28/4/246

7. “A Multidisciplinary Approach to Implement Personalized Breast Cancer Treatment and Care Plans”
by Rashida Haq, Amy Kong and Pauline Gulasingam
Curr. Oncol. 2021, 28(1), 767–782; https://doi.org/10.3390/curroncol28010075
Available online: https://www.mdpi.com/1718-7729/28/1/75

8. “Quality of Colon Cancer Care in Patients Undergoing Emergency Surgery”
by Keegan Guidolin, Rebecca Withers, Farhana Shariff, Shady Ashamalla and Ashlie Nadler
Curr. Oncol. 2021, 28(3), 2079–2086; https://doi.org/10.3390/curroncol28030192
Available online: https://www.mdpi.com/1718-7729/28/3/192

9. “Canadian Resources, Programs, and Models of Care to Support Cancer Survivors’ Transition beyond Treatment: A Scoping Review”
by Claudia Romkey-Sinasac, Stephanie Saunders and Jacqueline Galica
Curr. Oncol. 2021, 28(3), 2134–2145; https://doi.org/10.3390/curroncol28030198
Available online: https://www.mdpi.com/1718-7729/28/3/198

10. “Narratives of Survivorship: A Study of Breast Cancer Pathographies and Their Place in Cancer Rehabilitation”
by Åsa Mohlin and Katarina Bernhardsson
Curr. Oncol. 2021, 28(4), 2840–2851; https://doi.org/10.3390/curroncol28040249
Available online: https://www.mdpi.com/1718-7729/28/4/249

17 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Gynecologic Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Gynecologic Oncology” listed below:

1. “Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer”
by Yousef M. Al-saraireh, Fatemah O. F. O. Alshammari, Ahmed M. M. Youssef, Yahya M. Al-sarayra, Renata A. Al-saraireh, Ghadeer H. Al-muhaisen, Yanal S. Al-mahdy, Ahlam M. Al-Kharabsheh, Seham M. Abufraijeh and Hamzeh Mohammad Alrawashdeh
Curr. Oncol. 2021, 28(5), 3573–3584; https://doi.org/10.3390/curroncol28050306
Available online: https://www.mdpi.com/1718-7729/28/5/306

2. “The Challenge of Return to Work after Breast Cancer: The Role of Family Situation, CANTO Cohort”
by Elsa Caumette, Inès Vaz-Luis, Sandrine Pinto, Julie Havas, Thomas Bovagnet, Garazi Ruiz de Azua, Antonio Di Meglio, Anne-Laure Martin, Sibille Everhard, Paul Cottu et al.
Curr. Oncol. 2021, 28(5), 3866–3875; https://doi.org/10.3390/curroncol28050330
Available online: https://www.mdpi.com/1718-7729/28/5/330

3. “Feasibility of a Pilot Randomized Controlled Trial Examining a Multidimensional Intervention in Women with Gynecological Cancer at Risk of Lymphedema”
by Shirin M. Shallwani, Anna Towers, Anne Newman, Shannon Salvador, Angela Yung, Lucy Gilbert, Walter H. Gotlieb, Xing Zeng and Doneal Thomas
Curr. Oncol. 2021, 28(1), 455–470; https://doi.org/10.3390/curroncol28010048
Available online: https://www.mdpi.com/1718-7729/28/1/48

4. “Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost”
by Ioannis M. Koukourakis, Marianthi Panteliadou, Axiotis G. Giakzidis, Christos Nanos, Ioannis Abatzoglou, Alexandra Giatromanolaki and Michael I. Koukourakis
Curr. Oncol. 2021, 28(5), 3474–3487; https://doi.org/10.3390/curroncol28050300
Available online: https://www.mdpi.com/1718-7729/28/5/300

5. “Omental Macrophagic “Crown-like Structures” Are Associated with Poor Prognosis in Advanced-Stage Serous Ovarian Cancer”
by Yu-Ling Liang, Chang-Ni Lin, Hsing-Fen Tsai, Pei-Ying Wu, Sheng-Hsiang Lin, Tse-Ming Hong and Keng-Fu Hsu
Curr. Oncol. 2021, 28(5), 4234–4246; https://doi.org/10.3390/curroncol28050359
Available online: https://www.mdpi.com/1718-7729/28/5/359

6. “A Case of Stevens–Johnson Syndrome in Recurrent Late-Stage Ovarian Cancer Patient after Management of Chronic Pain with Elastomeric Pump”
by Andrej Cokan, Vida Gavrić Lovrec and Iztok Takač
Curr. Oncol. 2021, 28(4), 2928–2932; https://doi.org/10.3390/curroncol28040256
Available online: https://www.mdpi.com/1718-7729/28/4/256

7. “Radiation-Induced Emesis (RIE) in Extended-Field Radiotherapy for Gynecological Malignancies: Dosimetric and Non-Dosimetric Factors”
by Yu-Ming Wang, Yi-Fan Chen, Pei-Yi Lee, Meng-Wei Ho and Eng-Yen Huang
Curr. Oncol. 2021, 28(5), 3602–3609; https://doi.org/10.3390/curroncol28050308
Available online: https://www.mdpi.com/1718-7729/28/5/308

8. “Could the Long-Term Oncological Safety of Laparoscopic Surgery in Low-Risk Endometrial Cancer also Be Valid for the High–Intermediate- and High-Risk Patients? A Multi-Center Turkish Gynecologic Oncology Group Study Conducted with 2745 Endometrial Cancer Cases. (TRSGO-End-001)”
by Mehmet Ali Vardar, Ahmet Baris Guzel, Salih Taskin, Mete Gungor, Nejat Ozgul, Coskun Salman, Umran Kucukgoz-Gulec, Ghanim Khatib, Cagatay Taskiran, Ilkkan Dünder et al.
Curr. Oncol. 2021, 28(6), 4328–4340; https://doi.org/10.3390/curroncol28060368
Available online: https://www.mdpi.com/1718-7729/28/6/368

9. “ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer Group”
by Aristotelis Bamias, Konstantinos Koutsoukos, Nikos Gavalas, Roubini Zakopoulou, Kimon Tzannis, Nikos Dedes, Anna Boulouta, Charalampos Fragkoulis, Eythymios Kostouros, Athanasios Dellis et al.
Curr. Oncol. 2021, 28(6), 4474–4484; https://doi.org/10.3390/curroncol28060380
Available online: https://www.mdpi.com/1718-7729/28/6/380

10. “Clinical Study of Sentinel Lymph Node Detection Using Photodynamic Eye for Abdominal Radical Trachelectomy”
by Naomi Harano, Masaru Sakamoto, Souta Fukushima, Shinnosuke Iwai, Yuki Koike, Shingo Horikawa, Kayo Suzuki, Chikage Narui, Kazuko Matsuoka, Rinko Ozeki et al.
Curr. Oncol. 2021, 28(6), 4709–4720; https://doi.org/10.3390/curroncol28060397
Available online: https://www.mdpi.com/1718-7729/28/6/397

14 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Head and Neck Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Head and Neck Oncology” listed below:

1. “Discrimination of Cancer Stem Cell Markers ALDH1A1, BCL11B, BMI-1, and CD44 in Different Tissues of HNSCC Patients”
by Kariem Sharaf, Axel Lechner, Stefan P. Haider, Robert Wiebringhaus, Christoph Walz, Gisela Kranz, Martin Canis, Frank Haubner, Olivier Gires and Philipp Baumeister
Curr. Oncol. 2021, 28(4), 2763–2774; https://doi.org/10.3390/curroncol28040241
Available online: https://www.mdpi.com/1718-7729/28/4/241

2. “Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report”
by Cristina Luongo, Tommaso Porcelli, Francesca Sessa, Maria Angela De Stefano, Francesco Scavuzzo, Vincenzo Damiano, Michele Klain, Claudio Bellevicine, Elide Matano, Giancarlo Troncone et al.
Curr. Oncol. 2021, 28(6), 5401–5407; https://doi.org/10.3390/curroncol28060450
Available online: https://www.mdpi.com/1718-7729/28/6/450

3. “Differential Expression of Non-Coding RNA Signatures in Thyroid Cancer between Two Ethnic Groups”
by Kristiana Rood, Khodeza Begum, Hanmin Wang, Yan C. Wangworawat, Ryan Davis, Celina R. Yamauchi, Mia C. Perez, Alfred A. Simental, Ria T. Laxa, Charles Wang et al.
Curr. Oncol. 2021, 28(5), 3610–3628; https://doi.org/10.3390/curroncol28050309
Available online: https://www.mdpi.com/1718-7729/28/5/309

4. “Clinicopathological Risk Factors for Contralateral Lymph Node Metastases in Intraoral Squamous Cell Carcinoma: A Study of 331 Cases”
by Christian Flörke, Aydin Gülses, Christina-Randi Altmann, Jörg Wiltfang, Henning Wieker and Hendrik Naujokat
Curr. Oncol. 2021, 28(3), 1886–1898; https://doi.org/10.3390/curroncol28030175
Available online: https://www.mdpi.com/1718-7729/28/3/175

5. “Use of Propensity Score Matching to Compare Short Outcomes from Transoral and External Surgical Approaches in Patients with Deep-Lobe Parotid Pleomorphic Adenomas”
by Yue Fan, Shuguang Li, Shuting Yu, Xiaoli Zhu, Xiaohua Shi, Wuyi Li, Zhiqiang Gao and Xingming Chen
Curr. Oncol. 2021, 28(4), 3115–3123; https://doi.org/10.3390/curroncol28040272
Available online: https://www.mdpi.com/1718-7729/28/4/272

6. “Outcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy (CRT) in High-Risk Resected Oral Cavity Squamous Cell Carcinoma (OCSCC): A Multi-Institutional Collaboration”
by Arslan Babar, Neil M. Woody, Ahmed I. Ghanem, Jillian Tsai, Neal E. Dunlap, Matthew Schymick, Howard Y. Liu, Brian B. Burkey, Eric D. Lamarre, Jamie A. Ku et al.
Curr. Oncol. 2021, 28(4), 2409–2419; https://doi.org/10.3390/curroncol28040221
Available online: https://www.mdpi.com/1718-7729/28/4/221

7. “A Rare Coexistence of Paraneoplastic Cerebellar Degeneration: Papillary Thyroid Carcinoma”
by Zeynep Özözen Ayas and Gülgün Uncu
Curr. Oncol. 2021, 28(1), 560–564; https://doi.org/10.3390/curroncol28010055
Available online: https://www.mdpi.com/1718-7729/28/1/55

8. “Occurrence of Arrhythmias in Women with Thyroid Cancer Receiving Suppressive Doses of Levothyroxine”
by Karol Kaziród-Wolski, Aldona Kowalska, Janusz Sielski, Magdalena Biskup-Frużyńska and Grzegorz Piotrowski
Curr. Oncol. 2021, 28(6), 5009–5018; https://doi.org/10.3390/curroncol28060420
Available online: https://www.mdpi.com/1718-7729/28/6/420

9. “WNT8B as an Independent Prognostic Marker for Nasopharyngeal Carcinoma”
by Chawalit Ngernsombat, Pongphol Prattapong, Noppadol Larbcharoensub, Krittika Khotthong and Tavan Janvilisri
Curr. Oncol. 2021, 28(4), 2529–2539; https://doi.org/10.3390/curroncol28040230
Available online: https://www.mdpi.com/1718-7729/28/4/230

10. “Distinct Outcomes of Oropharyngeal Squamous Cell Carcinoma Patients after Distant Failure According to p16 Status: Implication in Therapeutic Options”
by Anouchka Modesto, Aurore Siegfried, Amelie Lusque, Sébastien Vergez, Jerome Sarini, Laurent Brouchet, Emmanuelle Uro-Coste, Pierre Graff-Cailleaud and Jean Pierre Delord
Curr. Oncol. 2021, 28(3), 1673–1680; https://doi.org/10.3390/curroncol28030156
Available online: https://www.mdpi.com/1718-7729/28/3/156

14 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Psychosocial Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Psychosocial Oncology” listed below:

1. “COVID-19 Pandemic Stressors and Psychological Symptoms in Breast Cancer Patients”
by Véronique Massicotte, Hans Ivers and Josée Savard
Curr. Oncol. 2021, 28(1), 294–300; https://doi.org/10.3390/curroncol28010034
Available online: https://www.mdpi.com/1718-7729/28/1/34

2. “Personality Traits and Urinary Symptoms Are Associated with Mental Health Distress in Patients with a Diagnosis of Prostate Cancer”
by Charles Gillis, Gabriela Ilie, Ross Mason, Gregory Bailly, Joseph Lawen, David Bowes, Nikhilesh Patil, Derek Wilke, Robert David Harold Rutledge, David Bell et al.
Curr. Oncol. 2021, 28(4), 2993–3002; https://doi.org/10.3390/curroncol28040262
Available online: https://www.mdpi.com/1718-7729/28/4/262

3. “Examining the Pathoplastic Moderating Role of Education on the Association between Depressive Mood and Self-Rated Health among Cancer Survivors: A Population-Based Study”
by Anao Zhang, Kaipeng Wang and Adam S. DuVall
Curr. Oncol. 2021, 28(5), 4042–4052; https://doi.org/10.3390/curroncol28050343
Available online: https://www.mdpi.com/1718-7729/28/5/343 

4. “Psychosocial Distress in Adult Patients Awaiting Cancer Surgery during the COVID-19 Pandemic”
by David Forner, Sarah Murnaghan, Geoffrey Porter, Ross J. Mason, Paul Hong, S. Mark Taylor, James Bentley, Gregory Hirsch, Christopher W. Noel, Matthew H. Rigby et al.
Curr. Oncol. 2021, 28(3), 1867–1878; https://doi.org/10.3390/curroncol28030173
Available online: https://www.mdpi.com/1718-7729/28/3/173

5. “Treatment Regret, Mental and Physical Health Indicators of Psychosocial Well-Being among Prostate Cancer Survivors”
by Cassidy Bradley, Gabriela Ilie, Cody MacDonald, Lia Massoeurs, Jasmine Dang Cam-Tu Vo and Robert David Harold Rutledge
Curr. Oncol. 2021, 28(5), 3900–3917; https://doi.org/10.3390/curroncol28050333
Available online: https://www.mdpi.com/1718-7729/28/5/333

6. “A Cross-Sectional Survey Exploring the Impact of the COVID-19 Pandemic on the Cancer Care of Adolescents and Young Adults”
by Kaitlyn Howden, Camille Glidden, Razvan G. Romanescu, Andrew Hatala, Ian Scott, Julie Deleemans, Karine Chalifour, Geoff Eaton, Abha A. Gupta, James M. Bolton et al.
Curr. Oncol. 2021, 28(4), 3201–3213; https://doi.org/10.3390/curroncol28040278
Available online: https://www.mdpi.com/1718-7729/28/4/278

13 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Medical Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Medical Oncology” listed below:

1. “Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome”
by Sim Vermeulen, Gil Awada, Marleen Keyaerts, Bart Neyns and Hendrik Everaert
Curr. Oncol. 2021, 28(3), 1630–1640; https://doi.org/10.3390/curroncol28030152
Available online: https://www.mdpi.com/1718-7729/28/3/152

2. “The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial Design”
by Deanna Saunders, Michelle Liu, Lisa Vandermeer, Mashari Jemaan Alzahrani, Brian Hutton and Mark Clemons
Curr. Oncol. 2021, 28(5), 3959–3977; https://doi.org/10.3390/curroncol28050337
Available online: https://www.mdpi.com/1718-7729/28/5/337

3. “Staging Investigations in Asymptomatic Early Breast Cancer Patients at the Cancer Centre of Southeastern Ontario”
by Dalia Kamel, Veronica Youssef, Wilma M. Hopman and Mihaela Mates
Curr. Oncol. 2021, 28(3), 2190–2198; https://doi.org/10.3390/curroncol28030203
Available online: https://www.mdpi.com/1718-7729/28/3/203

4. “Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice”
by Joyce O’Shaughnessy, Leisha A. Emens, Stephen Y. Chui, Wei Wang, Kenneth Russell, Shih-Wen Lin, Carlos Flores Avile, Patricia Luhn and Andreas Schneeweiss
Curr. Oncol. 2021, 28(4), 2741–2752; https://doi.org/10.3390/curroncol28040239
Available online: https://www.mdpi.com/1718-7729/28/4/239

5. “18F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center”
by Ur Metser, Claudia Ortega, Douglas Hussey, Rosanna Chan, Alejandro Berlin, Antonio Finelli and Patrick Veit-Haibach
Curr. Oncol. 2021, 28(5), 3251–3258; https://doi.org/10.3390/curroncol28050282
Available online: https://www.mdpi.com/1718-7729/28/5/282

6. “The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group”
by Kelvin K. W. Chan, Matthew C. Cheung, Dean A. Regier, Annette Hay, Alexander V. Louie, Winson Y. Cheung, Jean-Eric Tarride, Suji Udayakumar and Nicole Mittmann
Curr. Oncol. 2021, 28(5), 3649–3658; https://doi.org/10.3390/curroncol28050311
Available online: https://www.mdpi.com/1718-7729/28/5/311

7. “Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes”
by Sarah Sharman Moser, Jair Bar, Inna Kan, Keren Ofek, Raanan Cohen, Nikhil Khandelwal, Varda Shalev, Gabriel Chodick and Nava Siegelmann-Danieli
Curr. Oncol. 2021, 28(1), 317–331; https://doi.org/10.3390/curroncol28010036
Available online: https://www.mdpi.com/1718-7729/28/1/36

8. “Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group”
by Wei Fang Dai, Vanessa Arciero, Erica Craig, Brent Fraser, Jessica Arias, Darryl Boehm, Nevzeta Bosnic, Patricia Caetano, Carole Chambers, Barry Jones et al.
Curr. Oncol. 2021, 28(5), 4174–4183; https://doi.org/10.3390/curroncol28050354
Available online: https://www.mdpi.com/1718-7729/28/5/354

9. “Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise”
by Wei Fang Dai, Erica Craig, Brent Fraser, Alex Chambers, Helen Mai, M. Bryson Brown, Craig C. Earle, William K. Evans, Marc Geirnaert, Marianne Taylor et al.
Curr. Oncol. 2021, 28(6), 4645–4654; https://doi.org/10.3390/curroncol28060392
Available online: https://www.mdpi.com/1718-7729/28/6/392

10. “Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec”
by Jason S. Agulnik, Goulnar Kasymjanova, Carmela Pepe, Manjusha Hurry, Ryan N. Walton, Lama Sakr, Victor Cohen and David Small
Curr. Oncol. 2021, 28(6), 5179–5191; https://doi.org/10.3390/curroncol28060434
Available online: https://www.mdpi.com/1718-7729/28/6/434

12 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Neuro-Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Neuro-Oncology” listed below:

1. “Changes in Brain Energy and Membrane Metabolism in Glioblastoma following Chemoradiation”
by Astrid Ellen Grams, Stephanie Mangesius, Ruth Steiger, Ivan Radovic, Andreas Rietzler, Lisa Maria Walchhofer, Malik Galijašević, Julian Mangesius, Martha Nowosielski, Christian Franz Freyschlag et al.
Curr. Oncol. 2021, 28(6), 5041–5053; https://doi.org/10.3390/curroncol28060424
Available online: https://www.mdpi.com/1718-7729/28/6/424

2. “The Role of PET in Supratentorial and Infratentorial Pediatric Brain Tumors”
by Angelina Cistaro, Domenico Albano, Pierpaolo Alongi, Riccardo Laudicella, Daniele Antonio Pizzuto, Giuseppe Formica, Cinzia Romagnolo, Federica Stracuzzi, Viviana Frantellizzi, Arnoldo Piccardo et al.
Curr. Oncol. 2021, 28(4), 2481–2495; https://doi.org/10.3390/curroncol28040226
Available online: https://www.mdpi.com/1718-7729/28/4/226

3. “Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients”
by Archya Dasgupta, Jayson Co, Jeff Winter, Barbara-Ann Millar, Normand Laperriere, Derek S. Tsang, Monique van Prooijen, Andrei Damyanovich, Robert Heaton, Catherine Coolens et al.
Curr. Oncol. 2021, 28(1), 549–559; https://doi.org/10.3390/curroncol28010054
Available online: https://www.mdpi.com/1718-7729/28/1/54

4. The Influence of Gene Aberrations on Survival in Resected IDH Wildtype Glioblastoma Patients: A Single-Institution Study”
by Ondrej Kalita, Zuzana Sporikova, Marian Hajduch, Magdalena Megova Houdova, Rastislav Slavkovsky, Lumir Hrabalek, Matej Halaj, Yvona Klementova, Martin Dolezel, Jiri Drabek et al.
Curr. Oncol. 2021, 28(2), 1280–1293; https://doi.org/10.3390/curroncol28020122
Available online: https://www.mdpi.com/1718-7729/28/2/122

5. “A Contemporary Report of Clinical Outcomes in Patients with Melanoma Brain Metastases”
by William J. Phillips, Tabassom Baghai, Michael Ong, Bryan Lo, Andrea M. Ibrahim, Tyler K.T. Smith and Xinni Song
Curr. Oncol. 2021, 28(1), 428–439; https://doi.org/10.3390/curroncol28010045
Available online: https://www.mdpi.com/1718-7729/28/1/45

6. “Feasibility on the Use of Radiomics Features of 11[C]-MET PET/CT in Central Nervous System Tumours: Preliminary Results on Potential Grading Discrimination Using a Machine Learning Model”
by Giorgio Russo, Alessandro Stefano, Pierpaolo Alongi, Albert Comelli, Barbara Catalfamo, Cristina Mantarro, Costanza Longo, Roberto Altieri, Francesco Certo, Sebastiano Cosentino et al.
Curr. Oncol. 2021, 28(6), 5318–5331; https://doi.org/10.3390/curroncol28060444
Available online: https://www.mdpi.com/1718-7729/28/6/444

7. “Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma”
by Masazumi Fujii, Masao Kobayakawa, Kiyoshi Saito, Akihiro Inano, Akio Morita, Mitsuhiro Hasegawa, Akitake Mukasa, Takafumi Mitsuhara, Takeo Goto, Shigeru Yamaguchi et al.
Curr. Oncol. 2021, 28(1), 726–739; https://doi.org/10.3390/curroncol28010071
Available online: https://www.mdpi.com/1718-7729/28/1/71

8. “Hypofractionated Stereotactic Radiotherapy for the Treatment of Benign Intracranial Meningiomas: Long-Term Safety and Efficacy”
by Eric K. Nguyen, Gregory R. Pond, Jeffrey N. Greenspoon, Anthony C. Whitton and Crystal Hann
Curr. Oncol. 2021, 28(5), 3683–3691; https://doi.org/10.3390/curroncol28050314
Available online: https://www.mdpi.com/1718-7729/28/5/314

9. “Salvage Surgical Resection after Linac-Based Stereotactic Radiosurgery for Newly Diagnosed Brain Metastasis”
by Ryosuke Matsuda, Takayuki Morimoto, Tetsuro Tamamoto, Nobuyoshi Inooka, Tomoko Ochi, Toshiteru Miyasaka, Shigeto Hontsu, Kaori Yamaki, Sachiko Miura, Yasuhiro Takeshima et al.
Curr. Oncol. 2021, 28(5), 3683–3691; https://doi.org/10.3390/curroncol28050314
Available online: https://www.mdpi.com/1718-7729/28/5/314

10. “Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience”
by Maria Camila Quinones, Karl Bélanger, Émilie Lemieux Blanchard, Bernard Lemieux, Jean-Paul Bahary, Laura G. Masucci, David Roberge, Cynthia Menard, Carole Lambert, France Berthelet et al.
Curr. Oncol. 2021, 28(4), 3104–3114; https://doi.org/10.3390/curroncol28040271
Available online: https://www.mdpi.com/1718-7729/28/4/271

12 October 2023
Current Oncology | Top Cited Papers in 2021 in the Section “Hematology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2021 top cited papers in the Section “Hematology” listed below:

1. “A Review on Splenic Diffuse Red Pulp Small B-Cell Lymphoma”
by Elif Yilmaz, Arashpreet Chhina, Victor E. Nava and Anita Aggarwal
Curr. Oncol. 2021, 28(6), 5148–5154; https://doi.org/10.3390/curroncol28060431
Available online: https://www.mdpi.com/1718-7729/28/6/431

2. “Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on?”
by Mitchell Sabloff, Steven Tisseverasinghe, Mustafa Ege Babadagli and Rajiv Samant
Curr. Oncol. 2021, 28(1), 903–917; https://doi.org/10.3390/curroncol28010089
Available online: https://www.mdpi.com/1718-7729/28/1/89

3. “How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen”
by José Cabeçadas, Victor E. Nava, Joao L. Ascensao and Maria Gomes da Silva
Curr. Oncol. 2021, 28(6), 4611–4633; https://doi.org/10.3390/curroncol28060390
Available online: https://www.mdpi.com/1718-7729/28/6/390

4. “Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor”
by Omar Alkharabsheh, Alhareth Alsayed, Diana M. Morlote and Amitkumar Mehta
Curr. Oncol. 2021, 28(1), 837–841; https://doi.org/10.3390/curroncol28010081
Available online: https://www.mdpi.com/1718-7729/28/1/81 

5. “Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada”
by Jean Lachaine, Catherine Beauchemin, Kimberly Guinan, Philippe Thebault, Andrew Aw, Versha Banerji, Isabelle Fleury and Carolyn Owen
Curr. Oncol. 2021, 28(1), 332–345; https://doi.org/10.3390/curroncol28010037
Available online: https://www.mdpi.com/1718-7729/28/1/37

6. “Spinal Manifestation of Malignant Primary (PLB) and Secondary Bone Lymphoma (SLB)”
by Melanie Barz, Kaywan Aftahy, Insa Janssen, Yu-Mi Ryang, Georg Prokop, Stephanie E. Combs, Philipp J. Jost, Bernhard Meyer and Jens Gempt
Curr. Oncol. 2021, 28(5), 3891–3899; https://doi.org/10.3390/curroncol28050332
Available online: https://www.mdpi.com/1718-7729/28/5/332

7. “The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry”
by Chris Varghese, Tracey Immanuel, Anna Ruskova, Edward Theakston and Maggie L. Kalev-Zylinska
Curr. Oncol. 2021, 28(2), 1544–1557; https://doi.org/10.3390/curroncol28020146
Available online: https://www.mdpi.com/1718-7729/28/2/146

8. “Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma”
by Rami Abdulbaki, Parastou Tizro, Victor E. Nava, Maria Gomes da Silva and João L. Ascensão
Curr. Oncol. 2021, 28(6), 4821–4831; https://doi.org/10.3390/curroncol28060407
Available online: https://www.mdpi.com/1718-7729/28/6/407

9 October 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Bone and Soft Tissue Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Bone and Soft Tissue Oncology” shown below:

1. “A Case Series of Metastatic Malignant Gastrointestinal Neuroectodermal Tumors and Comprehensive Genomic Profiling Analysis of 20 Cases”
by Taylor Kandler, Eliane Cortez, Lani Clinton, Amanda Hemmerich, Osama Ahmed, Ralph Wong, Taylor Forns, Andrea J. MacNeill, Trevor D. Hamilton, Mohammadali Khorasani et al.
Curr. Oncol. 2022, 29(2), 1279–1297; https://doi.org/10.3390/curroncol29020109
Available online: https://www.mdpi.com/1718-7729/29/2/109 

2. “Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw”
by Veronica Mollica, Giacomo Nuvola, Elisa Tassinari, Maria Concetta Nigro, Andrea Marchetti, Matteo Rosellini, Alessandro Rizzo, Costantino Errani and Francesco Massari
Curr. Oncol. 2022, 29(3), 1709–1722; https://doi.org/10.3390/curroncol29030142
Available online: https://www.mdpi.com/1718-7729/29/3/142 

3. “Minimally Invasive Interventional Procedures for Metastatic Bone Disease: A Comprehensive Review”
by Nicolas Papalexis, Anna Parmeggiani, Giuliano Peta, Paolo Spinnato, Marco Miceli and Giancarlo Facchini
Curr. Oncol. 2022, 29(6), 4155–4177; https://doi.org/10.3390/curroncol29060332
Available online: https://www.mdpi.com/1718-7729/29/6/332

4. “Characteristic of Uterine Rhabdomyosarcoma by Algorithm of Potential Biomarkers for Uterine Mesenchymal Tumor”
by Saya Tamura, Takuma Hayashi, Tomoyuki Ichimura, Nobuo Yaegashi, Kaoru Abiko and Ikuo Konishi
Curr. Oncol. 2022, 29(4), 2350–2363; https://doi.org/10.3390/curroncol29040190
Available online: https://www.mdpi.com/1718-7729/29/4/190

5. “Outcomes of Hip Reconstruction for Metastatic Acetabular Lesions: A Scoping Review of the Literature”
by Sandeep Krishan Nayar, Thomas A. Kostakos, Olga Savvidou, Konstantinos Vlasis and Panayiotis J. Papagelopoulos
Curr. Oncol. 2022, 29(6), 3849–3859; https://doi.org/10.3390/curroncol29060307
Available online: https://www.mdpi.com/1718-7729/29/6/307 

6. “Megaprosthesis for Metastatic Bone Disease—A Comparative Analysis”
by Joachim Thorkildsen, Thale Asp Strøm, Nils Jørgen Strøm, Simen Sellevold and Ole-Jacob Norum
Curr. Oncol. 2022, 29(5), 3460–3471; https://doi.org/10.3390/curroncol29050279
Available online: https://www.mdpi.com/1718-7729/29/5/279

7. “Osseous Union after Mandible Reconstruction with Fibula Free Flap Using Manually Bent Plates vs. Patient-Specific Implants: A Retrospective Analysis of 89 Patients”
by Michael Knitschke, Sophia Sonnabend, Fritz Christian Roller, Jörn Pons-Kühnemann, Daniel Schmermund, Sameh Attia, Philipp Streckbein, Hans-Peter Howaldt and Sebastian Böttger
Curr. Oncol. 2022, 29(5), 3375–3392; https://doi.org/10.3390/curroncol29050274
Available online: https://www.mdpi.com/1718-7729/29/5/274

8 October 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Health Economics”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Health Economics” shown below:

1. “The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer—A Systematic Literature Review with Application to the Canadian Context”
by Ivan Yanev, Jessy Gatete, Jr., Armen G. Aprikian, Jason Robert Guertin and Alice Dragomir
Curr. Oncol. 2022, 29(5), 3393–3424; https://doi.org/10.3390/curroncol29050275
Available online: https://www.mdpi.com/1718-7729/29/5/275

2. “The Pathway for New Cancer Drug Access in Canada”
by Joanna Gotfrit, William Dempster, Johanne Chambers and Paul Wheatley-Price
Curr. Oncol. 2022, 29(2), 455–464; https://doi.org/10.3390/curroncol29020041
Available online: https://www.mdpi.com/1718-7729/29/2/41

3. “Determinants of the Cancer Drug Funding Process in Canada”
by Joanna Gotfrit, Ashley Jackson, John J. W. Shin, David J. Stewart, Ranjeeta Mallick and Paul Wheatley-Price
Curr. Oncol. 2022, 29(3), 1997–2007; https://doi.org/10.3390/curroncol29030162
Available online: https://www.mdpi.com/1718-7729/29/3/162

4. “Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations”
by Louise Binder, Majd Ghadban, Christina Sit and Kathleen Barnard
Curr. Oncol. 2022, 29(3), 1514–1526; https://doi.org/10.3390/curroncol29030127
Available online: https://www.mdpi.com/1718-7729/29/3/127

5. “Challenges and Adaptations for Providing Smoking Cessation for Patients with Cancer across Canada during the COVID-19 Pandemic”
by Graham W. Warren, Caroline Silverman and Michelle Halligan
Curr. Oncol. 2022, 29(4), 2263–2271; https://doi.org/10.3390/curroncol29040184
Available online: https://www.mdpi.com/1718-7729/29/4/184

6. “Equity-Oriented Healthcare: What It Is and Why We Need It in Oncology”
by Tara C. Horrill, Annette J. Browne and Kelli I. Stajduhar
Curr. Oncol. 2022, 29(1), 186–192; https://doi.org/10.3390/curroncol29010018
Available online: https://www.mdpi.com/1718-7729/29/1/18

7. “Survival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status”
by Marie-France Savard, Elizabeth N. Kornaga, Adriana Matutino Kahn and Sasha Lupichuk
Curr. Oncol. 2022, 29(1), 383–391; https://doi.org/10.3390/curroncol29010034
Available online: https://www.mdpi.com/1718-7729/29/1/34

8. “Rapid Review of Real-World Cost-Effectiveness Analyses of Cancer Interventions in Canada”
by Andrea M. Guggenbickler, Heather K. Barr, Jeffrey S. Hoch and Carolyn S. Dewa
Curr. Oncol. 2022, 29(10), 7285–7304; https://doi.org/10.3390/curroncol29100574
Available online: https://www.mdpi.com/1718-7729/29/10/574

9. “Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021”
by Catherine Lau and George Dranitsaris
Curr. Oncol. 2022, 29(11), 8031–8042; https://doi.org/10.3390/curroncol29110635
Available online: https://www.mdpi.com/1718-7729/29/11/635 

10. “Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s RWE Data Working Group”
by Wei Fang Dai, Claire de Oliveira, Scott Blommaert, Reka E. Pataky, David Tran, Zeb Aurangzeb, Cynthia Kendell, Chris Folkins, Chandy Somayaji, Jeff Dowden et al.
Curr. Oncol. 2022, 29(3), 2046–2063; https://doi.org/10.3390/curroncol29030165
Available online: https://www.mdpi.com/1718-7729/29/3/165

8 October 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Childhood, Adolescent and Young Adult Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Childhood, Adolescent and Young Adult Oncology” shown below:

1. “Subsequent Malignant Neoplasm of Bone in Children and Adolescent—Possibility of Multimodal Treatment”
by Anna Raciborska, Katarzyna Bilska, Tomasz Koziński and Carlos Rodriguez-Galindo
Curr. Oncol. 2022, 29(2), 1001–1007; https://doi.org/10.3390/curroncol29020085
Available online: https://www.mdpi.com/1718-7729/29/2/85

2. “The Impact of Exercise on Cardiotoxicity in Pediatric and Adolescent Cancer Survivors: A Scoping Review”
by Stephanie J. Kendall, Jodi E. Langley, Mohsen Aghdam, Bruce N. Crooks, Nicholas Giacomantonio, Stefan Heinze-Milne, Will J. Johnston, Melanie R. Keats, Sharon L. Mulvagh and Scott A. Grandy
Curr. Oncol. 2022, 29(9), 6350–6363; https://doi.org/10.3390/curroncol29090500
Available online: https://www.mdpi.com/1718-7729/29/9/500

3. “Recruiting Adolescent and Young Adult Cancer Survivors for Patient-Reported Outcome Research: Experiences and Sample Characteristics of the SURVAYA Study”
by Carla Vlooswijk, Lonneke V. van de Poll-Franse, Silvie H. M. Janssen, Esther Derksen, Milou J. P. Reuvers, Rhodé Bijlsma, Suzanne E. J. Kaal, Jan Martijn Kerst, Jacqueline M. Tromp, Monique E. M. M. Bos et al.
Curr. Oncol. 2022, 29(8), 5407–5425; https://doi.org/10.3390/curroncol29080428
Available online: https://www.mdpi.com/1718-7729/29/8/428

4. “The Transformation of Adolescent and Young Adult Oncological and Supportive Care in Canada: A Mixed Methods Study”
by Jonathan Avery, Emily Wong, Christine Harris, Stacy Chapman, Serena Uppal, Shaayini Shanawaz, Annemarie Edwards, Laura Burnett, Tushar Vora and Abha A. Gupta
Curr. Oncol. 2022, 29(7), 5126–5138; https://doi.org/10.3390/curroncol29070406
Available online: https://www.mdpi.com/1718-7729/29/7/406

5. “Reflections of Moral Suffering, Resilience, and Wisdom of Pediatric Oncology Social Workers during the COVID-19 Pandemic”
by Barbara Jones, Nancy Cincotta, Wendy Pelletier, Abigail Fry and Lori Wiener
Curr. Oncol. 2022, 29(9), 6177–6185; https://doi.org/10.3390/curroncol29090485
Available online: https://www.mdpi.com/1718-7729/29/9/485

7 October 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Dermato-Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Dermato-Oncology” shown below:

1. “Cutaneous Melanoma in Alpine Population: Incidence Trends and Clinicopathological Profile”
by Alessandra Buja, Massimo Rugge, Giuseppe De Luca, Emanuela Bovo, Manuel Zorzi, Chiara De Toni, Claudia Cozzolino, Antonella Vecchiato, Paolo Del Fiore, Romina Spina et al.
Curr. Oncol. 2022, 29(3), 2165–2173; https://doi.org/10.3390/curroncol29030175
Available online: https://www.mdpi.com/1718-7729/29/3/175

2. “Assessing Choroidal Nevi, Melanomas and Indeterminate Melanocytic Lesions Using Multimodal Imaging—A Retrospective Chart Review”
by Fredy Geiger, Sadiq Said, Anahita Bajka, Mario Damiano Toro, Maximilian Robert Justus Wiest, Marc Stahel, Daniel Barthelmes and Sandrine Anne Zweifel
Curr. Oncol. 2022, 29(2), 1018–1028; https://doi.org/10.3390/curroncol29020087
Available online: https://www.mdpi.com/1718-7729/29/2/87

3. “Treatment of Basal Cell Carcinoma with Electrochemotherapy: Insights from the InspECT Registry (2008–2019)”
by Giulia Bertino, Tobian Muir, Joy Odili, Ales Groselj, Roberto Marconato, Pietro Curatolo, Erika Kis, Camilla Kjaer Lonkvist, James Clover, Pietro Quaglino et al.
Curr. Oncol. 2022, 29(8), 5324–5337; https://doi.org/10.3390/curroncol29080423
Available online: https://www.mdpi.com/1718-7729/29/8/423

4. “Antibody-Negative Paraneoplastic Autoimmune Multiorgan Syndrome (PAMS) in a Patient with Follicular Lymphoma Accompanied by an Excess of Peripheral Blood CD8+ Lymphocytes”
by Thilo Gambichler, Yi-Pei Lee, Ilske Oschlies, Christina H. Scheel, Wolfram Klapper, Nico Nowack, Martin Doerler, Markus Stücker, Nasreddin Abolmaali and Laura Susok
Curr. Oncol. 2022, 29(4), 2395–2405; https://doi.org/10.3390/curroncol29040194
Available online: https://www.mdpi.com/1718-7729/29/4/194

5. “Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic”
by Marta Pabianek, Aleksandra Lesiak, Dariusz Nejc, Łukasz Kuncman, Joanna Narbutt, Małgorzata Skibińska and Magdalena Ciążyńska
Curr. Oncol. 2022, 29(10), 7794–7801; https://doi.org/10.3390/curroncol29100616
Available online: https://www.mdpi.com/1718-7729/29/10/616

6. “An Epidemiological Update on Indoor Tanning and the Risk of Skin Cancers”
by Clio Dessinioti and Alexander J. Stratigos
Curr. Oncol. 2022, 29(11), 8886–8903; https://doi.org/10.3390/curroncol29110699
Available online: https://www.mdpi.com/1718-7729/29/11/699

7. “Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis”
by Lise Mayrin Økland Thunestvedt, Lars Helgeland, Ingeborg Margrethe Bachmann, Åsa Karlsdottir, Torjan Magne Haslerud and Håkon Reikvam
Curr. Oncol. 2022, 29(4), 2193–2198; https://doi.org/10.3390/curroncol29040178
Available online: https://www.mdpi.com/1718-7729/29/4/178

8. “Intravascular Large B-Cell Lymphoma: A Review with a Focus on the Prognostic Value of Skin Involvement”
by Thomas Breakell, Heidi Waibel, Stefan Schliep, Barbara Ferstl, Michael Erdmann, Carola Berking and Markus V. Heppt
Curr. Oncol. 2022, 29(5), 2909–2919; https://doi.org/10.3390/curroncol29050237
Available online: https://www.mdpi.com/1718-7729/29/5/237

2 October 2023
MDPI Insights: The CEO's Letter #4 - MDPI Presence in China

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

Open Access in China

It is Saturday, 23 September, and I have just returned from an unforgettable 12-day trip to China, visiting our main offices in Beijing and Wuhan. In the wake of a packed and very enjoyable agenda of internal and external meetings, I would like to use this edition of the CEO Letter to showcase how MDPI supports the scholarly community in China.

Coincidentally, Jack McKenna, Communications Associate from MDPI’s corporate content team, has just released a blog article discussing China’s open access (OA) policy. It is a timely read, providing a concise overview of the development of the OA movement in China and reflecting on its future. I shall draw some content from Jack’s piece and use this edition of the CEO Letter to highlight the various ways in which MDPI is involved in this market. And it would be remiss of me not to include some pictures and highlights from my travels!

Open Access Policy in China

As per Jack’s post, in 2020, China became the world’s leading producer of research articles. Today, China is experiencing a “substantial growth rate in OA [Open Access] publication”. This growth is supported by the State’s commitment to research & development and its policy “requiring the promotion of open science”.

Over the past two decades, there have been gradual developments in China’s OA framework, with repositories and platforms being developed in a consistent manner. Currently, key institutions across China – including the National Science Library, the National Science and Technology Library, and the Natural Science Foundation of China – support OA. The State aims to establish consistent policies across government agencies – a framework for a more encompassing embrace of OA across institutions.

In China, the number of subscription-only articles decreased by nearly 30% over the 10-year period of 2011–2021, while gold OA increased by 22%. Between 2017 and 2020 alone, China published 800,921 academic papers in an OA format.

In 2023, as the leading publisher of academic research, China is pursuing “self-reliance”. Therefore, the State will be establishing consistent policies across government agencies, including those related to OA. Additionally, it will want to ensure that Chinese people can access the research that is supported by Chinese funding and produced by Chinese academics. For this reason, “Open Access is a matter of priority in China”.

MDPI Offices in China

 While the history of MDPI begins in Basel, Switzerland, the story of MDPI’s founder is very much rooted in China. Dr. Shu-kun Lin, Founder and President of MDPI, graduated with a BSc from Wuhan University in 1982. He also studied physical chemistry at the Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences (1982–1986; MSc in 1985), and at the University of Louisville, USA (1987–1989). Dr. Lin completed his doctorate in organic chemistry at the Swiss Federal Institute of Technology (ETH-Zürich) in 1992.


Stefan Tochev (CEO, MDPI) at MDPI’s Wuhan office.

In 2002, MDPI’s Basel headquarters moved to Matthäusstrasse 11, 4052 Basel, and Dr. Lin opened an editorial office in Qingdao, China, which launched the journal Marine Drugs in the following year. Below is a list of MDPI’s current offices in China and their respective dates of inauguration:

  • 2008: Beijing (Tongzhou, Haidian)
  • 2013: Wuhan (Hankou, Guanggu)
  • 2019: Tianjin
  • 2021: Dalian
  • 2021: Nanjing

Our Strength is in Our People

With over 6,000 MDPI staff, across 20 offices in 11 countries, MDPI is able to offer authors responsive and efficient round-the-clock support, enabling a rapid publication process.

In my experience, stakeholders are genuinely surprised when they realize the extent of our global operations. My response is to reiterate that our people are our strength. This is why we have fast and efficient processes and top-notch responsiveness. Our global presence ensures that your manuscript is constantly attended to, rather than sitting on someone’s desk. We prioritize our authors’ needs and act quickly to move things through the various stages of publication. MDPI is built on speed, convenience, and competence, which I believe are core pillars for success in any industry. We continually strive to improve our systems and processes on the basis of these core strengths. We literally have over 6,000 staff worldwide dedicated to serving your needs. It’s not magic: it’s people; it’s real.

Impactful Research

MDPI Awards

To support the academic community, and especially young researchers, and also to enhance communication among scientists, MDPI journals offer various awards in specific fields. We serve the scientific community by funding research to facilitate the development of sustainable global solutions through our annual World Sustainability Award and Emerging Sustainability Leader Award.

In 2022, MDPI made awards totalling over US$1 million in recognition and support of researchers worldwide.

Across our journal catalogue, we have granted over 2,000 awards to recognize and support researchers from all disciplines. Since 2016, these awards have served as a source of recognition, acknowledging the impact of research by heightening the influence of talented individuals. The award types mainly include the Young Investigator Award, the Best PhD Thesis Award, the Best Paper Award, and the Outstanding Reviewer Award.

To learn more about MDPI Awards and to find out which are currently available, please click here.

MDPI Awards to Scholars from China

Since 2021, there have been 23 Best Paper Awards granted to authors affiliated with Chinese institutions, identifying their papers as having high-quality scientific impact. A total of 45 Chinese scholars have received awards such as the Young Investigator Award, the Best PhD Thesis Award, the Outstanding Reviewer Award, and the Tu Youyou Award, among others. Prizes for these awards include MDPI grants for paid publications, totalling over CHF 70,000 for scholars affiliated with Chinese institutions.

MDPI’s Tu Youyou Award


Prof. Tu Youyou (left), Dr. Shu-Kun Lin (President, MDPI).

In 2015, Professor Tu Youyou was awarded the Nobel Prize in Physiology or Medicine “for her discoveries concerning a novel therapy against Malaria.” In order to commemorate Professor Tu’s contributions to human health and to promote the passion and spirit conveyed by her experiences, MDPI in 2016 established the ‘Tu Youyou Award’, which runs biennially to recognize outstanding scholars dedicated to the research of natural products and medicinal chemistry.

The 2022 Tu Youyou Award was granted to Prof. Dr. Xiaoguang Lei of Peking University. Click here to access the interview with the winner.

2015 Nobel Prize for Medicine Awarded to Professor Youyou Tu

Professor Tu’s work was celebrated in a Special Issue from Molecules on the occasion of her 80th birthday. The Special Issue: 'Artemisinin (Qinghaosu): Commemorative Issue in Honor of Professor Youyou Tu on the Occasion of her 80th Anniversary” was created five years before she won the Nobel Prize, highlighting the visibility MDPI provides researchers and their work.

Highly Cited Articles by Chinese Scholars Published in MDPI

Click here to access the most cited MDPI papers published by scholars affiliated with Chinese institutions. This list presents the most influential research from the more than 287,000 MDPI papers published by Chinese scholars. With over 9 million total citations, I encourage you to maximize your visibility and impact by publishing with MDPI, the number one most cited open access publisher.

Read more:

Inside MDPI

Stefan Tochev (CEO, MDPI) with the Beijing Marketing team.

Marketing Department in China

During my visit to our offices in Beijing and Wuhan, I had the opportunity to meet with, and to present to, our local marketing teams. These teams are responsible for various journal-related and corporate promotional activities, including newsletters, conferences, seminars, author training, journal awards, content creation, digital marketing, and social media.

I was pleased by the ambition and curiosity of our marketing colleagues. They showed a strong desire to collaborate and acquire knowledge and tactics to effectively market and promote MDPI-journal-related activities. I presented some of the principles and objectives that we apply in the Corporate Marketing and Communications department, and used the opportunity to strengthen our collaborative communications across offices.

Stefan Tochev (CEO, MDPI) with the Wuhan Marketing team.

Coming Together for Science

Collaborations, Scholarships and Meetings

MDPI maintains partnerships with nearly 190 learned societies and over 800 institutions and consortia, helping to facilitate the transition to OA publishing. Our commitment to working with institutions is evident in China, where we have successfully established over 35 Institutional Open Access Programs (IOAP) with esteemed institutions such as the Tsinghua University, Huazhong University of Science and Technology, and Shanghai Jiao Tong University.

Our institutional partnerships, waiver programs, and article processing cost discounts create diverse pathways to OA publishing for researchers worldwide.

Scholarships in China

Since 2021, several MDPI journals (Sensors, Photonics, Coatings, Materials, Energies, and Journal of Fungi) have funded full scholarships for four Master’s and five Ph.D. projects in China. These scholarships align with Tianjin University, Wuhan University of Technology, Central South University, the Chinese Academy of Sciences, and the China University of Petroleum (Beijing).

Meeting with the Society of Chinese University Journals (CUJS)


Prof. Tieming Zhang (President of CUJS, centre) and MDPI colleagues at CUJS office.

I am pleased to have participated in some highly productive meetings during my visit to China, including one with the Society of Chinese University Journals (CUJS). The meeting involved Prof. Tieming Zhang (President of CUJS), Assoc. Prof. Xin Zhang (Vice President and Secretary General), and Dr. Fei Gao (Executive Member of CUJS). Alongside my colleagues Dr. Guoshi Liu, Dr. Giulia Stefenelli, and Anita Sun, I represented MDPI and held an open discussion to address any questions regarding OA and MDPI.

We discussed several methods for collaboration, including a workshop on the future of peer review, MDPI sponsoring a funding grant for early-career researchers, and transitioning journals from diamond to gold OA. I am thankful for the opportunity to have met our colleagues at CUJS in person and feel very confident about our future collaborations in support of OA publishing in China.

MDPI hosts free academic seminars, author training sessions, and academic conferences as part of its commitment to enrich and support the scholarly community. CUJS often stages academic events (e.g., conferences, editor training, and editor competitions), and I believe there are great opportunities for CUJS and MDPI to collaborate accordingly.

Meeting with National Science Library, Chinese Academy of Sciences (NSLC)


Stefan Tochev (CEO, MDPI), Dr. Giulia Stefenelli (Chair of Scientific Officers, MDPI), Anita Sun (PR Manager, MDPI) and Dr. Guoshi Liu (Managing Director, MDPI) at the National Science Library, Chinese Academy of Sciences.

We also visited the NSLC Director, Xiwen Liu, and colleagues Ying Jin, Zhesi Shen, and Sichao Tong. Following our introductions, we gave a presentation on the history and editorial process at MDPI, discussing specific details related to MDPI’s business and data. We highlighted the status of our  IOAP collaborations in China and the makeup of our author base, specifically in China, and drew attention to the fact that MDPI has published research by authors from every country in the world. We then discussed the design indicators, calculation methods and implementation purposes of the ‘Early Warning Journal List’ and how we can have open communication to provide any data regarding MDPI journals. I am pleased to report that we reached a consensus on future communications, and am grateful to NSLC for hosting us in their offices.

In-person meetings with stakeholders provide an invaluable opportunity to communicate what MDPI is about and the various ways in which we serve the scholarly community. While digital marketing and online communication are essential, they are no replacement for the understanding and trust that come about through in-person interactions.

The Numbers

As at September 2023, China holds the largest position in MDPI’s global market, ranking as the largest contributor to the total number of papers published by MDPI.

At this point in time, there were more than 847,000 China mainland scholars who have published with MDPI, 51 of whom are Section-Editors-in-Chief (SEiC) of MDPI journals, with seven serving as Editors-in-Chief (EiCs) for journals such as Air, Big Data and Cognitive Computing, Blockchains, Future, Nanoenergy Advances, and Targets.

Our growth and presence in China are a true testament to the service we provide to the scholarly community, and to the relationships we foster through collaborative activities. We look forward to continuing to support the growth of the scholarly community in China, providing a valuable and trusted experience with MDPI.

Closing Thoughts

Final Reflections on our MDPI Offices in Beijing and Wuhan


Stefan Tochev (CEO, MDPI), Dr. Constanze Schelhorn (Indexing Manager, MDPI), Jiale Shang (Admin, Tongzhou, MDPI) at Beijing Capital International Airport, Beijing.

I spent approximately two weeks visiting some of our offices in China, and the first word that comes to mind when describing my experience is ‘hospitality.’ My colleagues and I were met with enthusiasm and delight at the airport by the Tongzhou Admin team (thank you, Jiale Shang, and thank you, Eric Wang, for keeping us organized on this trip!) and were taken care of with great attention. From hotels to transportation, dinners, and meetings, our stay was catered for perfectly.

Perhaps this is where MDPI’s focus on customers and service originates. At our core, we are a service company that provides a publishing platform for its authors. It’s therefore no surprise that authors consistently rate their experience with MDPI very highly.

95% of submitting authors rate their overall experience with the MDPI publication process as Excellent or Good (Springer Nature report 90%).

91% of submitting authors rate their overall experience with the MDPI peer review process as Excellent or Good.

Speed/Efficiency and Editorial Relationship are two key reasons underlying this high satisfaction score. ‘Editorial Relationship’ can be further explored, but in the past month, the most commonly noted aspects were the professionalism, kindness, availability, communicativeness, and personalized assistance provided by our editorial staff throughout the process. These attributes are at the core of our work across all our offices and continents.

Hospitality and Service

Just as our Chinese colleagues strove to keep us engaged by showing us the city sights (thank you, Thea Pan, and Jason Wu from the Wuhan Marketing team!) and sharing a variety of wonderful meals, our editorial staff are committed to serving our authors throughout their publishing journey. Our aim is to place the author at the centre of everything we do, eager to welcome our ‘guests’ and provide them with a pleasant publishing experience.

I asked my colleague Francis Wu (Senior Publisher, Wuhan office) where this hospitality originates. He responded that it is part of Chinese culture. I reflected long and deep on this answer. China is a vast country, and when visitors arrive, hosts want to ensure they feel welcomed and taken care of in order to maximize their time and visit. I can’t think of a better analogy for how I would want our authors to feel when they visit MDPI for their publishing needs. A company culture that prioritizes service, something that goes beyond products and productivity, and focuses on the overall experience. Over 6,000 people, across all MDPI offices, are ready, willing and able to go the extra mile for their colleagues and their customers. This is something I am truly proud of.

Stefan Tochev
Chief Executive Officer
MDPI AG

28 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Breast Cancer”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Breast Cancer” shown below:

1. “Applying Deep Learning for Breast Cancer Detection in Radiology”
by Ella Mahoro and Moulay A. Akhloufi
Curr. Oncol. 2022, 29(11), 8767–8793; https://doi.org/10.3390/curroncol29110690
Available online: https://www.mdpi.com/1718-7729/29/11/690

2. “Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?”
by Liqin Yao, Gang Jia, Lingeng Lu and Wenxue Ma
Curr. Oncol. 2022, 29(7), 4902–4913; https://doi.org/10.3390/curroncol29070389
Available online: https://www.mdpi.com/1718-7729/29/7/389

3. “Optimizing Adjuvant Treatment Recommendations for Older Women with Biologically Favorable Breast Cancer: Short-Course Radiation or Long-Course Endocrine Therapy?”
by Susan G. R. McDuff and Rachel C. Blitzblau
Curr. Oncol. 2023, 30(1), 392–400; https://doi.org/10.3390/curroncol30010032
Available online: https://www.mdpi.com/1718-7729/30/1/32

4. “Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program”
by Nicoletta Staropoli, Elena Geuna, Gaetana Rinaldi, Giancarlo Bisagni, Vieri Scotti, Giovanni Faggioni, Laura Vannini, Carlo Arcara, Gabriella Moretti, Marco Gunnellini et al.
Curr. Oncol. 2022, 29(9), 6635–6641; https://doi.org/10.3390/curroncol29090521
Available online: https://www.mdpi.com/1718-7729/29/9/521

5. “Are Columnar Cell Lesions the Earliest Non-Obligate Precursor in the Low-Grade Breast Neoplasia Pathway?”
by Sarah Strickland and Gulisa Turashvili
Curr. Oncol. 2022, 29(8), 5664–5681; https://doi.org/10.3390/curroncol29080447
Available online: https://www.mdpi.com/1718-7729/29/8/447

6. “Efficacy and Accuracy of Using Magnetic Seed for Preoperative Non-Palpable Breast Lesions Localization: Our Experience with Magseed”
by Anna D’Angelo, Charlotte Marguerite Lucille Trombadori, Flavia Caprini, Stefano Lo Cicero, Valentina Longo, Francesca Ferrara, Simone Palma, Marco Conti, Antonio Franco, Lorenzo Scardina et al.
Curr. Oncol. 2022, 29(11), 8468–8474; https://doi.org/10.3390/curroncol29110667
Available online: https://www.mdpi.com/1718-7729/29/11/667 

7. “Prevalence and Persistence of Anxiety and Depression over Five Years since Breast Cancer Diagnosis—The NEON-BC Prospective Study”
by Catarina Lopes, Luisa Lopes-Conceição, Filipa Fontes, Augusto Ferreira, Susana Pereira, Nuno Lunet and Natália Araújo
Curr. Oncol. 2022, 29(3), 2141–2153; https://doi.org/10.3390/curroncol29030173
Available online: https://www.mdpi.com/1718-7729/29/3/173

8. “Preoperative Radio(Chemo)Therapy in Breast Cancer: Time to Switch the Perspective?”
by Angel Montero and Raquel Ciérvide
Curr. Oncol. 2022, 29(12), 9767–9787; https://doi.org/10.3390/curroncol29120768
Available online: https://www.mdpi.com/1718-7729/29/12/768

28 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Oncology Nursing”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Oncology Nursing” shown below:

1. “Equity-Oriented Healthcare: What It Is and Why We Need It in Oncology”
by Tara C. Horrill, Annette J. Browne and Kelli I. Stajduhar
Curr. Oncol. 2022, 29(1), 186–192; https://doi.org/10.3390/curroncol29010018
Available online: https://www.mdpi.com/1718-7729/29/1/18

2. “A Continuing Educational Program Supporting Health Professionals to Manage Grief and Loss”
by Mary Jane Esplen, Jiahui Wong, Mary L. S. Vachon and Yvonne Leung
Curr. Oncol. 2022, 29(3), 1461–1474; https://doi.org/10.3390/curroncol29030123
Available online: https://www.mdpi.com/1718-7729/29/3/123

3. “Risk Stratification and Cancer Follow-Up: Towards More Personalized Post-Treatment Care in Canada”
by Robin Urquhart, Wendy Cordoba, Jackie Bender, Colleen Cuthbert, Julie Easley, Doris Howell, Julia Kaal, Cynthia Kendell, Samantha Radford and Jonathan Sussman
Curr. Oncol. 2022, 29(5), 3215–3223; https://doi.org/10.3390/curroncol29050261
Available online: https://www.mdpi.com/1718-7729/29/5/261

4. “Oncology Healthcare Professionals’ Mental Health during the COVID-19 Pandemic”
by Leeat Granek and Ora Nakash
Curr. Oncol. 2022, 29(6), 4054–4067; https://doi.org/10.3390/curroncol29060323
Available online: https://www.mdpi.com/1718-7729/29/6/323

5. “Lessons Learned from the Implementation of a Person-Centred Digital Health Platform in Cancer Care”
by Saima Ahmed, Karine LePage, Renata Benc, Guy Erez, Alon Litvin, Annie Werbitt, Gabrielle Chartier, Carly Berlin and Carmen G. Loiselle
Curr. Oncol. 2022, 29(10), 7171–7180; https://doi.org/10.3390/curroncol29100564
Available online: https://www.mdpi.com/1718-7729/29/10/564

27 September 2023
Current Oncology | Top Cited Papers in 2022 in the Section “Psychosocial Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Psychosocial Oncology” shown below:

1. “The Chemo-Gut Pilot Study: Associations between Gut Microbiota, Gastrointestinal Symptoms, and Psychosocial Health Outcomes in a Cross-Sectional Sample of Young Adult Cancer Survivors”
by Julie M. Deleemans, Faye Chleilat, Raylene A. Reimer, Mohamad Baydoun, Katherine-Ann Piedalue, Dana E. Lowry, Jan-Willem Henning and Linda E. Carlson
Curr. Oncol. 2022, 29(5), 2973-2994; https://doi.org/10.3390/curroncol29050243
Available online: https://www.mdpi.com/1718-7729/29/5/243

2. “The Psychosocial Impact of COVID-19 on Older Adults with Cancer: A Rapid Review”
by Ridhi Verma, Heather M. Kilgour and Kristen R. Haase
Curr. Oncol. 2022, 29(2), 589-601; https://doi.org/10.3390/curroncol29020053
Available online: https://www.mdpi.com/1718-7729/29/2/53 

3. “Assessing the Rela